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Abstract 
The prevalenee of allergie diseases is inereasing worldwide for unclear 
reasons. This sudden widespread inerease, partieularly in ehildren, suggests eauses that 
are not due to genetic makeup of individuals, but rather a change in environment and 
lifestyle factors. Growing epidemiologieal and immunological evidence supports the 
hygiene hypothesis, whieh states that deereased exposure to immune stimulating-
infections in early ehildhood is the cause of the rise in allergic diseases. Studies have 
shown that even bacterial components such as lipopolysaccharide (LPS) ean have a 
protective effeet. The receptor for LPS is Toll-like receptor 4 (TLR4), an innate 
immunologieal receptor, whieh may play an essential role in regulation of allergie 
disease. We investigated the expression of TLR4 in the nasal mucosa of allergic and 
non-allergic children and adults, the effects of LPS on allergic inflammation and the 
regulation of TLR4 expression. We hypothesized that LPS, through TLR4, could 
regulate allergic inflammation and that long-term allergic inflammation would limit these 
responses. 
Children and adults undergoing nasal surgery were recruited from the local 
hospitals. Nasal biopsies from the patients were explanted and cultured ex vivo with 
allergen and LPS. LPS could prevent allergen-induced Th2 cytokine production and 
inflammatory cell increases in explants from atopic children; this was through induction 
ofThl cytokines and IL-lO. TLR4 was also detected on CD4+CD25+ T cells. LPS did 
not provide the same protection in adults. Adults, especially atopic subjects, had less 
TLR4 immunopositive cells; hence, their reduced responsiveness to LPS. This suggests 
that factors could downregulate TLR4 in allergic adults. The U-937 monocytic cell line 
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was used as an in vitro model to study the regulation of TLR4 by interleukin-4 (IL-4), a 
T-helper type 2 (Th2) cytokine involved in allergic inflammation. U-937 cells cultured 
with IL-4 had decreased LPS responsiveness, TLR4 protein surface expression, TLR4 
mRNA expression and transcriptional activity of the upstream region of TLR4. This 
effect was tyrosine kinase and ST A T6 dependent. A ST A T6 binding site was determined 
in an area of the TLR4 gene necessary to mediate IL-4's inhibitory effects on TLR4 
transcription. IL-4 was also determined to reduce TLR4 expression in PBMCs, 
especially in CD4+ T cells purified from the blood of children. 
As predicted in epidemiological studies and animal studies, LPS was shown to 
provide anti-inflammatory effects against allergen in human nasal tissue. LPS may 
directly stimulate regulatory T cells (CD25+CD4+) to produce anti-inflammatory 
cytokine production. The effects of LPS exposure may be lost due to reduced expression 
of TLR4 by inflammatory cells, and this may be caused by the allergie inflammation 
itself. Therefore, development of allergie inflammation can down-regulate anti-
inflammatory mechanisms and promote long term chronic inflammation. 
6 
Résumé 
L'incidence des maladies allergiques i.e. atopiques augmente à travers le monde, 
pour des raisons qui demeurent inconnues. Cette augmentation marquée, particulièrement 
chez les enfants, suggère une origine autre que l 'hérédité, telle qu'une modification des 
facteurs liés à l'environnement et au mode de vie. De plus en plus de données 
épidémiologiques et immunologiques supportent l'hypothèse d'hygiéniste, selon laquelle 
une diminution de l'exposition à des infections stimulatrices pour le système immunitaire 
durant l'enfance contribuerait à l'apparition des maladies allergiques. Des études ont 
montré que certaines composantes moléculaires des bactéries, tels les lipopolysaccharides 
(LPS), pourraient avoir un effet protecteur. Le récepteur du LPS, 'Toll-like receptor 
4(TLR4)', est un récepteur de l'immunité innée jouant un rôle potentiel dans la régulation 
des maladies allergiques. Nous avons étudié l'expression de TLR4 au niveau des 
muqueuses nasales d'enfants et d'adultes allergiques et non-allergiques, ainsi que l'effet 
du LPS sur l'inflammation allergique et la régulation de l'expression de TLR4. Selon 
notre hypothèse de travail, le LPS, à travers l'activation de TLR4, pourrait réguler 
l'inflammation allergique, voire réduire l'inflammation propre à la réaction allergique, et 
ce phénomène pourrait être réprimé par la présence d'une inflammation allergique au 
long cours. 
Des enfants et adultes subissant une chirurgie nasale ont été recrutés dans des 
hôpitaux locaux. Des biopsies nasales ont été cultivées ex vivo en présence d'allergène et 
de LPS. Nous avons mis en évidence la capacité du LPS à empêcher le développement 
d'une inflammation de type 'T-helper' 2 (Th2) suite à l'exposition d'allergène dans les 
tissus provenant d'enfants atopiques. Ce phénomène résultait de l'induction de cytokines 
7 
Thl et de la production d'IL-lO. L'expression de TLR4 a également été détectée au 
niveau des lymphocytes T possédant les marqueurs membranaires CD4 et CD25. Une 
telle protection par le LPS n'a pas été observée chez les patients adultes. Ceci serait causé 
par un nombre inférieur de cellules exprimant TLR4, en particulier chez les adultes 
allergiques. Ces données suggèrent que certains facteurs pourraient diminuer l'expression 
de TLR4 chez les adultes allergiques. La lignée cellulaire de monocytes U-937 a été 
utilisée comme modèle in vitro pour étudier la régulation de TLR4 par l'interleukine-4 
(IL-4), une cytokine de type Th2 impliquée dans l'inflammation allergique. Les cellules 
U-937 cultivées en présence d'IL-4 ont une sensibilité inférieure au LPS, résultant d'une 
expression réduite du récepteur à la surface des cellules, d'une diminution de l'expression 
de l' ARN messager et de la transcription du gène TLR4. Ces effets étaient dépendants 
d'une activité de type tyrosine kinase et du facteur de transcription STAT6. Un site de 
liaison pour ST A T6 a été mis en évidence dans la région en amont du gène de TLR4, et 
qui s'avérait nécessaire aux effets inhibiteurs de l 'IL-4 sur la transcription de TLR4. 
L'expression de TLR4 à la surface des cellules mononuc1éées du sang périphérique des 
enfants était de plus diminuée en présence d'IL-4, en particulier au niveau des cellules T 
positives pour le marqueur CD4. 
Nous avons montré que le LPS possède des propriétés anti-inflammatoires envers 
la réponse immunitaire aux allergènes dans les muqueuses nasales humaines. Le LPS 
pourrait stimuler les cellules T régulatrices CD4+CD25+ à produire des cytokines anti-
inflammatoires. Les effets de l'exposition au LPS pourraient être perdus suite à la 
réduction de l'expression de TLR4 au niveau des cellules inflammatoires, un phénomène 
pouvant également résulter de la présence d'une inflammation allergique elle-même. 
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Ainsi, le développement d'une inflammation allergique peut diminuer les mécanismes 
anti-inflammatoires existants et promouvoir, à long terme, une inflammation chronique. 
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TIRAP TIR -domain-containing adaptor protein 
TLR Toll-like receptor 
TNFRSF9 Tumor necrosis factor receptor superfamily 9 
TNF-a Turner necrosis factor-alpha 
TRAF TNF receptor-associated factor 
TRAM TRIF -related adaptor molecule 
TRIF TIR-domain-containing adaptor prote in inducing IFN-p ( 
TSST-l Toxic shock syndrome toxin-l 
U International Unit 
Yc IL-2 receptor common gamma subunit 
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Chapter 1: Introduction 
1.1 Allergy History 
John Bostock, an English physician, reported in his own case history in 1819 a 
syndrome associated with nasal discharge, repeated paroxysms of sneezing, itching of the 
eyes, difficulty breathing and severe malaise[ 1, 2]. This is generally accepted as the first 
complete description of the malady known as hay fever, also known as allergie rhinitis. 
In the following nine years, Bostock was only able to report 28 other eases of hay 
fever[2-4]. Over the last two centuries, eases of allergie rhinitis and other allergic 
diseases have had a remarkable increase. Currently, epidemiological studies have 
estimated the world-wide average prevalence of allergic diseases at 15-20%[5-7]. 
Additionally, international comparisons have shown that considerable variation exists 
between countries in the prevalence of allergic diseases, ranging from about 1 % to almost 
30% in sorne surveys[6]. Current estimates for the prevalence of allergic disease in 
Canada and the United States c10sely follow the world-wide average. 
In 1873, Charles Blackley conducted the first experiments showing that hay fever 
cou Id be caused by a sensitivity to pollen[2, 8]. Later in 1906, Clemens von Pirquet 
coined the term allergy after noticing that patients who had previously received injections 
of horse serum or smallpox vaccine had quicker, more severe reactions to a second 
injection[9]. Allergy cornes from the Greek allas meaning "other" and ergon meaning 
"reaction," and was used to describe this hypersensitivity reaction. An allergen is defined 
as any substance, most often eaten or inhaled, that is recognized by the immune system 
and causes an allergic reaction. Charles Mantoux, shortly after von Pirquet, showed that 
tuberculin, a glycerin extract from cultures of bacteria that cause tuberculosis, 
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Mycobacterium tuberculosis, could also cause a hypersensitivity reaction[lO]. The 
Mantoux test, also known as the purified protein derivative (PPD) tuberculin test, is still 
used today as a diagnostic test for tuberculosis. 
Presently, types of hypersensitivity to antigens are classified into four types, in a 
classification scheme created by Gell and Coombs in 1968[ Il]. The term allergy is most 
often associated with Type 1 hypersensitivity, which is mediated by allergen-specific 
immunoglobulin E (IgE). Allergen-lgE reactions activate the release of inflammatory 
mediators and lead to an immediate reaction, within seconds to minutes. IgE-mediated 
diseases include atopic dermatitis, allergic asthma, allergic rhinitis and allergic 
conjunctivitis. 
1.2 Immune System Responses and Receptors 
The immune system of an organism is a complex array of cells and mediators that 
function to distinguish factors of an organism (self) from foreign substances (non-self). 
The immune system is then activated for the clearance of the non-self factors. There are 
two main responses of the immune system, called the humoral and cell-mediated immune 
responses. In humoral immune responses, antibodies are generated specifically for the 
antigen, and antibodies can neutralize invading microbes that possess the antigen on their 
surface, or they can flag the microbes for destruction by other cells, such as macrophages. 
An antigen is any molecule capable of causing the generation of antibodies. Humoral 
immune responses are important for protection from small extracellular pathogens such 
as bacteria and viruses and the neutralization of toxins and pathogenic factors but also 
protection from large extracellular pathogens such as multicellular parasites. In cell-
mediated immune responses, antibodies play a lesser role, and rather specific immune 
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cens are activated, such as macrophages, natural killer cens, and antigen specific 
cytotoxic T cens. Macrophages are activated to destroy engulfed microorganisms, while 
natural killer cells and cytotoxic T cells destroy other cell types that have been infected 
with pathogens. Cell-mediated immunity is important for protection from infections of 
microbes that can survive in phagocytic cells or that infect non-phagocytic cells. Hence, 
cell-mediated immunity is important for the removal of virus infected cells, intracellular 
bacteria, but it also plays a role in clearance of fun gal and protozoan infections. Cell-
mediated immune responses can also be generated against abnorrnally growing cells such 
as tumour cells. 
The immune system' s ability to discriminate between self and non-self is based 
on the evolution of cell surface receptors that can recognize specifie antigens and other 
molecules. Two main types of receptors exist, the adaptive immune receptors and the 
innate immune receptors. Adaptive immune receptors are present on lymphocytes, which 
have different effector functions depending on the type of receptor. During the 
maturation of lymphocytes, the adaptive immune receptors are generated by 
rearrangement of the genetic sequences encoding the receptor. In this fashion, receptors 
with unique recognition are created on each lymphocyte. B ceIls, which develop in the 
bone marrow, have antibodies with transmembrane regions anchoring them to the 
membranes. This B cell receptor complex can bind to antigen directly, and antibodies 
form part of an antigen recognition complex. T ceIls, which originate in the bone marrow 
but develop in the thymus, have an antigen recognition receptor composed of the CD3 
antigen and accessory molecules. T cell receptor complexes bind to allergen, but only 
wh en presented by other cell types called antigen-presenting cells. Binding of antigen to 
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the respective receptors, with appropriate co-stimulatory signaIs, activates effector cell 
function and proliferation. B cell effector ceIls, known as plasma cells secrete soluble 
cell-free antibodies. Two types of effector T cells exist, T helper cells and cytotoxic T 
cells. T helper cells produce mediators to activate other cell types, thus helping and 
coordinating the immune response, while cytotoxic T cells produce toxic proteins to 
eliminate infected cells in cell-mediated immune responses. Adaptive immune responses 
are antigen-dependent and this is important to avoid widespread responses that can cause 
damage to the host. Additionally, after activation by antigen, sorne cells develop into 
memory cells. These cells survive after the response to the antigen, and if the antigen is 
encountered again, the memory cells quickly activate and lead to a strong secondary 
response to clear the infectious organism. 
Innate immune receptors are an ancient system of receptors, that are inherited and 
that recognize conserved molecular patterns on microbes[12]. Innate immune receptors 
are believed to have evolved to recognize specific molecular determinants present in 
many pathogens. These molecules are known as pathogen associated molecular patterns 
(PAMPs) with their binding partners on immune cells known as pattern recognition 
receptors (PRRs). These are not rearranged like the adaptive immune receptors and are 
present on many cells types. Many PRRs exist and new members and associated P AMPs 
are still being discovered. PRRs are not involved in immune memory responses, but are 
believed to be important in initializing and directing adaptive immune responses 
(Diagram 1.1). 
A model for the immune system' s recognition and response functions was 
proposed in the late 1940s[ 13-15]. In this model, the immune system can directly 
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Diagram 1.1. Pathogen associated molecular patterns (PAMPs) and pattern recog-
nition receptors (PRRs) are part of the innate immune system. Recognition of 
PAMPs by PRRs on antigen presenting cells (APCs) leads them to increase phago-
cytosis, increase antigen presentation, increased surtàce expression of co-
stimulatory molecules and cytokine production. This leads to activation of T cells 
to produce cytokines and activate adaptive immune responses. 
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discem the differences between pathogens and the host, and will only react to pathogenic 
antigens. This model has been recently challenged, and reformulated. In the innate 
immune receptor model, proposed by Janeway, lymphocyte activation is controlled by 
PRRs and PAMPs[12]. PRRs react with PAMPs, and this will activate adaptive immune 
responses by lymphocytes. P AMPs would be a signal that a foreign antigen is present 
and an immune response is necessary. The innate immune receptor model was modified 
by Matzinger, to what is known as the "danger model"[ 16]. In this model, antigen is 
presented to lymphocytes by cells known as professional antigen-presenting cells (APCs) 
only if the host is threatened. Specifie danger signaIs, such as P AMPs or necrotic cells, 
activate the APCs to increase their ability to activate lymphocytes with antigen. Despite 
evidence for the "danger model", it is not completely accepted and it is thought that 
immune responses are not dependent on APCs alone and that danger signal can be 
recognized by lymphocytes directly. 
1.3 IgE, Atopy and Sensitization 
In 1865, Charles Blackley showed that a patient was sensitive to grass pollen by 
scarifying the patient's arm with a lancet and applying an occlusive bandage containing 
grass pollen to the skin[8]. The patient reacted with a skin reaction presenting swelling 
(wheal) and redness (flare) around the site of the bandage. This was credited as the first 
report on immediate skin reactions from allergie patients, and a similar assay is used in 
the clinic today to test for allergies. In 1921, Carl Prausnitz and Heinz Küstner 
performed an experiment that showed that wheal and flare reactions caused by allergens 
could be transferred by serum[17]. Due to its low levels in blood, it took 40 years to 
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determine that the causative factor was a type of immunogiobulin (Ig) which was named 
IgE[18,19]. 
In 1923, the term atopy, from the Greek word atopia meaning "out of place," was 
used to de scribe inherited hypersensitivity diseases[20]. Atopy is aiso sometimes defined 
as IgE-mediated sensitivity to allergens with a positive wheal and flare reaction wh en the 
skin is challenged with allergen. Although possessing a strong genetic component, 
environmental factors are now thought to be implicated in development of atopic diseases. 
Elevated levels of IgE in the serum is recognized as a characteristic of allergy[21, 
22]. Units used to quantify IgE were established in 1968 by the World Health 
Organization[23]. The standard was assigned an arbitrary mass unit, known as an 
International Unit (U). One unit of IgE was determined to be equivalent to 2.42ng of pure 
IgE [24]. In normal non-atopic aduit subjects, the serum concentration of total IgE 
ranges from 20kU/L (about 50ng/mL) to 40kU/L (about 100ng/mL) [25]. Levels as high 
as 375 kU/L (900ng/mL) can be found in adults with allergic disease. Due to large 
variation of total IgE measurements in patients with and without allergic symptoms, total 
serum IgE is not used as a predictor of allergic disease[22, 25, 26]. 
IgE is produced by B cells which are exposed to repeated allergen encounters and 
appropriate stimulation from T helper cells. IgE binds to receptors called FCE receptors 
on the surface of cells, such as mast cells and basophils. Wh en allergen is present, it 
binds to IgE, activates the receptor and the inflammatory cell produces numerous 
inflammatory mediators causing an allergic reaction. Inflammatory cells with IgE bound 
to their FCE receptors are said to be in their primed state. The process of IgE production 
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and priming of inflammatory cells is known as sensitization (Diagram 1.2). It is still 
unclear why allergens, which are presumed innocuous otherwise, cause sensitization. 
1.4 Airway Allergie Diseases 
Many individuals that expenence hypersensitivity to antigen in their upper 
airways (nasal passages) experience hypersensitivity in their lower airways. This has led 
to the concept of the united airways disease. In many reports, the fraction of asthmatics 
with symptoms of rhinitis has been considered to be around 85%[27, 28]. This may still 
be an underestimate as sorne asthmatic patients who consider themselves free of nasal 
symptoms demonstrate evidence of nasal inflammation[29]. Comparison of the 
pathology of allergic rhinitis and allergic asthma has shown many similarities. One of the 
main differences between the two airways is the presence of bronchial smooth muscle in 
the lower airways. Currently, both diseases are considered to be the same syndrome, but 
in different locations[28, 30], and there is evidence that therapeutic control of rhinitis is 
beneficial for asthma symptoms such as bronchial responsiveness[31, 32]. In prospective 
studies, allergic rhinitis has been shown as a risk factor leading to asthma, and the risk 
factor increases with the severity of the symptoms[33-35]; allergic rhinitics have a 2-3 
fold increased risk of developing asthma, while rhinitics with sinusitis have up to a 6 fold 
increased risk. From this evidence, it would seem that allergic asthma may stem from 
rhinitis, but the process is not understood. This thesis focuses on nasal inflammation and 
allergic rhinitis, but the conclusions developed may be extended to allergic asthma and 
even other allergic diseases. 
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Diagram 1.2. Allergen presentation by B cells can activate Th2 cells to produce 
cytokines and provide co-stimulatory signais such as CD40L leading to activation 
of B cells to differentiate into IgE-producing plasma cells. IgE can bind to IgE 
receptors on mast cells sensitizing them to allergen. Allergen can bind to IgE on 
mast cells causing cross-linking and triggering of the IgE receptors. This leads to 
mast cell activation and rapid degranulation of many inflammatory mediators such 
as histamine and cytokines. 
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1.5 Allergie Rhinitis CUnieal Definition 
Rhinitis is known as the inflammation of the mueous membrane of the nose. 
Symptoms include rhinorrhea, nasal obstruction, nasal itehing, and sneezing. Rhinitis 
may be either non-allergie or allergie in origin. Non-allergie rhinitis is eharaeterized by 
cloudy (white, yellow or green) nasal secretions and sneezing, and is predominantly 
eaused by virus or baeterial infections. 
Allergie rhinitis is clinically defined as a symptomatic disorder of the nose 
indueed by an IgE-mediated inflammation after allergen exposure of the membranes 
lining the nose. While sharing many symptoms, in eontrast to non-allergie rhinitis, nasal 
secretions are clear and watery. It was originally separated into perennial allergie rhinitis 
and seasonal allergie rhinitis. Perennial allergie rhinitis is most frequently eaused by 
indoor allergens present throughout the year sueh as du st mites, molds, inseet allergens 
and animal dander. Seasonal allergie rhinitis is related to outdoor allergens whieh are 
only present in the environment for diserete but reeurrent periods in the year and include 
pollens and molds. This definition has proved unsatisfaetory beeause sorne seasonal 
allergens in sorne parts of the world ean be perennial, many patients are sensitive to many 
allergens and present symptoms throughout the year, and there is a wide range of patient 
responses to perennial allergens that may not persist throughout the year[36]. Allergie 
rhinitis has been redefined by the Allergie Rhinitis and Hs Impact on Asthma (ARIA) 
organization[36]. Allergie rhinitis is now divided into either persistent or intermittent 
disease. Intermittent means that symptoms of allergie rhinitis are present less th an four 
days in a week or for less than four weeks in a year. Persistent means symptoms for 
allergie rhinitis are present for more than four days in a week and for more than four 
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weeks in a year. In addition, allergie rhinitis is further defined by wh ether presentation of 
symptoms is mild or moderate to severe. Mild allergie rhinitis is disease without any 
sleep disturbanee, troublesome symptoms, and impairment of daily aetivities including 
sehool, work, leisure or sports. Moderate to severe is classified as presenting one or more 
of the preceding conditions absent from mi Id allergie rhinitis. ARIA redefined allergie 
rhinitis to correct the diserepaneies of the older definitions, to help in standardizing 
epidemiologieal studies and to provide a basis for physieians and organizations to 
develop a local standard of care for their patients. 
1.6 Allergie Rhinitis: Type 1 Hypersensitivity Reaction 
The inflammatory mediators of the Type 1 hypersensitivity reaction in allergie 
rhinitis have been elucidated using allergen challenge of allergie individuals [37-39]. 
Two phases occur in this reaction leading to various symptoms (Diagram 1.3). The early 
phase of the hypersensitivity reaction occurs within minutes. It is as a result of the 
binding of allergen to IgE primed cells and activation of the FCI:: receptor. Triggering 
leads to the release of preformed mediators su ch as histamine, cytokines, cysteinyl 
leukotrienes and prostaglandins from the inflammatory cells into the surrounding tissue. 
These mediators, especially histamine, are potent proinflammatory mediators causing 
virtually aIl of the early phase responses in allergie rhinitis such as sneezing, pruritus, 
rhinorrhea, vasodilation and nasal congestion[40]. Vasodilation and chemotaetic factors 
lead to influx of lymphocytes, monocytes, macrophages, and granulocytes which 
coordinate the late phase reaction. The late phase reaction, usually seen 4 to 6 hours 
following the early phase can last 1 to 2 days. In the late phase, nasal congestion and 
cellular inflammation becomes more prominent. Maintenance of the late phase 
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Diagram 1.3. In the early phase ofthe hypersensitivity response, allergen causes the 
degranulation of mast cells. Mast cells release many mediators acting on many cell 
types and cause the symptoms of allergic rhinitis incJuding sneezing, pruritus, 
rhinorrhea, vasodilation and nasal congestion. Vasodilation, chemotactic factors 
and activated endothelium lead to influx of inflammatory cells into the tissue. The 
late phase is coordinated by these infiltrating cells, primarily eosinophils and Th2 
lymphocytes. 
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proinflammatory effects are attributed primarily to infiltrating T cells and eosinophils and 
the mediators they release[41]. 
1.7 Allergie Rhinitis: Cellular Inflammation 
Sensitization of the nasal mucosa in allergie rhinitis is associated with cellular 
change within the nasal mucosa[42]. Compared to non-allergic controls, large increases 
in the populations of lymphocytes, mast cells, granulocytes and macrophages are seen. 
These cells are either the result of proliferation at the site of inflammation or recruitment 
from local vasculature. Recruitment of cells from the vasculature involves surface 
changes in the endothelium that promote adherence of inflammatory cells. Inflammatory 
cells are then activated to cross the junctions between endothelial cells and through the 
basement membrane through a process called diapedesis. Cells th en migrate towards the 
site of inflammation. This whole process is mediated by a subset of cytokines known as 
chemokines that promote migration from zones of low chemokine concentration to zones 
of higher concentration called a chemokine gradient. It has also been shown that sorne 
inflammatory cells can be derived from local stem cells by in situ differentiation[43]. 
Once primed cells are in place and encounter allergen, they respond by producing 
cytokines and other mediators such as histamine that cause the allergie rhinitis symptoms 
and the early and late phase of the allergie response. A brief discussion of the cell types 
and main mediators involved in the allergie inflammation follows. 
1. 7.1 T Lymphocytes 
T eells possess the T eell reeeptor (TCR) eomplex whieh recogmzes short 
peptides derived from antigen complexed with major histoeompatibility complex (MHC) 
1 or MHC II. MHC 1 is expressed on virtually aIl eells of the body while MHC II is 
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mainly expressed on professional antigen-presenting cells. MHC I-antigen complexes 
are recognized by CD8+ cytotoxic T celIs, which clear cells infected with virus or 
bacteria or cells with abnormal proteins such as cancerous cells. MHC II-antigen 
complexes are recognized by CD4+ T helper celIs, and these cells produce many 
mediators leading to cell-mediated or humoral-mediated inflammatory responses. 
CD4+ T helper cells are the main coordinators of inflammation by producing 
soluble mediators and providing signaIs through cell adhesion molecules to other cells. 
They are the cell type found in greatest numbers both in normal and allergic nasal 
mucosa[42, 44]. T-helper cells were further divided by Mosmman and colleagues into T-
helper 1 (Thl) and T-helper 2 (Th2) subsets, based on the cytokines they produced[45]. 
Not only do the subsets pro duce different cytokines, they also coordinate different types 
of immune responses. Naïve Th celIs, CD4+ T cells never exposed to antigen, when 
activated by antigen-presenting cells pro duce cytokines from both subsets and are known 
as ThO cells[ 46]. If given the proper stimulus, naïve Th cells can differentiate into the 
biased Th 1 or Th2 subsets. The cytokine environment and signais that are received by the 
naïve T cells induce the differentiation. Bacterial innate immune responses lead to 
production of IL-12 and interferon-y (IFN-y) which drive the development of Thl 
cells[47]. Thl cells mainly produce high levels ofIFN-y, IL-2, IL-12 and Iymphotoxin-A 
(L TA) and are associated with cell-mediated immunity for clearance of intracellular 
pathogens. These cytokines promote T cell proliferation, macrophage microbicidal 
activity and antigen presentation, recruitment of phagocytic celIs, but are poor initiators 
of antibody production. Dysregulated Th 1 cytokine production can lead to 
immunopathology and organ-specific auto immune disease[ 48]. Conversely, production 
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of IL-4 early in an immune response directs the development of Th2-biased 
responses[49]; however, the innate immune response causing this phenomenon, 
particularly to allergens is not clear. The major Th2 cytokines are IL-4, IL-S, and IL-13 
and these have multiple effects on B cells, mast cells and eosinophils and are strongly 
implicated in atopy and allergie inflammation. Th2 cells can also direct humoral immune 
responses which are important in responses to large extracellular pathogens, such as 
parasitic worms. 
Th 1 and Th2 responses can cross-regulate each other by biasing an immune 
response one way or another. IL-4 can inhibit dendritic cell and macrophage production 
of IL-12, a potent stimulator of IFN-y production by T cells[47]. IL-4 also down-
regulates the IL-12Rp2 chain decreasing responsiveness of Th2 cells to IL-12[ 50], while 
IFN-y can enhance its production[51]. Additionally, IL-4 and IFN-y can inhibit the T-
helper cell production of each other[52]. 
Both Th 1 and Th2 cytokine responses are associated with transcription factors 
which control gene expression and lineage commitment by promoting transcription of 
genes and chromatin remodelling [53]. Chromatin remodelling is a process where DNA 
is made more or less accessible for transcription by modification of DNA and proteins 
and is coordinated by transcription factors specific for each lineage. One of the main 
transcription factors associated with Th! cells is T-Box Expressed in T Cells (T-bet) 
which controls IFN-y production[54, 55]. Expression ofT-bet is decreased in the airways 
of patients with asthma[56] concordant with decreased Th! cytokine production in 
asthma. Th2 commitment is associated with the transcription factors Signal Transducer 
and Activator of Transcription 6 (STAT6) and GATA-Binding Prote in 3 (GATA3)[57-
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59]. STAT6 is activated by IL-4 and IL-13 and it controls transcription ofGATA3[57]. 
GATA3 controls the expression of Th2 cytokines IL-4, IL-5 and IL-13 and other 
factors [ 60]. GAT A3 and STAT6 have been shown to be increased in the upper and lower 
airways in asthma and allergies [61-63]. Thl and Th2 associated transcription factors can 
further bias cytokine responses by inhibiting gene expression. T -bet can repress Th2 
lineage commitment by interfering with GATA3 activity[64]. STAT6 and GATA3 can 
also inhibit IFN-y production in Thl cells[65, 66]. 
Another subset of T -helper cells are known as Th3 cells. These cells secrete high 
levels of TGF-p but low levels of Thl and Th2 cytokines if any[67, 68]. They can 
suppress both Th 1 and Th2 cytokine production and are thought to have a role in mucosal 
tolerance to antigen but their role in atopy is unc1ear. 
Perhaps of greater interest are the CD4+CD25+ T-regulatory cells. They produce 
high levels of IL-IO and are involved in the maintenance of self-tolerance and 
suppressing immune responses. The expression of CD25 antigen, the IL-2 receptor a-
subunit, is induced in T cells upon antigen stimulation, but T -regulatory cells express 
high levels constitutively[ 69]. These cells were first discovered in the mid-1990s wh en 
depletion of CD25+ cells in mi ce resulted in a multiple organ autoimmunity[70]. Their 
population accounts for 5 to 10% of peripheral CD4+ T cells. Production of IL-lO by 
these can inhibit Th 1 and Th2 cytokine production and proliferation CD4+ T cells[71, 72]. 
A recently described transcription factor, Forkhead Box P3 (Foxp3), is associated with T-
regulatory cells [73]. Mutations in Foxp3 in mice lead to lethal autoimmune syndrome as 
a consequence of deficiency of T-regulatory cells[74, 75]. In humans, mutations in 
Foxp3 lead to the immunodysregulation, polyendocrinopathy, and enteropathy, X-linked 
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inheritance (IPEX) syndrome[76]. T-regulatory T cells are present in both atopic and 
non-atopic individuals, but T -regulatory cells from atopic patients have a significantly 
lowered activity in inhibiting proliferation and Th2 cytokine production of other cells, 
especially during allergen exposure[77, 78]. 
CD8+ cytotoxic T cells, although present in the nasal mucosa, are mainly 
associated with cell-mediated immune responses against viral infections. Sorne studies 
have shown that CD8+ T cells can produce IL-4 and stimulate B cells to produce IgE and 
pro duce IL-5 and induce tissue eosinophilia[79, 80]. CD8+ T cells may not play as great 
a role in controlling allergie inflammation as Th2 cells, but they may help promote and 
maintain it. 
1.7.2 B Lymphocytes and IgE Production 
B cells are also central for mediating atopic diseases, primarily due to their 
production of IgE. B cell development occurs in the bone marrow and is dependent upon 
the production of antibodies also known as immunoglobulin protein. Immunoglobulins 
are tetramers composed of two heavy chains and two light chains that are bound by 
disulfide bridges to form a three-dimensional "Y" shaped structure[81-83]. The heavy 
chains are larger and form the tail of the "Y". The two arms of the "Y" are where the 
light chains and heavy chains are linked by more disulfide bonds. Both the heavy chain 
and light chain have constant regions and variable regions at their amino-termini. The 
variable regions are formed by gene segments brought together by genomic 
recombination. Only B cells that are successful in rearranging both the heavy chain and 
light chain genes survive and proliferate to produce antibody. Successful B cells also 
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express a surface form of the immunoglobulin that they produce which is associated with 
accessory chains and forms a B cell receptor complex for activation of the cell by antigen. 
Digestion of immunoglobulins with papain yields three 50 kDa fragments[84]. 
Two fragments bind to antigen and are called Fab (antigen-binding fragment), while the 
third fragment forms prote in crystals readily and is called Fc (crystallisable fragment). 
The Fc portion is made up of constant regions of the two heavy chains (CH) and mediates 
binding to Ig receptors. There are five immunoglobulin CH classes in humans, called 
isotypes, based on the Fc portion expressed. Cil encodes for the IgM isotype, CcS encodes 
for IgD, four Cys encode for the IgOs, two Cas encode for the IgAs and Cf: encodes for 
IgE. Immunoglobulin mRNA is produced by transcription of the variable region and the 
constant region found downstream of it. When a B cell encounters an antigen and 
adequate stimulation from other cells, it is capable of changing its constant region gene 
transcribed by a process of isotype switching (Diagram 1.4). The CH genes for each 
isotype are arranged in a tandem array on chromosome 14q32 downstream of the heavy 
chain variable region. Specialized sequences of DNA called switch region sequences are 
found surrounding the CH genes[85]. IgE isotype switching is initiated by germline 
transcription from a promoter upstream of Cf:. This transcript, named If:Cf: RNA, 
contains an extra intermediate exon (lf:), the switch region Sf: and Cf:. After transcription 
of IECE RNA, the CE gene is translocated downstream of the variable region of the heavy 
chain, by intrachromosomal rearrangement and any intervening DNA is removed. Once 
the CE is downstream of the variable region, IgE mRNA production can occur. IECf: 
RNA transcription and splicing is essential for IgE isotype switching to take place[86, 87]. 
IECE transcription depends on the Th2 cytokines, IL-4 or IL-13 with the aid of trimeric 
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Diagram t.4. Th2 cytokines and CD40L cause isotype switching in B cells. IECE 
RNA is transcribed and the switch regions of IgM (Sil) and IgE (SE) are brought 
together bringing the constant region ofIgE (CE) downstream of the variable region 
of the heavy chain gene (VII). After the intrachromosomal rearrangement IgE 
mRNA can be produced and any intervening DNA is removed forming circular 
DNA. 
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CD40 ligand (CD40L)[88, 89]. Isotype switching and IEeE RNA transcription usually 
occurs in lymphoid organs, but they can also occur in the nasal mucosa upon allergen 
challenge [90]. IgE production is also increased in the nasal mucosa upon allergen 
exposure[90] and blockade of IL-4 by antisense oligonucleotides or neutralizing 
antibodies can reduce both IgE mRNA transcription and IeCe RNA transcription[91, 92]. 
Immature naïve B cells with functional BCR migrate out to secondary lymphoid 
organs. Following antigen stimulation, B cells either become memory B cells or plasma 
cells. These cells are able to secrete immunoglobulins based on their BCR, but the 
secreted immunoglobulins do not have the transmembrane region found in the BCR. 
Memory B cells retain their ability to recognize antigen and provide a high source of 
immunoglobulins wh en stimulated[93]. Plasma cells are terminally differentiated cells 
that produce large amounts of immunoglobulins[94, 95]. Plasma cells are no longer able 
to proliferate or switch isotype from the CUITent one they are secreting, and are relatively 
short lived[95]. 
B cell numbers are lower th an T cells in normal nasal mucosa[ 42, 44] and do not 
increase significantly upon allergen challenge of patients with rhinitis in the nasal mucosa, 
but increase in numbers in the blood [96]. 
1. 7.3 Antigen-presenting Cells 
Professional antigen-presenting cells take up antigen from the sUITounding 
environment, process it into smaller fragments that fit in the groove of the MHC II and 
then present the resulting complex at the cell surface[16]. The MHC II-antigen complex 
is recognized by the TCR of CD4+ T cells. Co-stimulatory molecules on antigen-
presenting cells are also necessary for CD4+ T cell activation. Co-stimulatory signaIs 
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mainly include B7 family proteins, such as B7-1 (CD80) or B7- 2 (CD86) interacting with 
CD28 on T cells, and members of the tumour necrosis factor receptor family such as 
CD40. The most common APCs include B cells, macrophages, and dendritic cells. 
The role of B cells as APCs in the nasal mucosa is not as clear as their role in 
antibody production. It is thought that transrnembrane immunoglobulin allows B cells to 
bind to antigen and selectively present this antigen to T cells[97]. It is possible that, 
although not part of the primary immune response, B cells in tissues promote secondary 
exposure to allergens and induce T cells to produce Th2 cytokines. ln vitro stimulation 
of B cells with antigen can induce them to stimulate Th2 cell IL-4 synthesis[98]. In 
addition, B cells stimulated with IL-4 and CD40L can be induced to produce IL-13 and 
IgE, potentially promoting Th2 inflammation[99]. 
Macrophages take up antigen by phagocytosis which can be non-specific or 
antibody-mediated through antibody receptors. Macrophages also express MHC II 
following activation. They are seen as scavenger cells that phagocytose antigen and are 
involved in clearance of small extracellular pathogens. In sorne circumstances, they can 
suppress adaptive immune response through mediators, such as IL-I0, which can inhibit 
Th cell and dendritic cell function[100, 101]. In addition, macrophages promote cell-
mediated responses by inducing Thl cell production ofIFN-y[102, 103]. Thus, their role 
in allergic disease is unclear. 
A clearer role can be seen for dendritic cells as they are the only cells capable of 
inducing a primary humoral or cell-mediated immune response[104-106]. High numbers 
of dendritic cells can be found in the epithelial surfaces of the upper airways[ 1 07]. Most 
dendritic cells in the periphery are functionally immature and cannot present antigen to T 
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cells efficiently. They can however present antigen to activated T cells for secondary 
immune responses; therefore, immature dendritic cells in the periphery may be involved 
in T cell memory responses. After taking up antigen in the periphery, immature dendritic 
cells migrate via the lymphatic system to lymphoid tissue. In the lymphoid tissue, 
dendritic cells change their phenotype and start expressing B7 family receptors, 
increasing their ability to activate T ceIls[ 108]. Dendritic cells express many PRRs and 
are highly responsive to P AMPs. When dendritic cells are exposed to antigen without 
P AMP stimulation or low level stimulation, they can promote Th2 cell differentiation, 
while in the presence of P AMPs, they can induce Th 1 cell differentiation[l 09]. After 
allergen sensitization, dendritic cell numbers increase in the airways[ Il 0, 111]. These 
cells are mature and may be important in interacting with primed T cells to induce them 
to produce Th2 cytokines in the presence of allergen, or for migrating to lymphoid tissue 
to promote greater lymphocyte reactions. In human blood, two types of dendritic cells 
exist, the myeloid dendritic cells(mDCs) that are derived from monocytes and the 
plasmacytoid dendritic cells (pDCs) that develop from lymphoid origins[112, 113]. In 
humans, mDCs pro duce a large amount of IL-12 and preferentially induce Th 1 
development, while pDCs pro duce lower amounts of IL-12 and preferentially induce Th2 
development[ 112, 114]. In mice, the opposite is seen where mDCs produce low IL-12 
and induce Th2 differentiation and pDCs produce high IL-12 and induce Th 1 
differentiation[I13, 115]. This may show a difference that exists between humans and 
mi ce or that the different dendritic cell lineages are not restricted in the Th phenotype that 
they induce and have multiple functions; pDCs have been shown to play an important 
role in tolerance to harmless antigen[116] and production of Type 1 IFNs after exposure 
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to viruses[117]. Stimulation of pDCs with PAMPs, such as CpG oligonucleotides, can 
also induce the generation of CD4+CD2S+ T regulatory cells[118]. In allergic diseases, 
dendritic cells may play a prominent role in both inducing primary and secondary recall 
responses to allergens through activation of T cells by antigen presentation. 
1.7.4 Mast CeUs 
Mast cells are one of the major inflammatory cells present in the nasal mucosa [44, 
119]. They originate from stem cells in the bone marrow. Mast cell precursors migrate 
from the bone marrow and localize to their site of action in various tissues. Mast cells in 
tissues are of two major types depending on the serine proteases they produce. Tissue 
mast cells can produce either tryptase, chymase, carboxylpeptidase and cathepsin G 
(MCTe) or just tryptase (MCT)[120, 121]. In the nasal mucosa, MCT are found close to or 
within the epithelium, while MCTe are found nearer to the nerves and blood vessels[122]. 
Mast cells express the high affinity IgE receptor FCtRI at their surface, which is a 
tetramer composed of an a chain, a ~ chain and two y chains[123]. The constant region, 
the crystallisable fragment of IgE (FCE) can bind to this receptor, effectively priming the 
mast cell for allergen. Allergen can cross-link IgE-FcERI complexes bringing them into 
proximity of each other and initiating rapid signal transduction cascades in the cytoplasm 
of the mast celIs[ 124]. Signal transduction cascades involve tyrosine phosphorylation, 
inositol phospholipid production, and entrance of calcium within the mast celIs[ 124]. 
These lead to mast cell activation and rapid degranulation of granules of stored 
preformed inflammatory mediators. Preformed mediators include mainly histamine, 
serine proteases, IL-4[12S] and tumor necrosis factor-a (TNFa)[126]. Histamine has 
immediate effects on surrounding cells to produce the immediate affects of an allergic 
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response[ 40]. IL-4 and TNF ex. promote cellular inflammation by activation of many cell 
types. At the same time, mast cell activation causes immediate production of the 
inflammatory lipid mediators prostaglandin D2 and leukotrienes C4 (L TC4). The lipid 
mediators can cause bronchoconstriction and enhance vascular permeability[ 121, 127]. 
Shortly after degranulation, mast cells also start producing other cytokines: granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-5 and IL-13[128, 129], which 
promote the late phase of the allergic reactions by promoting eosinophil development and 
survival. Mast cells also express CD40L and may play a role in IgE isotype 
switching[130]. 
1.7.5 Basophils 
Although basophils are granulocytes that express FCERI, Th2 cytokines and histamine, 
they are believed to be a separate lineage from mast eells[131]. Basophils develop in the 
bone marrow and represent less than 1 % of peripheral blood leukoeytes. Basophils 
produce many mediators, similar to mast cells, sueh as histamine, L TC4, IL-4, and IL-
13[132]. Conversely, PGD2 and IL-5 are not produeed by basophils[121]. Inereased 
numbers of basophils are se en in the tissue following allergen exposure in the late phase 
of allergie reactions[132, 133]. Due to their low levels in the blood, it has been difficult 
to aseribe a physiologie funetion for the basophil, but they may promote late phase 
inflammation by Th2 cytokine production and may also promote IgE c1ass switehing by 
their expression ofCD40L[130]. 
1.7.6 Eosinophils 
Eosinophils possess granules that stain with aeidie aniline dyes sueh as eosin. 
These cells are rarely found in the blood or nasal tissue in non-allergie subjeets, but tissue 
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eosinophilia is associated with allergic diseases and acute allergen exposure[122, 134]. 
Eosinophils develop and mature in the bone marrow from stem cells and are released to 
the peripheral blood as mature cells. These cells can also develop in the tissue from 
resident stem cells[43]. Eosinophils are characterized by their expression of cytotoxic 
granular proteins inc1uding major basic protein (MBP) and eosinophilic cationic prote in 
(ECP). MBP is directly toxic to respiratory epithelial cells and causes bronchial 
hyperresponsiveness and bronchodilation[135-l37]. Eosinophils also contain lipid 
bodies involved in lipid mediator production su ch as L TC4 [ 138]. Eosinophils can 
produce a large number of cytokines inc1uding transforming growth factor-~ (TGF-
~)[139], GM-CSF[140], IL-4[14l], IL-5[140], and TNF-a[142], although their 
contribution in cytokine production is much less than Th2 cells. They also express the 
Fc€RI[143] and CD40L[144] and can participate in IgE reactions. 
1.7.7 Epithelial CeUs and Goblet CeUs 
The epithelial cells of the nasal tissue form a barrier protecting the inner mue osa 
from the exterior environment. Allergie nasal mucosa is marked by areas of focal 
denudation, atrophy and squamous cell metaplasia, possibly as a result of inflammation 
and production of cytotoxic proteins su ch as MBP[135]. This condition is improved by 
local intranasal glucocorticoid treatment, suggesting that inflammation has a role in this 
pathology[145]. Loss of the integrity of the epitheliallayer may promote exposure of the 
mucosa by allergen and promote further inflammation. Aside from its barrier functions, 
epithelial cells can also play a role in the inflammatory process by producing cytokines 
and chemokines to recruit and activate cells. Cytokines produced by epithelial cells 
include IL-l~, IL-6, IL-lI, IL-13, IL-16, GM-CSF, and TGF-~[146]. Epithelial cells can 
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also produce many chemokines, such as eotaxin-l(CCL1)[147, 148], to recruit cells from 
the blood for inflammatory reactions in the tissue[146]. 
Goblet cells are uni cellular mucous-producing cells found above the basement 
membrane interspersing the epithelial cells. Roughly 10000/mm2 goblet cells can be 
found in normal nasal mucosa[149]. These cells produce the protective mucous layer 
over the epithelial cells which aids in pathogen and allergen clearance. It is not clear 
whether the numbers of goblet cells change during allergie rhinitis as reports in the 
literature are conflicting[ 150]. Increased numbers of goblet cells were reported in nasal 
smears from allergie patients during grass pollen season[ 151, 152], while in persistent 
rhinitis, goblet cell numbers did not change[ 153]. The mucin proteins, the glycoprotein 
component of mucous fluid, are inducible by Th2 cytokines[ 154-156] and are increased 
in airway allergie disease. 
1.8 Major Th2 Cytokine Functions 
Cytokines are a family of small glycosylated proteins, ranging from 8 kDa to 30 
kDa that are involved in many aspects of allergie rhinitis. Cytokines act through specifie 
cytokine receptors on the surface of target cells. Cytokines usually act on cells near the 
location where they were secreted or even on the cytokine producing cell, but they can 
also act at distant locations. Allergie rhinitis is believed to be driven by an imbalance 
between Thl(IFNy,IL-2, IL-12) and Th2(IL-4, IL-5, IL-9, IL-13) cytokines, with a 
predominant Th2 cytokine response[37, 157-159]. There may also be involved a loss or 
regulatory mechanisms such as loss of activity of T-regulatory cells[77, 78]. CUITent 
attempts at immunotherapy have as aim to reestablish the balance by increasing Th 1 
cytokines and immunosuppressive cytokines to counteract increased Th2 cytokines. The 
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following is a brief discussion of the roles of the major Th2 cytokines IL-4, IL-5 and IL-
13 and their involvement in allergic diseases. 
1.8.1 Interleukin-4 
IL-4 was discovered in 1986 as a factor capable of inducing B cell, T cell and 
mast cell proliferation[ 160]. IL-4 is present on chromosome 5 (5q31.1), the so-called 
Th2 cytokine gene cIuster, alongside IL-3, IL-5, IL-9, IL-13 and GM-CSF [161, 162]. 
IL-4 is mainly produced by T cells, particularly Th2 cells, but is also produced by mast 
cells[125], basophils[132] and eosinophils[14l]. IL-4 is essential in promoting the 
commitment of T helper cell precursors to produce the Th2 subset of cytokines and is 
important for the development of humoral mediated immunity[163-165]. IL-4 increases 
expression of MHC c1ass II molecules on B cells resulting in increased allergen 
presentation capacity to Th2 cells[166]. On the vasculature, IL-4 promotes expression of 
VCAM-l on endothelium, thereby allowing for recruitment of eosinophils and other 
inflammatory cells such as T cells, monocytes, and basophils from the blood into sites of 
inflammation [ 167]. IL-4 can regulate production of eotaxin, a potent eosinophil 
chemoattractant, by fibroblasts, endothelial and epithelial ceIls[ 168-170]. IL-4 also 
induces isotype switching, a process leading to the production of IgE by B cells, and after 
switching occurs, IL-4 potentiates IgE production. Furthermore, IL-4 enhances the IgE-
mediated response by upregulating IgE receptors on inflammatory cells within the airway 
such as mast cells[ 171, 172]. IL-4 can also stimulate mucus cell secretions and 
metaplasia[ 154]. 
IL-4 mediates its actions through the IL-4 receptor composed of two subunits, IL-
4 receptor a-subunit (IL-4Ra) and the IL-2 receptor common y subunit(yc)[173, 174] 
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(Diagram 1.5). The Yc is aiso part of the IL-2, IL-7, IL-9 and IL-15 receptors. Binding of 
IL-4 to the receptor activates Janus kinases (Jaks) which phosphorylate tyrosine residues 
of the intracellular domain of the receptors. ST AT6 is recruited to the receptor and is 
phosphorylated by the Jaks. STAT6 does so by binding to phorphorylated tyrosine 
residues through a specialized protein domain called Src-homology domain 2 (SH2). IL-
4Ra is associated with Jakl[175] and the Yc is associated with Jak3 [175, 176] and both 
can phosphorylate ST A T6. Phosphorylated ST A T6 homodimerizes through SH2, 
migrates to the nucleus, binds to ST AT6-response elements and once there it regulates 
transcription of many inflammatory genes[ 177]. Many genes activated by ST A T6 are 
important for allergic inflammation, and STAT6 deficient animaIs have defective IL-4 
responses[ 58]. 
1.8.2 Interleukin-13 
IL-13 was first described in 1993, as a cytokine produced after activation of T 
cells[ 178]. The IL-13 gene is found only 12kbp from the IL-4 gene on chromosome 
5q31.1 [179]. IL-13 has a 70% sequence homology with IL-4 and binds a heterodimer 
composed of the IL-4Ra chain and an IL-13Ra chain, either low affinity IL13Ral or 
high affinity IL13Ra2[180, 181]. Due to the redundancy in IL-4Ra binding, both IL-4 
and IL-13 exhibit sorne degree of functional overlap. Similarly to IL-4, over-expression 
of IL-13 within the lungs results in IgE production, eotaxin, inflammation, mucus hyper-
secretion, eosinophilia and upregulation of VCAM-1 [146, 182]. However, in animal 
models of antigen challenge, IL-13 can cause airway hyperreactivity to contractile 
agonists[ 156]. The expression of IL-13 is more widespread than IL-4[ 183], and it is 
suggested that IL-13 has effects on other processes such as fibrosis and airway 
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Transcriptional 
--~~ Regulation 
Diagram 1.5. The major pathway activated by IL-4 through the IL-4 receptor is the 
Jak-STAT pathway. The IL-4 receptor is composed of the IL-4 receptor a-chain 
(IL-4Ra) and the IL-2 receptor y common subunit (IL-2Ryc). IL-4Ra is associated 
with Janus kinase 1 (Jakl) and IL-2Ryc is associated with Jak3. Wh en activated, 
these phosphorylatc tyrosine (Y) residues on IL-4Ra. Phosphorylated tyrosines 
recruit STAT6 to the receptor and Jaks phosphorylate this protein. Phosphorylated 
STAT6 can homodimerize which leads to its activation, translocation to the nucleus 
and binding to DNA through special sequences. STAT6 can associate with CREB-
binding prote in (CBP) and nuclear receptor coactivator 1 (NCoA-I) to regulate tran-
scription by chromatin remodeling and activation of RNA polymerase. 
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hyperreactivity. Like IL-4, IL-13 induces tyrosine phosphorylation cascades through its 
receptor. IL-13 activates JAKI through IL-4Ra chain, leading to activation of STAT6, 
but not JAK3 as the IL-13Ra subunits do not associate with Yc. IL-13Rul can associate 
with JAK2 and Tyk2 for its signal transduction[184]. IL-4 can also bind to the IL4Ru-
IL13Rul complex to mediate its effects[185]. Both IL-4 and IL-13 can activate insulin 
receptor substrate-phosphatidylinositol 3'-kinase pathways for cell survival and 
proliferation through this receptor[ 186]. The IL-13Ru2, has a short intracellular region 
that is thought to downregulate the actions of IL-13 by acting as a decoy receptor[187]. 
IL-13Ru2 has also been shown to inhibit IL-4 activation of ST A T6 by interaction of its 
cytoplasmic domain with the IL-4 receptor[ 188]. A recent report has shown that IL-13 
RU2 may indeed initiate signal transduction by binding IL-13, and its activation leads to 
production ofTGF-p in macrophages[189]. 
1.8.3Interleukin-5 
Interleukin-5 was cloned as a factor causing the growth and differentiation of 
eosinophils [190-192]. IL-5 is the most important Th2 cytokine associated with 
eosinophils, and it can regulate most aspects of eosinophil behavior. Mice that are 
genetically engineered to express high levels of IL-5 have life-Iong eosinophilia in their 
lungs[193]. In addition, intravenous injections of antibodies blocking IL-5 can decrease 
asthmatic sputum eosinophilia[ 194]. IL-5 promotes survival by blocking eosinophil 
apoptosis[ 195]. IL-5 can also activate eosinophil secretion, cytotoxicity and 
chemotaxis[ 196]. IL-5 activates eosinophils to upregulate integrin receptor expression, 
which promotes adhesion to VCAM-expressing endothelial cells and eosinophil 
accumulation in the tissue[ 197, 198]. IL-5 is produced by T helper cells, cytotoxic T 
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lymphocytes and mast cells, but a major source of IL-S is the eosinophils themselves 
[199]. 
The receptor for IL-S interacts with a heterodimeric receptor composed of an a-
subunit and a ~-subunit shared with GM-CSF and IL-3 receptors[200]. IL-5 signal 
transduction, like IL-4 and IL-13, involves tyrosine phosphorylation cascades involving 
JAK2 and STAT5a and STAT5b and activation of Lyn and Syk tyrosine kinases[201, 
202]. 
1.9 Possible Reasons for Increasing Prevalence in Allergie Diseases 
1.9.1 Genetic Predispos irions 
Although many processes and mediators of allergie intlammation and Type 1 
hypersensitivity have been characterized, no clear explanation exists for the large 
increases seen in disease prevalence. In 1916, a study was published showing that 50% 
of patients with allergie rhinitis and asthma had a positive family history for these 
diseases [203]. Yet, such a rapid increase in the number of people with allergy over the 
past 50 years denotes changes in the environment or lifestyle and not a pure genetic cause. 
Nevertheless, the sensitivity to allergen and the severity of the allergie disease may 
depend on the genetic susceptibility of the individual. A number of genetic studies, using 
linkage analysis, fine mapping studies and gene expression studies have implicated a 
number of potential genes leading to a predisposition for atopy. Almost all genes 
involved in the development of the IgE-mediated intlammatory cascade have been linked 
with the development of atopy and asthma (for recent review see [204]). For example, 
the IL-4 gene cluster containing the IL-4, IL-5 and IL-13 genes[205, 206] and the high 
affinity IgE receptor [207] are highly linked to the development of atopy. Genetic studies 
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have also becorne so sophisticated that genes are being linked to atopic disease before a 
clear role in disease is determined. Sorne exarnples of recent genes discovered include 
arginase[208], a disintegrin and rnetalloproteinase dornain 33 (ADAM33)[209], PHD 
Finger Protein Il (PHF11)[21O, 211], dipeptidyl peptidase X (DPPlO)[212], G prote in-
coupled receptor 154 (GPR154)[213] and defensin pl (DEFB1)[214]. What role and how 
great a role these and other genes play in the developrnent of atopy is still undetermined 
but their study rnay show thern as potential therapeutic targets and give a clearer 
understanding of how allergies develop. Many genes diseovered in the genetie studies are 
assoeiated with single nucleotide polyrnorphisrns (SNPs), whieh provide a greater or 
lesser susceptibility to disease. For exarnple, SNPs found in STAT6 have been 
assoeiated with allergie disease and asthrna and an inereased production of serum 
IgE[215-217]. 
1.9.2 Pollution 
It has long been speeulated that pollution plays a large role in the inereased 
prevalenee of atopie diseases. The Industrial Revolution began in England during the 
late 18th century and the beginning of the 19th eentury and was assoeiated with the first 
massive chernieal pollution in human history. Sinee then pollution has beeome a global 
problem and its inerease may be assoeiated with inereasing atopie diseases. It is thought 
that ehronic ehemical damage to the epithelial barriers of the body eould facilitate the 
entry and sensitization to allergens. Animal models have shown allergie sensitization ean 
be increased by S02 and diesel exhaust[218, 219]. In hurnans, exposure of the nasal 
rnueosa to diesel exhaust ean also inerease IgE levels[220, 221]. A strong association 
was also determined between allergie rhinitis to cedar pollen and locations close to heavy 
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traffic[222], but in other studies the same association was not seen[223]. N02 present in 
car exhaust was associated with an increased prevalenee of asthma and allergie 
rhinitis[224]. In one study, ozone (03) was able to increase the sensitivity to allergen 
doses[225], but other studies were not able to reproduce this finding[226, 227]. Although 
pollution may exacerbate the effects of allergens, it is thought that it is not the underlying 
cause of the development of atopy. In addition, the variation of the results obtained 
between epidemiological reports suggests the need of large global longitudinal studies to 
study pollution and its link to allergic diseases[228]. 
1.9.3 Tobacco Smoke 
Tobacco smoke is a complex mixture of various particles and organic compounds 
that have many harmful health effects. Parental, particularly maternai smoking is 
associated with an increased wheezing and asthma in children[229]. With respect to 
allergic sensitization, atopic smokers compared to non-smokers also have increased 
levels oflgE[230]. Mixed results have been obtained for passive smoke exposure to be a 
risk factor for sensitization of children to indoor allergens, with sorne studies showing a 
link and others not[229, 231, 232]. Maternai smoking during pregnancy has been shown 
to be a risk factor for sensitization and wheezing during childhood [233, 234], but other 
studies have not found this association[235]. It is difficult to discern how great a factor 
tobacco smoke plays in allergic disease and more studies are required. 
1.9.4 Obesity 
Obesity may also be a risk factor for atopy but discrepancies are seen in the 
epidemiological reports. In a European study, men and women with a high BMI (>30) 
had a higher incidence of wheeze and shortness of breath compared to subjects with a 
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lower BMI (20-25)[236]. BMI was not associated with allergic rhinitis, total IgE or 
specific IgE in this study. In children, no association is seen between BMI and atopy, 
regardless of sex[237]. In a recently conducted study using male conscripts in Sweden, 
asthma was shown to be associated with a high BMI, but allergic rhinitis was not[238]. 
Contrary to the European studies, in a longitudinal study conducted in New Zealand, 
BMI was positively associated with atopy and IgE levels in women but no association 
was seen in men[239]. Supporting evidence shows that obese women with atopy versus 
atopic non-obese women have three times higher total and specific IgE levels[240]. 
1.9.5 Family Size and Day Care 
There is much evidence demonstrating that family size has a role to play in 
decreasing atopy. The number of older and younger siblings is inversely related to the 
occurrence of atopic diseases and specific IgE in children, adolescents and adults[241-
244]. This relationship is strongest for atopic eczema[245] and hay fever[246, 247], but 
weaker for protection from asthma[246, 248, 249]. Reasons for this difference either lie 
in the definition of asthma used for the studies or that the development of sorne forms of 
asthma may be different from other atopic diseases[250, 251]. In addition to increased 
number of siblings, young children who are exposed to day cares also have reduced 
atopic diseases[252, 253]. 
1.9.6 Hygiene Hypothesis 
Many epidemiological studies have found a strong inverse relationship between 
infections in early life and the subsequent development of atopic diseases[250]. One of 
the first studies that linked the two was conducted in 1976, looking at serum IgE levels, 
in white population and Métis Indians from Saskatchewan in Canada[254]. Gerrard et al. 
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found that the prevalence of asthma and eczema was signiticantly higher in the white 
population compared to the Métis population; in contrast, a higher prevalence of helminth 
infestations and untreated viral and bacterial infections were seen in the Métis population 
compared to the white population. Soon after, in another study, Anderson reported that 
in Papua New Guinea, respiratory infections in children occurred more frequently where 
asthma prevalence was low[255]. The hygiene hypothesis also follows from the sibling 
and daycare effect mentioned earlier. Increased contact between children promotes 
childhood infections, and this would be protective against atopy. These pioneering 
studies and the numerous others that followed led to what is known as the hygiene 
hypothesis, tirst proposed in 1989[247]. It postulates that in the absence of common 
environmental immunological challenges, an infant's immune system may not develop 
properly, leading to unregulated responses to allergens. More recent studies have directly 
correlated the level of sanitations with the incidence of allergic diseases[256]. 
Additionally, prevention or cure of certain infections has shown to increase the risk of 
allergic diseases. For example, a pneumococci vaccination program in South Africa led 
to an increased incidence of atopy[25 7]. 
1.10 Animal Model Support for the Hygiene Hypothesis 
Largely due to recently accumulating immunological evidence to support the 
epidemiological studies, the hygiene hypothesis is slowly becoming the most plausible 
hypothesis to explain the temporal and regional differences in the prevalence of atopic 
diseases. A number of animal models of infection and antigen sensitization have been 
created to test the hygiene hypothesis. In studies using mi ce infected with attenuated 
Mycabacterium bavis, also known as the Bacillus Calmette-Guerin (BCG) used for 
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vaccination against tuberculosis, a suppression of allergen-induced airway eosinophilia 
by 60-70% with a decrease in IL-5 production by T cells and decreased airway reactivity 
was observed[258, 259]. Peritoneal injections of mice with heat-killed lactobaccilus 
reduced IgE production in mice fed allergen with an increase in IL-12 production[260]. 
1.11 Mechanisms of the Hygiene Hypothesis 
Two main mechanisms have been proposed to form the immunological basis of 
the hygiene hypothesis[261]. The first mechanism is based on the competition of anti-
infectious immune responses with allergen immune responses. As the burden of 
infectious material is less, antigen-presenting cells are more likely to present allergen to T 
cells. Allergen specific T cells would increase due to activation and proliferation, and 
these would compete with other T cells for homeostatic factors. 
The second mechanism is based on loss of suppressor mechanisms that would 
prevent or control allergic inflammation [261, 262] (Diagram 1.6). Exposure to bacterial 
products may promote development of Th 1 cytokine production and responses, which 
would prevent overactive Th2 immune responses. Sorne of the regulation cou Id also be 
mediated by CD4+ CD25+ T regulatory cells, a population of cells which cou Id be 
increased by exposure to infections to maintain homeostasis. CD4+ CD25+ T cells are 
present in both allergic rhinitis patients and non-allergic individuals, and are capable of 
suppressing both Thl and Th2 cytokine production[78, 263]. However, in vitro 
experiments have shown that while CD4+ CD25+ T ceIls from non-atopic individuals 
retain suppressive ability, this is reduced in atopic CD4+ CD25+ T ceIls, particularly 
during the poIlen season[77, 262]. Similarly, during birch-poIlen season, CD4+ CD25+ T 
ceIls from aIlergic patients are defective at down-regulating IL-13 and IL-5 production, 
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Diagram 1.6. The hygiene hypothesis proposes that exposure to infections and 
pathogen associated molecular patterns (PAMPs) helps the proper development of 
regulatory mechanisms, such as Th 1 cytokines and T-regulatory cytokines, against 
the development of allergic disease. Without this regulation, Th2 cytokines are 
produced which cause the development of IgE sensitization and promote allergic 
inflammation by activation and priming of effector cells. 
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while still retaining their ability to inhibit IFN-y production[78]. The mechanism by 
which the activity of CD4+ CD2S+ T cells is differentially regulated in atopic and non-
atopic individuals remains to be determined. 
1.12 Lipopolysaccharide 
The hygiene hypothesis has been extended not only to include to bacterial and 
viral infections but also exposure to bacterial components, such as lipopolysaccharide 
(LPS); numerous epidemiological and animal model studies haves shown that LPS can be 
protective against the development of atopic diseases. The work of this thesis focuses 
largely on the actions of LPS in atopic disease. This P AMP is a potent inducer of 
inflammatory reactions and may play a role in inhibiting the development of atopic 
disease. The following is a summary of the studies performed on LPS and its effects in 
the airways, its involvement in sepsis, its structure and its receptor. 
1.12.1 Airway Exposure to LPS 
Several epidemiological studies have shown that LPS can be protective against 
the development of allergie diseases. The first direct in vivo evidence that LPS exposure 
from the domestic environment protected against allergen sensitization was reported by 
Gereda et al[264]. In a pool of children aged between 9 and 24 months, concentrations of 
house-dust endotoxin and allergen were measured. A significant amount of LPS was 
found in common house dust, and these levels did not vary much throughout the year 
[264]. Allergen sensitization was measured by skin-prick testing. It was found that 
sensitized children lived in homes with significantly lower concentrations of endotoxin, 
compared to non-sensitized infants. Additionally, IFN-y positive CD4+ T cell numbers 
were positively correlated with house-dust endotoxin concentrations, suggesting that 
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in do or endotoxin exposure enhanced Th 1 immunity and may prote ct from allergen 
sensitization. In a second study, children aged between 5 to 10 year olds were recruited 
and living-room floor du st was analyzed for endotoxin[265]. Allergen-specific IgE levels 
were quantified in this study, and it was determined that sensitization to allergen was 
negatively correlated to endotoxin levels. In addition, higher levels of endotoxin were 
associated with less severe sensitization to one antigen and were protective against 
sensitization to more than one allergen. Increased endotoxin levels in house dust reduced 
the risk of atopic eczema, but the risk of respiratory infections and bronchitis was 
increased[266]. Results from the first two studies were confirmed by Braun-Fahrlander 
et al. in a study involving children aged 6 to 13 years of age[267]. High endotoxin levels, 
in mattresses, were once again correlated with decreased occurrence of hay fever, atopic 
asthma and sensitization to allergens. Interestingly, peripheral blood leukocytes isolated 
from the children from low endotoxin households produced more TNF-a, IFN-y, IL-1O 
and IL-I2 compared to children from high endotoxin households after stimulation with 
LPS or Staphylococcal Enterotoxin B. The authors speculated that exposure to high 
levels of endotoxin resulted in a generalized tolerance to immunological stimulus. 
Although endotoxin seems to be protective for the development against atopic 
diseases in children, it may be a risk factor for occupational asthma in adults[268]. 
Occupational asthma is thought to be caused by ab normal agents in the workplace such as 
dusts, chemicals, fumes or vapours and is not necessarily IgE-mediated. In addition to 
household dust, LPS can be found in high concentrations in air pollution[269], organic 
dusts [270], and even cigarette smoke[271]. Concentrations of endotoxin in the air are 
strongly associated with acute decreased airflow in cotton workers[272] and swine 
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farmers[273]. Endotoxin and grain dust can even cause airflow obstruction in previously 
unexposed individuals[274-276] and increased neutrophil levels in the airways[277]. 
Additional reports have also shown that endotoxin levels in households may be related to 
clinical severity of asthma[275, 278, 279]. 
In experimental settings, wh en human subjects are exposed to pure endotoxin by 
inhalation, they experienced acute clinical effects su ch as fever, shivering, joint pain, 
malaise, increased blood and airway neutrophil levels, dry cough, dyspnea, reversible 
bronchial obstruction and a impairment in lung function and forced expiratory volume in 
1 second (FEV t)[268, 275, 280, 281]. Considerable variability is seen in the magnitude 
of these symptoms in reported responses to LPS challenges. In one study of 77 naïve 
subjects exposed to endotoxin, only half the subjects reported fever, about a third felt 
chest tightness, and exposure caused only a small dose-related decrease in FEV t and a 
slight increase in bronchial hyperresponsiveness[276]. In another study, normal subjects 
had no brochial hyperresponsiveness upon LPS challenge[282]. Subjects with asthma 
also seem to respond more than patients without asthma[282-284]. Kline and eolleagues 
recruited 72 healthy, non-allergie, and non-smoking subjects, aged 18 to 50 years of age 
to study variable responses to LPS[269]. Based on the FEV t following inhalation of 
increasing doses of LPS and in vitro production of IL-6 and IL-8 from peripheral blood 
monocytes and alveolar macrophages, three phenotypes were determined: sensitive, 
intermediate and hyporesponsive. This variability observed may depend on genetics of 
the individuals but also other extrinsic factors. From the different epidemiological 
studies, it seems that endotoxin may be protective against allergen sensitization in early 
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life and the development of atopy, but it may be detrimental, ean cause non-allergie 
asthma for sorne patients and may exacerbate already established asthma. 
Animal models and in vitro experiments have been performed to try and replicate 
the results of epidemiological studies. In a study by Tulic et al., airbome exposure of 
endotoxin to 8-10 week old rats one day before intraperitoneal OV A exposure or 4 days 
after the OV A exposure protected against the development of ovalbumin specific 
IgE[285]. When LPS exposure to the rats occurred 6 to 10 days after sensitization with 
OV A, OV A challenge caused a greater lung cellular influx and increased vascular 
leakage compared to rats not exposed to LPS but sensitized to OV A. In this model, LPS 
could also reduce bronchial hyperresponsiveness to methacholine challenges and 
eosinophilia caused by OV A. In a mouse model of allergic asthma, LPS administration 
suppresses IgE-mediated and mast cell-dependent allergen responses, pulmonary 
inflammation, alrway eosinophilia, mucus production and aIrway 
hyperresponsiveness[286]. The effects of LPS seemed to be independent of IL-12, IFN-y 
but did require the presence of inducible nitric oxide synthase (iNOS). In addition to a 
role for nitric oxide in diminishing airway hypereactivity, IL-I0 may play a role in 
diminishing airway inflammatory events in these models[287]. In another study, 
cockroach antigen sensitized mice were administered different doses of LPS before 
antigen challenge[288]. In this model, airway hyperresponsiveness and eosinophillevels 
and Th2 cytokines levels in the lungs decreased and neutrophils and Th 1 cytokine levels 
increased. In contrast to these studies, Wan and colleagues showed that mice exposed to 
airbome endotoxin before ovalbumin sensitization and 5 days during ovalbumin 
sensitization had enhanced IgE expression and increased eosinophils in bronchoalveolar 
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lavages (BALs) [289]. Low doses of LPS have also been shown to promote Th2 
responses to allergen while high doses of LPS promote Thl responses[290]. When low 
doses of endotoxin were given to sensitized mi ce during challenge, IL-5 expression and 
eosinophilia were promoted[29 1]. In addition, it has been proposed that endotoxin in low 
doses is necessary for the development of optimal Th2 responses to an allergen in 
mice[290, 292]. Taking aIl these studies together, it can be seen that the effect of LPS on 
allergic responses can vary depending on dose and timing with respect to sensitization. 
In animal models, exposure to LPS before allergen sensitization is protective, 
suggesting the evolution of anti-inflammatory mechanisms in early life. To investigate 
this phenomenon in humans, Tulic and colleagues used a human ex vivo tissue culture 
model to determine the responses of non-atopic children(aged 3.6 ± 0.7 years old) to 
LPS[293]. Tissue was resected from the inferior turbinate of the nasal passages and 
incubated with different doses of LPS for 24 hours. In this model, as the tissue is 
incubated outside the body, systemic infiltrates are eliminated as responses to challenges 
are solely derived from tissue constituents. LPS caused a large increase in macrophages, 
mast cells, elastase positive cells and surprisingly large increases in T cells. The increase 
in T cells was due to proliferation and was LPS dose dependent. Numbers of IL-2, IFN-
Y and IL-12 mRNA positive cells were also increased within the tissue. In addition, many 
of the proliferating T cells were determined to be CD4+CD25+ cells, and IL-lO mRNA 
positive cells were increased within the tissue after LPS stimulation. It is possible that 
non-atopic children have LPS sensitive CD4+CD25+ T regulatory cells that produce IL-I 0 
upon endotoxin exposure. These naturally occuring cells could be able to provide anti-
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inflammatory signaIs to protect against the development of Th2 inflammation in the 
tissue. 
1.12.2 LPS and Sepsis 
LPS can have strong widespread effects wh en present in the vasculature. It is one 
of the agents capable of causing the signs and symptoms of sepsis. Systemic 
inflammatory response syndrome (SIRS) is defined as a response with two or more of the 
following: increased or decreased temperature, increased or decreased leucocyte count, 
tachycardia, and rapid breathing[294-296]. Sepsis is defined as SIRS combined with a 
documented infection. 
Infections that cause sepsis include Gram positive and Gram negative bacteria, 
fungi, viruses and parasites. Usually the infections are contained locally by the immune 
system, but ifthis system fails, a systemic response to the infection occurs. Inflammatory 
responses and neuroendocrine responses lead to generalized inflammation, coagulation, 
dysfunction in the circulatory system, acute organ dysfunction, multiple organ 
dysfunction syndrome and eventually death. Severe sepsis is defined as sepsis with at 
least one sign of organ hypoperfusion or dysfunction, and septic shock is severe sepsis 
with refractory arterial hypotension[296]. 
LPS causes effects on multiple cell types, but adoptive transfer experiments in 
mice have shown that cells that mediate the toxic effects of LPS during sepsis are of 
hematopoietic origin[297]. More specificaIly, macrophages seemed to be the primary 
cell type mediating these effects[298]. One of the major products produced by 
endotoxin-activated macrophages is TNF -u. Administration of high doses of TNF -u can 
cause many of the toxic effects of LPS including fever, vascular Ieakage, blood 
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coagulation, and widespread tissue injury[299, 300]. In addition to TNF-a, LPS can 
induce the production of many different proinflammatory cytokines including IL-l, IL-6, 
IL-8, IL-12 and many lipid mediators[30 1, 302]. These cytokines can activate production 
of multiple proinflammatory factors such as nitric oxide and chemokines[303]. 
Additionally, LPS induced cytokine cascades can promote the production of Th 1 
cytokine production from T cells, to stimulate a cell-mediated immunity for clearance of 
the pathogen. 
Many efforts have been made to determine agents capable of reducing the toxic 
effects of LPS. The anti-inflammatory cytokine, IL-10 can be induced by LPS, and can 
limit the activation caused by LPS and prevent toxicity[304, 305]. Sorne studies have 
been performed on other cytokines, particularly the Th2 cytokines IL-4 and IL-13. In 
vitro, IL-4 can inhibit LPS-induced human monocyte production of IL-l, TNF-a, IL-6, 
IL-IO and IL-12 [306-310]. In vivo, IL-4 has been extensively studied as an agent 
capable of preventing sepsis. One report showed that mice given recombinant IL-4 were 
capable of surviving lethal sepsis-causing doses of Pseudomonas aeruginosa[311]. IL-13 
is also protective against sepsis, and can reduce LPS-induced IL-6, IL-8, IL-lp and TNF-
a[ 178, 312, 313]. Although the mechanisms have not been determined, IL-4 and IL-13 
activation of ST A T6 may play a role, as ST A T6 deficient mice have uncontrolled 
production of cytokine and chemokine production when given LPS[314]. Corticosteroids 
have also been shown to downregulate the LPS responses[315]. 
1.12.3 LPS Structure 
Bacteria can be differentiated into two groups based on their ability to retaining 
the violet dye/iodine complex, in a procedure called the Gram stain[316]. Gram negative 
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bacteria have two cell membranes, an interior cell membrane composed of a phospholid 
bilayar and a secondary outer cell membrane. The outer cell membrane is composed of 
proteins and a lipid bilayer. The inner leatlet of the bilayer is composed of phospholipids 
but the outer membrane is mostly composed of LPS also known as endotoxin [317]. LPS 
contributes to the integrity of the outer membrane and protects the cell against bile salts 
and antibiotics[318]. 
In 1879, Louis Pasteur discovered that patients with sepsis had microbes in their 
blood [319]. Soon after, Richard Pfeiffer associated the term endotoxin as an agent 
responsible for causing the fever and shock in animaIs injected with heat-killed Vibrio 
cholerae[320]. By using chemical and biochemical analysis, it was concluded that 
endotoxin was a glucolipid complex[321]. Finally, in the 1960s and early 1970s the 
endotoxin component structures were determined, consisting of lipid A[322], the core 
sugars (R antigen) and the distal O-antigen polysaccharide (0 antigen)[323](Diagram 
1.7). Lipid A portion causes the actions of endotoxin[324], while the R- and O-antigens 
are immunogenic and cause the production of antibodies, useful for antibody-dependent 
phagocytosis. Most studies on the structure and production of LPS have been performed 
using Escherichia coli. E. coli lipid A consists of a disaccharide moiety attached to four 
branched fatty acids by ester linkages (Diagram 1.7)[325]. The core oligosaccharide 
attaches to one of the sugars in the disaccharide. Attached to the core is the 0 antigen, a 
large polymer consisting of repeating oligosaccharide subunits. The 0 polysaccharide 
maintains the hydrophilic nature of LPS molecule. 
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Gill or GalNAc or GleNAc 
Outer core Inner core 
O-antigen Core region Li idA 
Diagram 1.7. LPS is composed oflipid A, a core region and an O-antigen. Lipid A 
is composed of a disaccharide ofbiphosphorylated glucosamine(G1cN). Fattyacids 
are linked to the disaccharide, two of which are branched. One the GlcNs of the 
disaccharide is Iinked to the core region. The inner core is a short chain 6-7 sugar 
residue oligosaccharides consisting of keto-deoxyoctulonate (Kdo) and heptulose 
(Hep). The outer core is composed of more sugars including glucose (Glu), galac-
tose (Gal) and N-acetyl-glucosamine (GleNac). The 0 antigen is a large polymer 
consisting of repeating oligosaccharide subunits made up of 3 to 5 sugars, usually 
Glu, GleNac and and N-acetyl-galactosamine(GalNac). The 0 antigen can be 
highly branched with individual chains varying up to 40 subunits of sugars. 
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1.13 Toll-like Receptor Proteins 
1.13.1 TLR4 Discovery 
In 1965, the tirst steps to determine the identity of the LPS receptor were laid out. 
It was discovered that LPS functioned in an antigen-independent manner not requiring T 
cells or antigen presentation to mediate its effects [326, 327]. A spontaneous mutation 
occurred in the C3H strain of mice forming a substrain designated as C3HlHeJ. These 
mice are tolerant to LPS and have a strong susceptibility to infections[328, 329]. The 
mutation was identified to affect a single genetic locus called Lps [330, 331]. Another 
spontaneous mutation that caused hyporesponsiveness to LPS was discovered in another 
strain of mouse, the C57BL/lOScCr strain[332]. After crossing C3HIHeJ and 
C57BL/lOScCr strains, complementation, the acquisition of LPS sensitivity, was not 
observed, suggesting that LPS sensitivity in both mouse strains resided in the Lps locus. 
Parallel research in fruit flies in the early 1980s leading up to the late 1990s gave 
headway into identification of the gene at the Lps locus. The Toll (meaning "great" in 
German) gene was discovered as part of a set of 12 genes that are involved in establishing 
dorsoventral polarity in embryogenesis of the fruit fly, Drosophila melanogaster[333-
335]. Toll was later found to play an important role in innate immune reactions to 
bacteria and fungi[336-338]. Drosophila Toll cytoplasmic domain was found to have 
high homology with the interleukin-l receptor[339]. By homology searching, the first 
mammalian Toll-like prote in was cloned and designated as Toll/IL-l receptor-like (TIL) 
and was thought to have developmental functions like in fruit flies[340]. In 1997, by 
comparing the sequence of Toll to a human expressed sequence tag (EST) database, 
Medzhitov et al., discovered and cloned a human Toll (hToll) analog [341]. The hToll 
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was also capable of activating nuclear factor-K B (NF-KB) in a biochemical assay, but no 
ligand was discovered. Soon after in a similar process, Rock et al. compared fruit fly 
Toll to EST databases and determined 5 genes with sequences similar to Toll, that were 
designated Toll-like receptors (TLRs) 1 to 5[342]. In this screen TIL was found to be 
TLRI and hToll was found to be TLR4. 
The identity of the Lps locus was only cleared up in genetic studies of the late 
1990s. Before then, a plasma protein was shown to bind to LPS and enhance the 
sensitivity of mononuclear cells to LPS[343-346]. LPS-binding protein (LBP) was 
produced constitutively by the liver and was inducible by LPS challenge. In 1990, 
another molecule essential for LPS sensing was discovered, called CDI4[347]. CDl4 
could be associated with the plasma membrane of cells by a glycosylphosphatidylinositol 
anchor, but it does not span the membrane and it was not clear how signal transduction 
could be triggered by LPS to the interior of the cells. In 1998-1999, through laborious 
genetic screening and physical mapping of the Lps locus in mice, the Tlr4 gene was 
discovered and was shown to be the LPS receptor[348-350]. 
1.13.2 TLR Family and Ligands 
The TLR family is an ancient family of proteins with homologs in insects and 
even in plants[351]. Even if ligands have not been ascribed to them, TLRs play a role as 
PRRs in the innate immune systems leading to responses against pathogens (Table 1.1). 
Ten TLRs are present in humans, but mice have 13[352]. They can associate to form 
dimers, and thus can increase the number of potential ligands that they can bind to. Sorne 
TLRs, especially TLR2 and TLR4, have been shown to bind to several ligands. TLRs are 
expressed in both lymphoid and nonlymphoid tissues, and the pattern of expression varies 
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with the cell type, tissue and species studied[353]. TLRs share several common features 
including an extracellular domain made up of multiple leucine-rich repeats (LRRs), a 
single membrane spanning domain and a highly conserved cytoplasmic signaling domain 
homologous to the IL-I R called a Toll/IL-I R (TIR) domain. The extracellular domain 
LRRs form a horseshoe-shaped solenoid with a broad hydrophobic surface for binding of 
ligands[3 54]. Due to a high conservation of the TIRs in the cytoplasmic domain, IL-l R 
and TLRs use corn mon adaptor proteins for signal transduction cascades. Sorne TLRs can 
bind to endogenous ligands and it is thought that these can serve as danger signaIs to 
mobilize the immune system against tissue damage, but may also contribute to 
auto immune diseases[355]. 
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Table: 1.1 Mammalian Toll-like receptors and their ligands: 
Table summarized from references [353, 355-357] with additional infonnation. 
Toll-like receptor Ligands and potentialligands Reference 
TLRI (with TLR2) Tri-acyllipopeptides (bacteria) [358] 
Soluble factors (Neisseria menin!{itides) 135~ 
TLR2 Peptidoglvcan (Gram-positive bacteria) [360-362] 
Lipoproteinllipopeptides (various pathogens) 1363-368] 
Lipoteichoic acid (Gram-positive bacteria) [362,369] 
Lipoarabinomannan (mycobacteria) [370] 
Modulin (Staphylococcus epidermidis) [371] 
G lycoinositolphospholipids (Trypanosomes) [372] 
Glycolipids (Treponema) 13731 
Porins (Neisseria) [374] 
Zymosan (fungi) [365] 
L yso-phosphatidylserine_(Schistosoma) [3751 
Atypical LPS [376,377] 
Heat shock proteins l endogenous) [378,379] 
HMGB 1 (endogenous) [380] 
TLR3 Double-stranded RNA (virus) [381] 
mRNA (endogenous) [382] 
TLR4 Lipopolvsaccharides, lillid A (Gram-negative bacteril!l _[348,350,360,383-387] 
Taxol (plant) [388-390] 
Protein F (respiratory syncytial virus) 1391J 
Asper!{illus fumigatus hyphae [392] 
HSP60 (Chlamydia) [393,3941 
Envelope proteins (viruses) [395] 
Heat shock proteins (endogenous) [378,379] 
HMGBl (endogenous) _[38Ql 
Fibronectin extra domain A (endogenous) [396] 
Fibrinogen (endogenous) [3971 
Lung surfactant prote in A (endogenous) [398] 
Minimally modified-Iow-density lipoprotein (endogenous) [399] 
Heparan sulfate (endogenous) [400,4011 
Hyaluronan fragments (endogenous) [402,403] 
Saturated fattv acids (endogenous) 14041 
TLR5 Flagellin (bacteria) 1405,406J 
TLR6 (with TLR2) Di-acyllipopeptides (mycoplasma) [407,408] 
Peptidoglycan, zymosan 14091 
TLR7 Single-stranded RNA (viral and synthetic) [410,411] 
Imidazoquinolines (antiviral agents) [412] 
Guanine nucleoside analogs (antiviral agents) [413] 
TLR8 Single-stranded RNA (viral) 14101 
Poly(G)-containing DNA oligonucleotides [414] 
TLR9 CpG DNA (bacteria and Herpes simplex virus) 1415-417~ 
DNA (endogenous) [418-421 ] 
TLRI0 Unknown 
TLR11112 (mice) Uropathogenic Escherichia coli 14221 
Profilin-like molecules from protozoa [423] 
TLR13 (mi ce) Unknown 
LY 64 (RPI05) LPS [424] 
72 
1.13.3 TLR 4 Express ion and Signal Transduction 
TLR4 is expressed on many different cell types including monocytes [ 425], 
macrophages[425], immature dendritic ceIls[426], myeloid dendritic cell [113], mast 
cells[427, 428], neutrophils[425] and eosinophils[429]. B cells express low levels of 
TLR4[430] but express another member of TLR family called RP105[424], which can 
recognize LPS, associate with TLR4 and transduce signaIs to the interior of the cells[431]. 
Low levels of TLR4 mRNA have been shown on T cells by PCR[432], but mouse 
CD4+CD25+ T regulatory cells have been shown to express high levels of TLR4[433]. 
TLR4 is also expressed on structural cells including intestinal epithelial ceIls[ 434], 
pulmonary epithelial ceIls[435, 436], nasal epithelial cells[437], endothelial cells[438], 
vascular smooth muscle cells[ 439], airway smooth muscle ceIls[ 440] and fibroblasts[ 441]. 
Expression levels are variable on the different cell types with cells of the immune system 
expressing the highest levels. In sorne cells, such as intestinal epithelial cells, TLR4 is 
found mostly associated with the Golgi apparatus and expressed at almost undetectable 
levels on the cells surface in normal conditions[442, 443]. 
The LPS receptor complex is very sensitive, being able to recognize most types of 
lipid A molecules at picomolar concentrations[444]. TLR4 is physically associated with 
the prote in MD-2 in its extracellular domain, and MD-2 is essential for binding of LPS 
and activation of TLR4[445-447]. MD-2 associates with TLR4 in the endoplasmic 
reticulum or the cis Golgi, and then the TLR4/MD-2 complex moves to the cell 
surface [ 448]. The CUITent model of LPS cell activation involves either direct binding of 
LPS to CD 14 on the surface of cells, binding of LPS to the soluble form of CD 14 
(sCD14) or binding ofLPS to LBP which transfers LPS to CD14[347, 449, 450]. CD14 
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also has many LRRs forming a horseshoe-like solenoid[451]. Membrane bound CD14 or 
sCDl4 then associates with the TLR4IMD-2 complex on the surface of ce Ils causing LPS 
to bind to TLR4 and activate signal transduction[452, 453]. 
Signal transduction involves association of proteins through domains, 
phosphorylation of proteins by kinases and protease degradation of inhibitors (Diagram 
1.8)[356, 357]. TLR4, like other TLRs and the IL-IR possess a TIR domain. Upon 
binding of its ligand, TLR4 dimerizes and undergoes conformational changes that are 
transmitted to the interior of the cell membrane. Conformational changes cause the 
association of the TIR domain of TLR4 to the TIR domain of the adaptor prote in myeloid 
differentiation primary response gene 88 (MyD88)[454-456]. The N-terminal portion of 
MyD88 possesses a death domain which can, when MyD88 is activated by TLR4, recruit 
the serine/threonine kinase IL-IR-associated kinase 4 (IRAK4) through its own death 
domain[454, 455]. IRAK4 phosphorylates and activates IRAK 1 [457]. IRAK 1 can 
autophosphorylate residues in its N-terminus which enables association with another 
adaptor protein called TNF receptor-associated factor 6 (TRAF6)[458]. IRAK 1 and 
TRAF6 disengage from the receptor and interact at the plasma membrane with a complex 
consisting of the serinelthreonine kinase TGF -p-activated kinase 1 (TAK 1) and the two 
adaptor proteins TAKl- binding protein 1 (TABI) and TAB2[459]. TAB2links TAKI to 
TRAF6 and T AB 1 functions as an activator or T AK 1 [460, 461]. TRAF6 interaction with 
the TAKI complex induces phosphorylation ofTAB2 and TAKI which then translocates 
with TRAF6 and T AB 1 to the cytoplasm. 
The main signal transduction pathways activated by LPS lead to activation of the 
transcription factor NF-KB. The NF-KB family consists of five members including 
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Diagram 1.8. TLR4 like other TLRs is a transmembrane receptor containing a 
leucine rich repeat domain in the extracellular portion that forms a horseshoe shaped 
solenoid. TLR4 is associated with MD-2. CD 14 binds to LPS and transfers it to 
TLR4-MD-2 complex to initiate signal transduction events. TLR4 signal transduc-
tion involves two major pathways. The MyD88-dependent pathway requires the 
MyD88 adaptor protein, causes activation of kinases ultimately leading to phos-
phorylation of IKB and liberation of NF-KB to cause transcription of genes. The 
MyD88-independent pathway also leads to NF-KB activation but with slower kinet-
ics and activation of IRF3 which transcribes genes such as IFN-~. 
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reticuloendotheliosis viral oncogene (REL), p65 (REL-A), REL-B, p50 and p52. These 
proteins homo and heterodimerize, and once active, they associate with NF-KB binding 
sites in the genome to promote the transcription of genes. NF -KB proteins are usually 
sequestered in the cytoplasm by association with members of the inhibitors of KB (lKB) 
family. IKB releases NF-KB wh en it is phosphorylated by the IKB kinase (lKK) complex 
which is composed of IKK-a, IKK-~ and IKK-y proteins[462, 463]. When IKB is 
phosphorylated, it is degraded by the 26S proteasome. In the TLR4 pathway, activated 
TAKl phosphorylates IKK, ultimately leading in NF-KB activation, translocation to the 
nucleus and transcriptional activation of LPS response genes. The TIR-domain-
containing adaptor protein (TIRAP) is an adaptor protein similar to MyD88 and plays an 
essential role in TLR4 signaling [464, 465]. The role which TIRAP plays in signal 
transduction is unclear, but it can associate with TLR4, with MyD88 and is thought to be 
involved in recruitment ofMyD88 to TLR4[357, 464]. 
MyD88-deficient mice are unresponsive to IL-l and microbial components that 
activate TLR2, TLR5, TLR7 and TLR9[356, 357, 466]. In these mice, sorne functions 
are still maintained in response to LPS, albeit at slower kinetics, showing the existence of 
a MyD88-independent pathway[467]. The MyD88-independent pathway can induce 
genes such as the IFN-~ and IFN-y-inducible lOKDa prote in (lP-lO or CXCLlO)[468] 
and cause the maturation of dendritic cells[ 469]. The LPS activation of the MyD88-
independent pathway involves activation of IFN regulatory factor 3 (IRF3)[ 4 70]. IRF3 is 
activated by phosphorylation, which leads to its homodimerization and localization to the 
nucleus, and it is involved in transcription of IFN-~ and IP-lO. The TRAF-family-
member associated activator-binding kinase 1 (TBKl), which are related to IKK, is 
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believed to cause the phosphorylation of IRF3 in TLR4 signal transduction[357, 471, 
472]. Two other adaptors, TIR-domain-containing adaptor prote in inducing IFN-~ 
(TRIF)[473] and TRIF-related adaptor moiecule (TRAM) [474] have TIR domains and 
participate in the MyD88-independent pathway, aithough the precise mechanism is 
unknown. TRAM can associate with TLR4 and may form a bridge to recruit TRIF [475]. 
The MyD88-independent pathway aiso invoives activation of NF-KB, but by siower 
kinetics th an the MyD88-dependent pathway. This pathway aiso invoives TRIF and 
invoives physicai association of the TRIF N-terminus to TRAF6[476, 477]. Recent 
evidence points to interaction of receptor-interacting prote in 1 (RIP1) with TRIF to 
interact with TRAF6 and TAKI to activate NF-KB [478,479]. 
1.13.4 TLR4 regulation 
Infectious agents can affect TLR4 levels. Mycobacterium avium can decrease 
TLR4 mRNA expression in macrophages[ 480]. Respiratory syncytial virus can 
upregulate TLR4 and sensitize airway epitheIiai cells to endotoxin[ 481]. Hepatitis C 
virus can aiso induce mononuclear cell TLR4 expression[ 482]. In areas endemic for 
schistosomiasis, infected chiidren were shown to have decreased responses to LPS[444]. 
In contrast, in an animal model, helminth infections were shown to upregulate TLR4 
levels on mucosai T cells[483]. Even bacteriai products can modulate TLR4 Ieveis. LPS 
itself can Iead to an internalization of the TLR4/MD-2 compIex[484], but has no 
significant effect on the level of expression in human monocytes[485]. In contrast, LPS 
can induce upregulation of TLR4 mRNA expression in hum an vascular endotheliai cells 
and airway smooth muscle cells [440,486]. Other bacteriai products, such as toxic shock 
syndrome toxin-l (TSST -1) or staphylococcal endotoxin A (SEA) can upregulate both 
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TLR4 and MD-2 mRNA and surface expression[485]. It would seem that most infections 
can lead to an upregulation ofTLR4. 
Cytokines can also play a role in TLR4 regulation. IL-l ~ and TNF -u can induce 
the expression of TLR4 mRNA in airway smooth muscle cells[ 440]. Colony stimulating 
factor-l (CSF-l) can enhance LPS responsiveness of macrophages[487]. The Thl 
cytokine IFN-y can prime human monocytes and macrophages to respond to LPS by 
upregulating their levels of expression of TLR4[488]. It seems that Th2 cytokines and 
factors also have an effect on TLR4. As mentioned above, IL-4 and IL-13 can both 
inhibit LPS responsiveness and are protective against the development of sepsis (section 
1.12.2). It has been shown that the Th2 cytokine IL-4 decreases surface expression of 
TLR4 on human peripheral blood monocytes[314, 489]. Protein expression was affected 
but the mechanism for this downregulation was not determined. The interleukin 1 
receptor-like 1 (ILIRL1), is a receptor expressed by fibroblasts, mast cells and Th2 cells 
but not Thl cells[490]. Triggering of ILIRLI leads to downregulation of TLR4 in 
mice[491, 492], and in humans[493]. The ligand for ILIRLI has recently been 
determined to be IL-33, which has a significant role to play in inducing Th2 
cytokines[ 494, 495]. 
Few studies have been performed on the transcriptional regulators of TLR4. The 
promoter and transcription factor involved in basal transcription have been described by 
Rehli and colleagues[496]. Upstream of the promoter, an IFN response factor (lRF) 
binding site and an Ets binding site were found to be constitutively associated with PU.I 
protein and IFN consensus sequence binding protein. These proteins are thought to drive 
basal transcription for TLR4 in myeloid cells. In another study, Ishida et al. 
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demonstrated that TLR4 can be downregulated by reactive oxygen species in hypoxic 
conditions[ 497]. This was caused by decreased translocation of the transcription factor 
activator prote in 1 (AP-l) to the nucleus and binding to an AP-l binding site upstream of 
the TLR4 promoter. 
1.13.5 Association ofTLR4 with Atopy 
TLRs are part of the innate immune system and are passed on to progeny with 
little if no genetic change. Genetic studies have been conducted to determine whether 
specific single nucleotide polymorphisms in the TLR4 gene are associated with atopy. If 
polymorphisms are present in the gene, they may affect the expression of TLR4, the 
ability of TLR4 to recognize LPS or to initiate signal transduction events. Two 
polymorphisms, an A to G substitution at nucleotide 896 (ASp299 to Gly299) and a C to T 
substitution at nucleotide 1196 (Thr399 to né99) have been associated in causing reduced 
function of TLR4[498-500]. Although no association was seen with asthma and the 
ASp299 to Gly299 substitution, this polymorphism is highly associated with worse atopy 
severity scores[501]. Other polymorphisms have shown no link with atopic 
symptoms[502]. More studies need to be performed to better understand if there is a link 
between atopy and TLR4 polymorphisms, but these studies are difficult to perform due to 
the large part that environmental factors play in allergy development. 
Lauener et al. have directly compared the expression of TLR4 mRNA between 
children from a farming environment versus children from a non-farming 
environment[503]. TLR2 and CD14 but not TLR4 levels were significantly higher in 
children raised on farms. However, in this study, children were not compared based on 
their level of atopy or levels of exposure to TLR ligands. In a recent study, levels of 
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TLR4, have been eompared between allergie and non-allergie mothers and the eord blood 
from their ehildren[504]. It was found that maternaI allergies were associated with 
significantly lower levels of TLR4 mRNA and prote in surface expression in maternai 
blood and cord blood samples. No studies have been performed to compare TLR4 levels 
in allergie and non-allergic adults. 
1. 14 Rationale 
Atopic diseases are associated with the production of Th2 cytokines and 
inflammatory cells, and are believed to be caused by a lack of stimulation in early life. 
According to the hygiene hypothesis, LPS can trigger maturation of the immune system, 
promoting Th 1 immune responses and T regulatory immune responses to counterbalance 
the Th2 immune response. Previous studies have shown that LPS can cause the 
production of Th 1 cytokines and inflammatory cell proliferation in the nasal mucosa of 
non-atopic children[293]. In addition, large amounts of T cells that expressed CD25 and 
IL-IO were present after stimulation of the nasal tissue of the children with LPS. 
Whether these factors or cells play a role in controlling allergen-induced responses in 
children needs to be determined. Children may have the plasticity to respond to LPS and 
to develop anti-inflammatory reactions against allergens; it is possible that adults have 
lost these anti-inflammatory mechanisms during the development of allergie 
inflammation. Th2 cytokines and ST AT6 can reduce LPS induced sepsis, and long-
standing Th2 inflammation in atopic adults may reduce LPS responsiveness and its 
potential prote ct ive effects. 
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1.15 Hypothesis 
Firstly, it IS hypothesized that LPS could prevent allergen induced Th2 
inflammation within the nasal mucosa of children with atopy and this Th2 regulation is 
provided either by induction of Th1 cytokines or IL-lO(Diagram 1.9). In addition, the 
responses of children would be different from adults who are allergic. Secondly, it is 
hypothesized that Th2 cytokines, such as IL-4, have a role in modifying the responses to 
LPS through the downregulation of TLR4 via ST AT6(Diagram 1.10). 
1.16 Aims 
1.16.1 General Aims: 
The general aim of this thesis was to examine the local inflammatory events that 
occur in the nasal mucosa of children in the presence of allergen and LPS. This is 
followed by a comparison between atopic adults and atopic children. If a difference is 
observed, then an investigation into possible mechanism would be performed. 
1.16.2 Specifie aims: 
The specific aims of this thesis were: 
1. To assess the effects of LPS on ex vivo allergen challenge, using explanted nasal 
mucosal tissue, from atopic children, and then to me as ure the inflammatory cell numbers 
and mRNA for inflammatory cytokines. If Th 1 cytokines or IL-10 are produced in the 
mucosa, the anti-inflammatory effects of these will be evaluated by incubating the tissue 
with neutralizing antibodies. 
2. To compare the effects of LPS in adults and children, to determine whether adults 
with atopy have lost protective anti-inflammatory mechanisms present in children. To 
determine whether LPS can cause proliferation of CD3 positive T cells in the nasal 
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mucosa ofchildren, to determine ifthese cells also express TLR4 and can produce IL-ID, 
and to determine if a similar population exists in atopic and non-atopic adults. 
3. If levels of TLR4 are different between adults and children, or between atopic and 
non-atopic adults, tirst to determine if IL-4 can affect the LPS response and the 
expression of TLR4. Second, if IL-4 can affect TLR4 levels, to determine whether 
associated transcription factors, su ch as STAT6 play a role in regulating the expression of 
TLR4. Finally, to determine if Th2 cytokines can affect the levels of TLR4 expression in 
monocytes and T cells from children. 
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Diagram 1.9. ft is hypothesized that LPS can prevent allergen-induced Th2 cyto-
kine production by inducing the production of IFN-y, IL-l 0 and IL-I2. This action 
would be by activation ofTLR4 present on antigen presenting cells, but also directly 
on T-regulatory (Treg) cells in the nasal mucosa of children. These mechanisms 
may be absent in adults. 
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Diagram 1.10. It is hypothesized that IL-4 plays a raIe in modifying the response to 
LPS by downregulation of TLR4 via the activation of STAT6. This would affect 
many cell types including monocytes and T cells in children and adults. 
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Chaoter 2: Materials and Methods 
2.0 Summary of Experimental Design 
To address the questions put forward in this thesis, two major studies were 
conducted. In the first study, human subjects were recruited, and immune responses in 
nasal biopsies from the subjects were investigated. Inflammatory responses were a result 
of ex vivo exposure of the nasal tissue to specific allergens and bacterial LPS. 
Inflammatory cell numbers and cytokine mRNA expression was measured. Tissue was 
also incubated with antibodies that block cytokine activity to determine how 
inflammatory responses are regulated. Inflammatory responses were compared between 
atopic and non-atopic individuals and between children and adults. AdditionaIly, TLR4 
expression in the tissue was measured and was localized to certain cell types in children. 
The experiments performed in the first studies inc1ude culture and stimulation of nasal 
explants, immunohistochemistry , in situ hybridization and fluorescent 
immunohistochemistry . 
In the second study, TLR4 regulation was investigated. Firstly, an in vitro cell 
model was used to observe the effects of IL-4 on TLR4 transcription and protein 
expreSSIOn. The experiments involved cell culture, real-time quantitative PCR (QPCR), 
flow cytometry and the luciferase assay. Secondly we investigated the mechanism by 
which IL-4 mediated these effects. These experiments involved real-time QPCR, protein 
overexpression, luciferase assays and chromatin immunoprecipitation. Finally, we 
wanted to determine wh ether comparable effects were seen in cells taken from the 
peripheral blood of children. In this last part, experiments involved density gradient 
centrifugation of cells, cell culture and flow cytometry. The experiments conducted in the 
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studies yielded enough data to allow us to answer the proposed hypothesises and to fonn 
a conclusion. 
2.1 Nasal Mucosa Expiant Model Experiments 
2.1.1 Patient Characteristics 
Twenty-two children and seventeen adults were recruited from the local hospitals. 
Fifteen atopic children (3.2±0.4 years old) and seven non-atopic children (3.8±O·7 years 
old) of both sexes were recruited from the ear, nose, and throat clinic of the Montreal 
Children's Hospital (Montreal, Canada). Atopy was confinned by skin-prick testing, 
where drops containing corn mon allergens including housedust mite, grass pollen, 
ragweed extract, and cat and dog antigens were placed on the foreann of the subject and 
scratched into the skin using a pointed tool. A wheal and tlare reaction was deemed 
positive if greater than 5mm in diameter. Non-atopic children had no history of asthma 
or other allergie diseases and had negative wheal and tlare upon skin-prick testing. Ten 
adults with intennittent allergie rhinitis (40.4±5.3 years old) and seven nonatopic adults 
(35.2±6.8) were recruited from the Notre-Dame Hospital (Montreal) and the Jewish 
General Hospital (Montreal). Nasal mucosal tissue (approximately 5mm in diameter) was 
resected from the inferior turbinate of adults and children undergoing tonsillectomy, 
adenoidectomy, nasal septal surgery, or sinus surgery. Ali children and adults were 
asymptomatic at the time that the samples were taken; biopsies were also done outside of 
the ragweed season. Individuals were excluded if they had had any viral or bacterial 
infections during the month before surgery or were taking anti-intlammatory medication 
regularly. Informed consent was obtained from parents of children or from adult 
participants before the procedure. The study was approved by the ethics committees of 
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the McGill University Health and Research Centre and the Centre hospitalier de 
l'Université de Montréal. 
2.1.2 Tissue Culture Media 
Freshly prepared bicarbonate-buffered culture medium (BCM) was used for the 
transport, culture and challenge of the explanted mucosal tissue. This media was 
specially designed to culture resected biopsies of animal airways[505, 506] and human 
tissue[507]. Basic BCM is composed of minimal essential medium (MEM) powder, 
Earl's salts, L-glutamine and sodium bicarbonate in ultra-purified distilled water. 
20mLlL of 50X MEM amino acid solution, 10mLiL of 100mM sodium pyruvate, 
lOmLiL of lOOX MEM vitamin solution, O.l~g/mL of bovine insulin, O.l~g/mL vitam in 
A, 0.1 ~g1mL of hydrocortisone and 50~g1mL of gentamycin were added to the basic 
BCM solution. After mixing, the pH of the solution was adjusted to a pH of 7.25 
(physiologie pH) and then was filter sterilized with a vacuum. Each biopsy sample was 
placed in bicarbonate-buffered culture medium immediately after excision and 
transported to the Meakins-Christie Laboratories for culture. The time between removal 
of tissue and culture of nasal mucosa was less than 1 hour in aIl cases. 
2.1.3 Nasa! Expiant Culture and Stimulation 
Explanted biopsies were eut in evenly sized pieces and each piece was placed on a 
30mm filtered-well insert (Millicell CM, Millipore Corp) with a O.4~m pore diameter 
within a six-weIl culture plate containing 2mL of BCM. The filter-well insert allowed 
the tissue to be bathed in BCM but not to be immersed. As the nasal epithelium is 
normally in contact with atmospheric air, use of the filtered-well inserts more closely 
mimicked in vivo conditions. Each weIl contained either BCM, BCM with an allergen 
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specifie for the individual patient's atopy, BCM with O.1llg/mL of LPS from Escherichia 
coli serotype 026:B6 (Sigma-Aldrich) or BCM with alIergen combined with LPS. The 
dose of LPS used was determined as the optimum dose for the nasal expIant model in a 
previous report[293]. AlI tissue cultures were incubated at 37°C in a tissue and celI 
culture incubator in 5% CO2 and 95% air for 24 hours. 
Ten of the fifteen atopic children had a positive skin prick test for house dust mite 
allergen (Dermatophagoides farinae), two were positive to ragweed alIergen (Ambrosia 
artemisiifolia) and two were positive for dog dander allergen and one to cat alIergen. AlI 
atopic adults were sensitive to ragweed alIergen. The amount of alIergen used for 
stimulation was a concentration of 2000 prote in nitrogen units (PNU)/mL for D farinae, 
1000 PNU/mL for ragweed, and 10 PNU/mL for dog or cat alIergen. 
Depending on the method used for purification of LPS, significant levels of 
contaminants may be included, and these may have effects on other TLRs[508-510]. A 
purity of greater than 99.9% can be achieved by performing phenolchloroform-petroleum 
ether extraction followed by electrodialysis and conversion of the LPS into a uniform 
salt[511, 512]. A subset of biopsies from three atopic children and from three atopic 
adults was cultured with highly purified LPS from E. coli serotype R515 (Alexis 
BiochemicaIs). This preparation is a strong activator of TLR4 but has no effect on other 
TLRs, and was used to show that effects were mediated by TLR4 aione. 
To examine the functionai role of specifie cytokines, in four experiments, samples 
of atopic mucosa from chiidren were aiso incubated with neutralizing antibodies. 
Antibodies used were specific at blocking the effects of interleukin-12 (O.9)lg/mL), 
interleukin-lO (O.03)lg/mL), and IFN-y (O.06)lg/mL). The anti-IL-12 antibody was a 
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purified mouse IgOI monoclonal antibody from a mouse hybridoma and was specifie for 
human IL-12 p35/p40 heterodimer (R&D Systems; clone 24910). The anti-IL-1O 
antibody was a purified mouse Ig028 monoclonal antibody from a mouse hybridoma 
(R&D Systems; clone 23738). The anti-IFN-y antibody was a purified mouse IgG2A 
monoclonal antibody from a mouse hybridoma (R&D Systems; clone 25718). 
Concentrations for each antibody used were based on experiments performed by the 
manufacturer where the dose used could cause 50% neutralization in activity for each 
respective cytokine. Control antibodies for each blocking antibody were used, and these 
were matched by isotype and concentration. 
2.1.4 Tissue Processing 
For this part of the study, the tissue was processed for the examination of cellular 
prote in expression and mRNA, using the techniques of immunohistochemistry (Section 
2.1.13) and in situ hybridization(Section 2.1.7), respectively. Proliferation of cells 
within the tissue was measured using the 5-bromo-2' -deoxyuridine (BrdU) incorporation 
as say (Section 2.1.16). Co-Iocalization of different proteins was determined by using 
fluorescent immunohistochemistry (Section 2.1.15). Therefore, after culturing, the tissue 
was processed according to standard protocols established for the respective techniques. 
2.1.5 Fixation 
Fixation of the tissues was performed as previously described[513]. Fixation 
prior to freezing of the tissue has the advantage of maximally retaining the RNA within 
the tissue and preserving its morphology[ 514]. Freshly prepared 4% paraformaldehyde 
(PF) dissolved in phosphate buffered saline (PBS) has proven to be the best compromise 
for permeability of probes, preservation and maintainenance of cellular morphology. 
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Before addition of PF, PBS is treated with 0.1 % diethylpyrocarbonate (DEPC) for at least 
1 hour at 37°C to inactivate RNAses. The DEPC-PBS is autoclaved for at least 15 
minutes to inactivate DEPC, converting it to carbon dioxide and ethanol. PF powder is 
dissolved to a concentration of 4% in PBS at a temperature between 55-66°C in a fume 
hood. The solution was not allowed to rise above 60°C, as this would reduce the activity 
of PF. Biopsies were placed in the 4% PF solution for two hours and then washed two 
times with PBS sucrose (15%) solution 1 hour and ovemight in a final wash. The washes 
removed excess PF, preventing over-fixation, and removed excess water from the tissue. 
This prevents the tissue from cracking during the freezing process as water would expand 
as it freezes. 
2.1.6 Blocking and Sectioning 
Multiple embedding media exists for blocking tissue. For this study, optimal 
cutting temperature (OCT; Tissue-Tek) media was found suitable for in situ hybridization, 
immunohistochemistry and fluorescent immunohistochemistry. When blocking the nasal 
biopsy, care must be given in orientating the tissue so that sections of the block contain 
both the epithelial and submucosal layers. The fixed tissue is placed in a droplet of OCT 
on a small square of cardboard paper using forceps. The paper is th en submerged in 
isopentane cooled with liquid nitrogen. The OCT immediately freezes over the biopsy. 
For in situ hybridization, the biopsy blocks are sectioned using a cryostat at a 
thickness of 5 microns. The glass slides used to collect the section were coated with 
poly-L-Iysine (PLL) solution before use. PLL gives the slides a positive charge causing 
the adherence of the tissue by ionic bonding[515]. After sectioning, the slides were 
incubated ovemight at 37°C to dehydrate the tissue and maximize adherence. It is 
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important that the tissue be firmly adhered to the slide due to the rigorousness of the in 
situ hybridization protocol which consists of multiple washes and enzymatic treatments. 
After incubation, the slides were kept at -80°C to maximally preserve the RNA until use. 
For immunohistochemistry and fluorescent immunohistochemistry, biopsy blocks 
were also cryostat sectioned at a thickness of 5 microns. Slides were immersed in a 
60/40 acetone/methanol solution for no longer than 7 minutes to fix the tissue onto the 
slide. PLL coated slides were not required as immunohistochemistry does not have as 
many washes as in situ hybridization and does not require enzymatic treatment. Fixation 
in acetone/methanol dehydrates the tissue; therefore, ovemight incubation was not 
necessary. Slides for immunohistochemistry were stored at -20°C to preserve proteins 
until use. 
2.1.7 Hybridization Probe Constructions 
In this thesis, antisense RNA probes that were radioactively Iabelled were 
prepared to measure the cytokine mRNAs. Probes were derived from cDNA Iibraries or 
reverse transcription-PCR (RT-PCR) from native mRNA. The probe DNA were cloned 
into different vectors, which were replicated in bacteria, extracted with the maxiprep 
protocols (Qiagen), Iinearized with different restriction enzymes and transcribed in vitro. 
Antisense probes were used to detect the cytokine mRNAs and sense probes, transcribed 
from the same plasmids, were used as negative controls for the hybridization. See table 
2.1 for plasmid constructs and enzymes used to generate the sense and antisense probes. 
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Table 2.1 Plasmid constructs and enzymes for in situ hybridization 
Cloned Restriction Transcription Restriction Transcription 
enzyme for enzyme for Probe fragment Vector 
antisense antisense enzyme for enzyme for 
size probe probe sense probe sense probe 
IL-4 318 pGEM-T Sphl T7 EcoRI Sp6 
IL-5 570 pGEM-4 Xbal Sp6 BamHl T7 
IL-IO 880 pGEM-7 Sphl Sp6 HindIII T7 
IL-13 1282 Bluescript Notl T7 BamHl T3 
IFN-y 1213 pGEM-I Xbal T7 Smal Sp6 
IL-12p35 NIA pGEM-3 Sphl T7 HinclI Sp6 
1 Glaxo Wellcome Biomedical Research, Geneva, Switzerland 
2 Cloned into pcDSRa from cDNA library and subcloned into pGEM-7 vector [516] 
3 Cloned into pSE 1 vector from cDNA library and subcloned into Bluescript vector (ref 177) 
4 Cloned into pBR322 vector and subcloned into pGEM-l [517] 
5 Cloned into pGEM-3 [518] 
Source 
1 
1 
2 
3 
4 
5 
For each linearization, plasmid was digested with the restriction enzyme and 
appropriate salt buffer. Plasmids were digested ovemight at 37°C and DNA gel 
electrophoresis of a sample was performed to determine if the linearization was complete. 
After linearization, the template DNA was extracted using phenol chloroform, followed 
by precipitation with 4M sodium acetate solution and ice cold ethanol at -20°C ovemight 
or for 2 hours at -80°C. The DNA was centrifuged and vacuum dried and resuspended in 
DEPC-treated RNase-free water. 
2.1.8 ln Vitro Transcription 
1.01lg of linearized plasmid was added to 10111 of 5X transcription buffer (200mM 
Tris-HCl; pH 7.5, 20mM MgCh, !OmM spermidine, 5mM NaCI), !OOmM DTT, 25U/mL 
of ribonuclease inhibitor (to reduce degradation of probe transcripts), nucleotide mixture 
(2.5IlM of rATP, rCTP, rGTP), 25 mCu of 35S_rUTP and !O units of specifie RNA 
polymerase (see Table 2.1). The mixture was incubated for 60 minutes in a 37°C water 
bath. RNase-free DNase was added after incubation to degrade the plasmid. The probe 
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was extracted from unincorporated nucleotides by addition of 1 O~glmL of tRNA, 150~L 
of 4M NaCI and phenol-chloroform mixture. After centrifugation at 12,000g, the 
aqueous phase was removed and extracted with an equal volume of chloroform to remove 
any residual phenol. The aqueous phase was treated with 1 00~1 of 7M ammonium 
acetate and 750~1 of co Id absolute ethanol and the probe was precipitated at -20°C 
ovemight. The mixture was centrifuged, the supematant was removed and was 
centrifuged and vacuum dried. The pellet was resuspended in DEPC-treated RNase-free 
water. Incorporation of 35S into the riboprobe was assessed using a J3-emission counter 
by placing 1 ~l of probe into 5mL of scintillation solution to determine the total counts 
per minutes (cpm). Probes used for in situ hyrbidization were always greater than 
1.0X106 cpm. 
2.1.9 Pre-hybridization 
It is important to prepare the tissue sections for in situ hybridization by 
permeabilizing the cell membranes to allow efficient probe entry and to rem ove proteins 
which could bind non-specifically to the probe[519, 520]. CelI surface proteins were 
removed and membranes permeabilized by immersing the slides for 5 minutes in O.lM 
glycine/PBS and then 0.3% Triton-X-100IPBS solution. Intracellular proteins were 
degraded by applying a solution of l~g/mL ofproteinase K in lM Tris-HCl (pH 8.0) and 
0.5M EDTA and PBS for 20 minutes at 37°C. Further permeabilization and fixation of 
nucleic acids was performed by immersing the slides in 4% PF-PBS solution for 5 
minutes. Non-specifie binding was reduced by immersing the slides in 0.25% acetic 
anhydride and O.IM triethanolamide for 10 minutes at 37°C followed by immersion in 
O.IM N-ethylmalamide and O.IM iodoacetamide for 20 minutes at 37°C. Tissue was 
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stabilized by submersion in 50% deionizing formamide in 4X standard saline citrate 
(SSC) solution for IS minutes at 37°C. An SSC (IX) solution is composed of ISOmM 
sodium chloride and ISmM sodium citrate. Slides were finally dehydrated by immersion 
in increasing concentrations of ethanol (70%, 90%, and 100%) for S minutes each and 
were air dried for 2 hours. 
2.1.10 Hybridization 
Radiolabelled in situ hybridization was performed as previously described[SI9, 
S20]. Hybridization buffer (90% of total) was composed of SO% deionizing formamide, 
20% Oenhardt's solution (BSA, FicolI, and polyvinyl-pyrolidone), 10% dextran sulphate, 
0.5% sodium pyrophosphate, 0.5% SOS and 9% of 100mM OTT. To the hybridization 
buffer, 0.75Xl06 cpmlsection of riboprobe diluted in lOmM OTT (10% of total) was 
added. Each slide was incubated with ISIlL of the complete solution and covered with 
dimethyldichlorosilane-coated coverslips. Slides were hybridized overnight at 42°C in a 
humid cham ber containing SSC solution. The humid cham ber prevents evaporation of 
the hybridization/probe solution. 
2.1.11 Post-hybridization 
AlI washes were performed by immersion the slides in a dish containing wash 
solutions for 20 minutes in a 42°C water bath. Slides were dipped in 4X SSC to remove 
the coverslip from the slides. The slides were then washed by three immersions in 4X 
SSc. The higher temperature and high salt concentration helps remove non-specifie 
binding of the probes to the sample. After the washes, ISIlL of 20llg/mL of RNase A 
dissolved in 4M NaCI, lM Tris and O.SM EOTA was added. The RNase A de grades any 
single stranded RNA, which includes unbound probe and other RNA species, but not 
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double-stranded probe RNA complexes. After RNase A treatment, the sections were 
washed with decreasing concentrations of SSC (2X, IX, 0.5X and O.IX). After the 
washes, the slides were dehydrated by immersion in increasing concentrations of ethanol 
(70%,90%, 100%) containing 0.3% acetic anhydride for 10 minutes each. 
2. J. J 2 Autoradiography 
To visualize cRNA probe binding to mRNA, the slides were dipped in liquid 
photographic emulsion in the dark and left to dry overnight in complete darkness. 
Exposure of the emulsion took place in light-proof sealed boxes at 4°C for 10-15 days. 
Slides were developed un der a red light using Kodak D-19 (Eastman Kodak) developing 
solution for 3 minutes and a half with gentle agitation. The reaction was stopped by 
placing the slides in water. Fixation of the developing solution was performed by 
immersing the slides in Rapid Fixer solution for 5 minutes and then rinsing with water for 
20 minutes. Using a razor blade, excess emulsion was scraped away. Slides were 
counterstained with haematoxylin, a blue coloured basic dye that combines with acidic 
substances such as nucleic acids. This creates a contrast for histological analysis by light 
microscopy. Slides were dehydrated using increasing concentrations of ethanol (70%, 
90%, and 100%) and finally two five minute immersions in xylene. Coverslips were 
affixed to the slides by using entellan. The slides were then viewed by light microscopy 
and positive hybridization is observed as a cluster of small black silver grains over 
counterstained cells. A positive signal was viewed significant accumulation of sil ver 
grains over cells compared to the sense control. 
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2. J. J 3 Immunohistochemistry 
To detect levels of specific inflammatory cells within the tissue, 
immunohistochemistry was performed on the frozen sections. Sections were hydrated 
in Tris buffered saline (TBS) and then incubated with a commercial serum-free universal 
blocking solution (DAKO) for 15 minutes at room temperature. This solution is a 
mixture of 0.25% case in in PBS, a stabilizing protein and 15mM sodium azide. Casein is 
a hydrophilic protein which can reduce non-specific binding of antibodies to the tissue, 
and eliminates the need to use serum for blocking[521, 522]. AlI antibodies used for 
immunohistochemistry were diluted in a commercially available antibody diluent 
(DAKO), composed of 50mM Tris-HCl, 0.1 % Tween, 15mM sodium azide and 
stabilizing proteins that reduce background staining. This antibody diluent is compatible 
with both polyclonal and monoclonal antibodies. 
Table 2.2 Primaries antibodies for immunohistochemistry 
Antibody Supplier Clone Isotype Species MonoclonallPolyclonal Dilution 
CD68 DAKO EBMll IgOI mouse Monoclonal 1/50 
MBP DAKO BMKI3 IgOI mouse Monoclonal 1/30 
Elastase DAKO NP57 IgGi mouse Monoclonal 1/30 
Tryptase Cedarlane AAI IgOI mouse Monoclonal 1/250 
CD3 DAKO T3-4B5 IgOI mouse Monoclonal 1/100 
CD25 DAKO ACT-I IgOI mouse Monoclonal 1/5 
IL-5 DAKO 14611 IgG mouse Monoclonal 1/25 
IL-12 Santa Cruz 24910 IgGi mouse Monoclonal 1/100 
IL-IO DAKO 23738 IgGl mouse Monoclonal 1/100 
IFN-g R&D 25718 Ig02a mouse Monoclonal 1/50 
IL-2 R&D --- IgO goat Polyclonal 1/25 
TLR4 Santa Cruz --- IgG rabbit Polyclonal III 0 
The alkaline phosphatase anti-alkaline phosphatase (APAAP) 
immunohistochemistry technique was used for markers that were detected with primary 
antibodies derived from mice[523]. Primary antibody characteristics and concentrations 
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used are in Table 2.2. Sections were incubated with 45 to 60J.1L of the primary antibody 
solution and incubated in a humid chamber ovemight at 4°C. The following day, slides 
were washed with two 5 minute washes in TBS. After the washes, 45 to 60J.1L of rabbit 
anti-mouse polyclonal IgG (DAKO, 1/10 in diluent) was added for 30 minutes at room 
temperature. The slides were washed twice again with TBS for 5 minutes. 45 to 60J.1L of 
a mixture of mouse monoclonal anti-alkaline phosphatase (DAKO, clone APIB9) and 
calf intestinal alkaline phosphatase (DAKO, 1/60 in diluent) were added for 30 minutes at 
room temperature and washed twice with TBS. To visualize the APAAP complexes, 
slides were incubated for a maximum of 20 minutes with 0.5mg/mL of fast red 
chromagen (Sigma) dissolved in a O.1M Tris solution (pH 8.2) ofO.5mM napthol AS-MX 
phosphate, 2% dimethylformamide, and 1 mM levamisole. Alkaline phosphatase forms 
red precipitates over the APAAP complexes, which are visible by light microscopy. 
Slides were counterstained with haematoxylin, a mounting agent was added and 
coverslips were glued on to the slides using entellan. 
IL-2 immunohistochemistry was performed by adding the primary antibody 
(Table 2.2) ovemight at 4°C. The slides were washed and a secondary biotinylated rabbit 
anti-goat polyclonal antibody (DAKO) was added for 30 minutes at room temperature, 
and washed twice with TBS. Streptavidin-alkaline phosphatase (DAKO, diluted 1/200) 
was added to bind to the biotinylated secondary antibodies. After washes, the antibody 
complexes were stained using fast red similarly to the AP AAP technique. 
TLR4 immunohistochemistry was performed by adding the primary antibody 
(Table 2.2) ovemight at 4°C. The si ides were washed and a secondary biotinylated swine 
anti-rabbit polyclonal antibody (DAKO, diluted 1/300) was added for 30 minutes at room 
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temperature, and washed twice with TBS. Streptavidin-alkaline phosphatase (DAKO, 
diluted 1/200) was added to bind to the biotinylated secondary antibodies. After washes 
the antibody complexes were stained using fast red similarly to the APAAP technique. 
After cover slipping, red positive cells were enumerated using light microscopy. 
The primary antibody was substituted with an isotype and species matched irrelevant 
antibody for the negative control of the immunohistochemistry. 
2.1.14 Light Microscopy 
For in situ hybridization and immunohistochemistry, positive cells were counted 
by two observers unaware of the experimental origin using a light microscope with 400X 
magnification and an eyepiece with a grid attachment. In either case, it is not possible to 
quantify the actual number of mRNA copies or protein molecules detected; thus, positive 
cells were counted, and this technique is referred to as point counting. In the airway 
epithelium and subepithelium, the number of positive cells was averaged from six to 
eight random, non-overlapping fields and expressed as the mean number of positive cells 
per field. Inter-observer variability was determined to be less than 10%. 
2.1.15 Fluorescence Immunohistochemistry 
Fluorescent immunohistochemistry was used to examme colocalization of 
different markers. Slides were incubated with serum-free universal blocking solution, 
washed and different combinations of antibodies were applied. To examine TLR4 
positivity on T-cells, siides were incubated with R-phycoerythrin-labelled goat polyclonal 
anti-CD3 (Cedarlane, undiluted) for 30 minutes at room temperature, washed twice with 
TBS, and incubated with fluorescein isothiocyanate (FITC)-labelled monoclonal mouse 
anti-TLR4 (Santa Cruz, clone HTA125, undiluted) for 30 minutes. A similar protocol 
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was used to examine whether TLR4 positive cells contained IL-lO. For this stain instead 
of anti-CD3 antibody, R-phycoerythrin-Iabelled mouse monoclonal anti-IL-10 (Cedarlane, 
clone A5-4, diluted 1/25) antibody was used. The expression of cells positive for CD4 
and CD25 was examined by using allophycocyanin labelled mouse monoclonal anti-CD4 
(BD Pharmingen, clone L200, diluted 1/60) followed by incubation with FITC-Iabelled 
mouse monoclonal anti-CD25 (BD Pharmingen, clone M-A251, diluted 1/50). After 
addition of the antibodies the si ides were washed and covered with PermaFIuor 
(Shandon) mounting media and coyer slipped before analysis using a fluorescent 
microscope (see Section 2.1.17). 
2.1.16 BrdU Cel! Proliferation Assay 
Proliferation of cells in response to LPS within the tissue was studied using BrdU 
uptake technique[524, 525]. Cell proliferation was studied by addition of BrdU (Roche 
Diagnostics) to the BCM or BCM with 0.1 J.!g/mL of liposaccharide, and the tissue was 
cultured for 24 hours. After incubation, tissue was fixed, blocked in OCT, and sectioned 
as described above. The tissue was incubated with FITC-Iabelled mouse BrdU specifie 
antibodies (clone BMG 6H8; Roche Diagnostics) for 30 minutes at 37°C to determine 
cellular incorporation of BrdU. Slides were washed three times with PBS. Slides were 
covered with PermaFluor mounting medium, coverslipped and evaluated using a 
fluorescence microscope. 
2.1.17 Fluorescence Microscopy 
Slides stained for fluorescent immunohistochemistry or for BrdU cell 
proliferation assay were viewed at 660X magnification using a fluorescence microscope. 
Fluorescent dyes absorb light at high energy and a certain wavelength. Sorne of the 
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energy is converted into heat, but sorne of the energy is released as a photon at a larger 
wavelength than the wavelength of the light absorbed. FITC produces green fluorescence, 
R-phycoerythrin produces red fluorescence and allophycocyanin produces deep red 
fluorescence. When the green and red fluorescence are overlapped with ImageJ software 
(National Institutes of Health), of co-Iocalization of antibodies produces a yellow signal. 
Immunofluorescence for BrdU was semiquantified by use of ImageJ software and 
expressed in fluorescent cells per field. 
2.1.18 Statistics 
Analysis was performed using the statistical software package, Systat version 10 
(Systat Software Inc.). Immunohistochemistry and in situ hybridization results were 
evaluated similarly. For each marker studied, such as cytokine mRNA or particular cell 
type, a two-way ANOV A model was performed with treatment (BCM, LPS, allergen and 
allergen plus LPS) as the factor of interest and with the participant evaluated as the 
blocking factor. This model shows if a difference exists between the different treatments 
among the participants. A post-hoc Dunnett's many-to-one test was used to compare the 
stimulation conditions to the baseline. This was to determine wh ether the control (BeM) 
was different from aIl the stimulations. If a difference was seen using the Dunnett's test, 
it was be determined where it lies by using a post-hoc Tukey's test. P values less th an 
0.05 were considered as being significant. 
2.2 Cell Line Model Experiments 
2.2.1 U-937 Cel! Culture Media 
Media for cell culture was based on Roswell Park Memorial Institute formulation 
1640 (RPMI-1640) basic media used for the culture ofperipheral blood leukocytes[526]. 
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RPMI-1640 is bicarbonate-buffered, contains essential amino acids, salts, vitamins, and 
sugars for growth. RPMI-1640 with 2mM L-glutamine, 1.5g/L sodium bicarbonate was 
supplemented as per recommend by the ATCC for optimal growth of U-937 cells. The 
final solution contained 10% fetal calf serum, 10mM hydroxyethylpiperazine 
ethanesulfonic acid (HEPES) buffer, and 1.0mM sodium pyruvate. 10mLiL of 100X 
penicillinlstreptomycin antibiotic solution was added to prevent bacterial growth during 
culture. The complete RPMI culture media was filter sterilized using a vacuum. U-937 
cell cultures were maintained between 0.25XI06 celIs/mL and 1.5XI06 celIs/mL, and all 
experiments were conducted when the cells were in log phase of growth. Stimulations of 
the U-937 cells were performed first by seeding the cells into a 12 weIl plate with a 
density of IX106cells/mL. U-937 cell culture and stimulations were performed in a 37°C 
incubator containing 5% CO2 and 95% air. 
2.2.2 Real-time QPCR 
Real-time QPCR was performed to determine TLR4 mRNA expression under 
various conditions. AlI experiments used commercially available recombinant human IL-
4 (R&D Systems). U-937 cells were seeded for stimulation and incubated with 
concentrations of IL-4 ranging from O.lng/mL to 50ng/mL for 12 hours and with 
lOng/mL of IL-4 for time points ranging from 6 hours to 24 hours. After incubations, the 
cells were centrifuged and washed with ImL of PBS. After the wash, total RNA was 
extracted from the cells using the RNeasy mini kit (Qiagen). Cells were incubated in a 
celllysis solution containing p-mercaptoethanol and guanidium isothiocyanate. The ce Ils 
were homogenized using the needle aspiration technique and RNA was extracted using 
silica membrane columns. RNA on the membrane was washed and eluted using RNase 
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free water. RNA samples were quantified using a spectrophotometer and only RNA 
samples with an A26o/ A280 ratio greater than 1.9 were used. 
1.0~g of RNA from each sample was used for oligo deoxythymidylate (oligo dT) 
mediated reverse transcription using the enzyme SuperScriptII reverse transcriptase 
(Invitrogen). RNA was mixed with l~L of 0.5~g/~L of oligo dT, l~L of dNTP mix 
(lOmM of dATP, dCTP, dTTP and dGTP) and water to a final volume of 12~L. This 
mixture was heated to 65°C for 5 minutes and quickly chilled on ice. The contents were 
centrifuged and 4~L of reverse transcription buffer (250mM Tris-HCl, pH 8.3; 375mM 
KCI; 15mM MgCh), 2~L ofO.1M DTT and l~L ofribonuclease inhibitor (40units/~L) 
were added. This mixture was heated at 42°C for 2 minutes and l~L (200units) of 
SuperScriptll RT was added. This final solution was incubated at 42°C for 50 minutes. 
The enzyme was inactivated by heating the solution for 15 minutes at 70°C. The cDNA 
could then be used as a template for PCR and was stored at -20°C until needed. 
Real-time QPCR was performed using the LightCycler real-time system (version 
1.2; Roche). This system consists of a thermal chamber that uses air to rapidly heat and 
cool the PCR samples. Samp1es are loaded in glass capillaries which have an optimal 
surface-to-volume ratio to ensure rapid equilibration between the air and the reaction 
components. The fluorescent dye Sybr Green 1 was used to quantify the PCR reactions in 
real-time. The excitation and emission maxima of Sybr Green 1 are 494 nm and 521 nm, 
respectively. The LightCycler system uses a blue light emitting diode, which emits light 
at 470 nm exciting the Sybr Green 1 and a fluorescence detector, which takes up light at 
530nm. The LightCycler software records the data and calculates the threshold cycle (Ct) 
for each sample. 
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Commercially available PCR mixes have been developed for the LightCycler 
system. For this thesis, aIl experiments were performed using the QuantiTect Sybr Green 
PCR mix for a two-step RT-PCR (Qiagen). A two-step RT-PCR is performed by doing 
the reverse transcription reaction separate from the PCR. In a one-step reaction, the 
reverse transcription reaction and PCR are done in a single reaction tube. One-step 
reactions have less risk of contamination, but are less efficient reactions. The QuantiTect 
mix contains HotStarTaq DNA Polymerase, PCR buffer (Tris HCl, KCl, (NH4)2S04, and 
5mM MgCh; pH 8.7), dNTPs, and Sybr Green 1. For each reaction, IJ.lL of cDNA was 
added to lOJ.lL of mix, 1 J.lL of primers (20J.lM of each) and 8J.lL of nuclease-free distilled 
deionized water. HotStarTaq is a modified Taq DNA polymerase that is in its inactive 
state at room temperature. This prevents the formation of misprimed products and 
primer-di mers during reaction setup and the first denaturation step, leading to high PCR 
specificity and accurate quantification. The enzyme was activated by an incubation step 
of 15 minutes 95°C before the PCR. 
Primer sequences for the TLR4 and for the house-keeping gene aminolevulinate 
delta-synthase 1 (ALAS1) are found in Table 2.3. ALASI is the first enzyme in the heme 
synthesis pathway, catalyzing the condensation of glycine with succinyl-CoA to form 
delta-aminolevulinic acid[ 527]. ALAS 1 is expressed constitutively in aIl tissues of the 
body. The expression of ALAS 1 did not vary significantly between samples of U-937 
cDNA, validating its use as a house-keeping gene for normalization of expression of 
other genes. For both PCR reactions, identical conditions were used. After 15 minutes of 
incubation at 95°C, 35 cycles of amplification were performed. Each cycle consisted of 
15 seconds at 94°C to denature the DNA, 30 seconds at 56°C to cause annealing of the 
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primers to the DNA, and 20 seconds at noc to allow extension of the primers by the 
polymerase. After extension, the LightCycler activated the blue LED and detected levels 
of Sybr Green 1 fluorescence. 
DNA standards for the real-time QPCR assay were constructed by first 
performing a PCR using cDNA from the U-937, and running a DNA gel electrophoresis 
of the products. The bands were cut out with a razor and purified by using the QIAquick 
Gel Extraction kit (Qiagen). Extracted bands were incubated at 50°C to melt the agarose 
in a high salt solution containing guanidine thiocyanate. DNA was bound to the gel 
membrane, was washed and eluted in 10mM Tris-HCl. After purification, the PCR 
products were ligated into the plasmid pGEM-T (Promega) by TA-cloning using T4 
DNA ligase. 3flL of PCR product was added to 5flL of ligation buffer (60mM Tris-HCI 
at pH 7.8, 20mM MgCh, 20mM DTT, 2mM ATP, and 10% polyethylene glycol), IflL of 
the plasmid pGEM-T (50ng/Il!), and IflL of T4 DNA ligase (3 Weiss units/,.tl). The 
ligation took place ovemight at 4°C. After the ligation, 5flL of the plasmid solution was 
mixed with 25flL of MAX Efficiency DH5a Competent cells (Invitrogen). The bacteria 
and plasmid were incubated on ice together for 30 minutes. The bacteria were heat-
shocked for 45 seconds in a 42°C water bath, and quickly put on ice again for 5 minutes. 
200flL of SOC medium (0.5% yeast extract, 2.0% tryptone, 10mM NaCI, 2.5mM KCI, 
lOmM MgCI2, and 10mM MgS04) was added and the bacteria were placed in a 37°C 
shaker incubator at 225rpm for an hour. The bacterial suspension was poured and spread 
onto a solid agar plate containing LB/ampicillin medium (0.5% yeast extract, 1.0% 
tryptone, 10mM NaCI, IOOllg/mL ampicillin, and 1.5% agar). 30 minutes before plating 
the bacteria, 100111 of 100mM IPTO and 20111 of 50mglmL X-Gal was spread over the 
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LB/ampicillin plate for blue and white selection. The bacteria were cultured ovemight 
and white colonies were selected and placed in 3mLs of LB/ampicillin liquid broth 
ovemight, in a 37°C shaker incubator at 300rpm. Purification of plasmid DNA was 
performed using the QIAprep Spin Miniprep kit (Qiagen). DNA was washed and eluted 
in 50~L of 10mM Tris HCI (pH 8.5). 2~L of the plasmid preparations were digested 
with restriction enzymes and fragments were analyzed by DNA gel electrophoresis to 
determine if the PCR products were cloned into pGEM-T. 50~L of the miniprep cultures 
containing positive clones was added to 150mL of LB/ampicillin liquid broth ovemight, 
in a 37°C shaker incubator at 300rpm. Plasmid DNA was extracted using the HiSpeed 
Plasmid Maxi kit (Qiagen). Plasmid DNA was quantified with a spectrophotometer and 
copy numbers were calculated using the following formula: 
(Amount in copies/ill) = <NA> X (DNA sample concentration in g/ul) 
(Molecular weight in g/mole) 
NA is Avogadro's number (6.022 x 1023 copies/mole). The molecular weight of double-
stranded DNA can be obtained by multiplying the number of base pairs of the DNA by 
the average molecular weight per base (660g/molelbp). The plasmids were also 
sequenced by using high throughput terminal dideoxylnucleotide fluorescent capillary 
electrophoresis by the McGill University and Genome Québec Innovation Centre using 
T7 and Sp6 primers and enzymes. The standard curve was produced by making five 
different log dilutions (5X 1 06 copies of plasmid to 5X 102 copies of plasmid) of purified 
pGEM-T plasmid with the cloned insert; 1 ~L of each dilution of plasmid DNA was 
added instead of cDNA to the Quantitect mix with the primers. Plasmid dilutions for the 
standard curve and a negative control, containing every reagent except DNA, were run 
alongside of each set of U-937 cDNA samples in the LightCycler system. Absolute 
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quantification of both TLR4 and a house-keeping gene ALAS 1 was performed by 
comparing the Ct values of the samples to the standard curve. The copy numbers of 
TLR4 were normalized with the copy numbers of the ALASI. 
Table 2.3 Primer sequences for real-time QPCR 
PCR Primer name Sequence Tm Product Genome 
Target sizeJbp) Position 
TLR4 TLR4 Primer 1 CAACCAAGAACCTGGACCTG 60 151 Exon2 
TLR4 Primer 2 GAGAGGTGGCTTAGGCTCTG 59 Exon3 
ALAS1 ALAS 1 Primer 1 CCCATGAGTTTGGAGCAATC 60 156 Exon 9 
ALAS 1 Primer 2 ACCCTCCAACACAACCAAAG 60 Exon 10 
2.2.3 Flow Cytometry 
Surface expression of TLR4 by U-937 cells was determined by using flow 
cytometry. After culturing the U-937 cells with and without IL-4 the cells were prepared 
for flow cytometry. Cells were washed by adding ImL of staining buffer (PBS and 1 % 
fetal calf serum), centrifuging for 5 minutes at 300g and removing the staining buffer. 
lXl06 U-937 cells were used per staining condition. AlI antibodies used were diluted in 
staining buffer. Cell pellets were resuspended in IOOIlL of staining buffer containing 
2.5Ilg/lX106 cells of mouse IgG2A monoclonal anti-human TLR4 antibody (BD 
Pharmingen; clone HTAI25). The cells were incubated with the primary antibody at 4°C 
for 30 minutes. The cells were washed twice with staining buffer and the cell pellets 
were resuspended in IOOIlL of staining buffer containing 0.25Ilg/lX106 cells of goat 
polyclonal FlTC-labelled anti-mouse IgGzA antibodies (Santa Cruz). Again, cells were 
incubated at 4°C for 30 minutes. The cells were washed twice and resuspended in 600llL 
of staining buffer and were ready for flow cytometry analysis, using a F ACSCalibur flow 
cytometry system and CellQuest Software (BD Biosciences). FITC emits green 
fluorescence and is detected by the fluorescent 1 (FL 1) sensor of the F ACSCalibur. 
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Relative TLR4 surface expression on the cells was determined using the mean fluorescent 
intensity (MFI) and substracting the MFI of the background. Negative controls for the 
experiment included cells that were not stained with any antibodies and cells that were 
incubated with the secondary antibody but not the first antibody. 
2.2.4 NF-KB luciferase reporter assay 
pNF-KB Luc (BD Biosciences) is a reporter plasmid containing four tandem 
copies of the NF -KB consensus sequence. Large amounts of endotoxin free purified 
preparations of pNF -KB Luc plasmid were made using EndoFree Plasmid Maxi kit 
(Qiagen). Endotoxin levels were assessed to be less than 0.125 EU/mL by the limulus 
amebocyte lysate (LAL) gel clot assay (Biowhittaker). U-937 cells were washed with 
sterile PBS and lX106 cells were seeded into a 12 weIl culture plate. Each transfection 
mix was prepared by mixing 1.0/lg of pNF-KB Luc and 0.03/lg of Renilla luciferase 
control vector with serum-free and additive free RPMI-1640, for a total of 75/lL. 6/lL of 
Superfect transfection agent (Qiagen) was added and was mixed in by vortexing, and the 
tubes were centrifuged to collect everything at the bottom of the tube. Superfect 
transfection agent is a solution of polyamidoamine dendrimers which provides high 
transfection efficiencies in a broad number of cell lines. The tranfection mix was 
incubated at 10 minutes at room temperature before addition of 200/lL of cell growth 
medium, containing serum and antibiotics. This solution was pipetted up and down twice 
to mix and immediatcly added drop-wise onto the eells in the wells. The cells wcre 
incubated for 24 hours with the transfection mixture in a 37°C incubator. 
After the transfections, the cells were stimulated with or without lOng/mL of IL-4 
for 24 hours, and th en stimulated with 0.25/lg/mL of LPS from E.coli 0111:84 for 6 
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hours. The cells were collected from the 12 well plates and placed in microcentrifuge 
tubes, pelleted by centrifugation for 5 minutes at 300g, and washed twice with 1 mL of 
PBS. 250~lL of Iysis buffer (Promega; 25mM Tris-phosphate pH 7.6, 2mM OTT, 2mM 
1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, 1 % Triton X-IOO) was 
added to the cell pellets and was mixed for 15 minutes on a rocking platform. Cells in 
this Iysis solution are ready for the luciferase assay and can be stored at -20°C until use. 
The luciferase assay was performed by using the Dual-Iuciferase reporter assay 
system (Promega) and a Lumat LB9507 luminometer (Berthold). Reagent formulations 
for the dual-Iuciferase reporter assay are proprietary and specially designed for this assay. 
For the assay 100J.!L of LARII solution is aliquoted into an optically c1ear polystyrene 
tube. 20J.!L of cel! lysate is added to the LARII and mixed by pipetting 2 to 3 times. The 
tube was placed in the luminometer for a 10 second acquisition of light production by the 
firefly luciferase reaction. 100J.!L of Stop & Glo Reagent was th en added and the tube 
was vortexed for 10 seconds to quench the firefly luciferase. The tube was placed again 
in the luminometer for a 10 second acquisition of light production by the Renilla 
luciferase. Relative light units (RLUs) were calculated by normalizing firefly luciferase 
activity against Renilla luciferase activity. Negative controls for the reaction included 
cells that contained no plasmids in the transfection mix and cells that were transfected but 
were not stimulated with IL-4 or LPS. 
2.2.5 Luciferase Assay: TLR4 Upstream region 
Transcriptional regulation of TLR4 by IL-4 was measured by a luciferase reporter 
assay. 4.3-kilobases of U-937 genomic DNA containing the promo ter and the region 
upstream of the TLR4 gene was amplified using the TaqPlus Precision PCR System 
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(Stratagene) similar to previously described method[496]. The TaqPlus Precision PCR 
System is composed of a specially optimized PCR buffer for long-range PCR reactions 
and a mixture of Pfu and Taq DNA polymerases, which catalyze highly efficient addition 
of nucleotides with extremely low error rates. A mixture was prepared of 10JlL of 10X 
TaqPlus Precision buffer, 0.8 JlL of dNTPs (25mM of dATP, dCTP, dTTP and dGTP), 
1JlL of genomic DNA (250 ng/Jll), 2.5JlL of each primer (Table 2.4; 100 ng/Jll) and 1JlL 
of TaqPlus Precision polymerase mixture (5 V/JlL). The mixture was vortexed to mix 
and centrifuged briefly to collect all drops to the bottom of the tube. The PCR mixture 
was overlayed with mineraI oit to avoid evaporation and placed in a thermal cycler. The 
PCR tubes were heated at 94°C for 1 minute. 35 cycles were performed of the following 
steps: 94°C for 1 minute, 57°C for 1 minute and 72°C for 5 minutes. PCR products were 
separated by DNA gel electrophoresis and the appropriate band was excised and purified 
with the QIAquick Gel Extraction kit. 
The TLR4 gene possesses a natural NcoI site and the 3' primer was designed to 
use this site for cloning. The 5' primer used for the PCR added an Sstl at the 5' end of 
the PCR product for directional cloning in the luciferase reporter plasmid pGL3-Basic 
(Promega). Both pGL3 and PCR product were digested overnight with Sstl and NcoI in 
water and One-Phor-All proprietary potassium acetate buffer (GE Healthcare). The 
digestion products were run on a DNA agarose gel and purified with QIAquick Gel 
Extraction kit. 3JlL of digested PCR product was mixed with 1 JlL of digested pGL3, 4JlL 
of 5X ligase reaction buffer (250mM Tris-HCl, pH 7.6; 50mM MgCh; 5mM ATP; 5mM 
OTT; and 25% polyethylene glycol), 1 JlL of T4 ONA ligase and Il JlL of distilled water. 
This solution was incubated overnight at 4°C. 5JlL of the ligation reaction was 
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transformed into MAX Efficiency DH5a Competent cells by heat shock (section 2.2.2). 
pGL3 has the ampicillin resistance gene, but it does not contain the ~-galactosidase gene; 
therefore, bacteria transformed with the vector was grown on agar plates containing 
LB/ampicillin media, but a blue and white selection was not performed. Colonies that 
grew on the agar plate were cultured for plasmid minipreps (section 2.2.2). Restriction 
mapping was used to confirm that the DNA sequence cloned in the correct orientation. 
EndoFree maxipreps (Qiagen) was performed on positive cultures to prepare large 
amounts of endotoxin free purified plasmids. Endotoxin levels were assessed to be less 
than 0.125 EU/mL by the Limulus Amebocyte Iysate gel clot assay. Samples were 
sequenced by the McGill University and Genome Québec Innovation Centre using 
primers used for the PCR and primers designed at 600 base pair intervals, to sequence the 
entire insert. 
Table 2.4 Primer sequences for c10ning 
PCR Primer name Sequence Product size Restriction 
Product (bp) Enzyme 
TLR4-N TLR4-N 5' -CTGAGCTCCACA TTCTGCAGT A 4371 SstI 
Primer 1 AACTTGGAGGC -3' 
TLR4-N 5' -CACGCAGGAGAGGAAGGCCA NcoI 
Primer 2 TGGCTG-3' 
TLR4-N2 TLR4-N2 5' -CTGAGCTCT ATCAAGCGGTTT 3450 SstI 
Primer 1 CCTCTCC-3' 
TLR4-N2 5' -CACGCAGGAGAGGAAGGCCA NcoI 
Primer 2 TGGCTG-3' 
TLR4-N3 TLR4-N3 5' - CTGAGCTCCT AGGCCGTGGGA 3072 SstI 
Primer 1 TATGTTC -3' 
TLR4-N3 5' - CACGCAGGAGAGGAAGGCCA NcoI 
Primer 2 TGGCTG-3' 
STAT6 STAT6 5' -GGGGT ACCCCGGCACGACGGGA 3324 Kpnl 
Primer 1 AG-3' 
STAT6 5' -GTTTCT AGAAACCACA TGTCA Xbal 
Primer 2 G-3' 
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U-937 cells were seeded into 12 well plates and were transfected with 61lL of 
Superfect, 1 Ilg of TLR4-N plasmid and O.03Ilg of Renilla control vector. The ceIls were 
transfected for 24 hours and stimulated for different time points with lOng/mL of IL-4 
before performing the luciferase assay. A Dual-Iuciferase reporter assay was performed 
similarly to the NF-KB luciferase reporter assay (Section 2.2.4). Negative controls 
inc1uded ceIls transfected with TLR4-N plasmid but were not stimulated with IL-4, as 
weIl as untransfected ceIls. 
2.2.6 Luciferase Assay: STAT6 
The source of STAT6 was a pVL1393 baculovirus vector containing the full 
length human STAT6 (Dr James Ihle, Saint Jude Children's Research Hospital). The 
ST A T6 insert in the vector was amplified using the TaqPlus Precision PCR System in a 
similar reaction as was used to amplify TLR4-N fragment (section 2.2.5). The primers 
used added KpnI and XbaI restriction endonuc1ease sites to the end of the PCR product 
(Table 2.4). The PCR product was purified from gel and digested overnight with KpnI 
and XbaI in water and One-Phor-AIl buffer. The plasmid pcDNA3.1lHygro (+) 
(lnvitrogen) was also c1eaved with KpnI and XbaI. The resulting fragments were 
extracted from gel and ligated together using T4 DNA ligase (section 2.2.5). Ligated 
product was transformed into MAX Efficiency DH5a Competent ceIls and plasmids were 
extracted using EndoFree maxipreps. Plasmids were sequenced and endotoxin levels 
were below 0.125 EU/mL by the LAL gel clot assay. The pcDNA-ST A T6 plasmid 
contains a start and stop codon as weIl as a Kozak sequence necessary for translation[528, 
529]. The pcDNA-STA T6 plasmid contains a human cytomegalovirus immediate-early 
promoter/enhancer sequence that permits high-Ievel expression of STAT6[530]. It also 
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contains a bovine growth hormone polyadenylation signal to promote increased 
transcription termination and polyadenylation of the mRNA[531]. There is also p-
lactamase gene to select for bacteria that have been transformed with the plasmid. 
The ability of the transfected pcDNA-STAT6 plasmid to cause overexpression of 
STAT6 in U-937 cells was determined by Western blotting technique. lX106 U-937 cells 
were transfected with 61-lL of Superfect and several concentrations of pcDNA-ST AT6 
ranging from 0.51-lg to 2.01-lg for 24 hours. Cells were centrifuged and incubated for 1 
hour at 4°C with ImL oflysis buffer containing 20mM Tris, pH 7.5, 150mM NaCI, 2mM 
EDT A, and 1 % of the non-ionic detergent NP-40. In addition, the lysis buffer contained 
a complete Protease Inhibitor Cocktail Mini tablet (Roche Applied Sciences) to prevent 
proteases from digesting the extracts. 30l-lg of proteins from the cell lysates were 
separated out by SDS-P AGE with a Laemmli glycine based discontinous buffering 
system. Lysates were solubilized in hot 2X SDS gel sample buffer and heated in a boiling 
water bath for 5 minutes before loading into the wells of the vertical polyacrylamide gel 
apparatus. Proteins were transferred to a PVOF membrane for immunoblotting. The 
membrane was first incubated for 1 hour with blocking solution containing 3% BSA in 
TBS (50mM Tris, pH 7.4, 0.5M NaCI and 0.05% Tween 20). The membrane was 
incubated overnight at 4°C with agitation in TBS containing 1 % BSA and 1/2000 dilution 
of rabbit anti-STAT6 polyclonal antibodies (R&D Systems). The membrane was 
repeatably washed with TBS and incubated for one hour with TBS containing 1 % BSA 
and a secondary goat anti-rabbit polyclonal antibody linked to horseradish peroxidase 
(HRP; R&O Systems; dilute 1/2500). The membrane was washed again with TBS and 
bands were visualized usmg the proprietary reagent mixture Enhanced 
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Chemiluminescence (ECL) Plus (Amersham). The high intensity chemiluminescence 
signal was detected by incubating the membrane with autoradiography photographic film 
for 15 seconds in an x-ray film cassette. The film was then immediatedly developed with 
an automatic film developer to produce a picture of the ST AT6 bands. Antibodies were 
stripped off by submerging the PVDP membrane in 100mM 2-mercaptoethanol, 2% SDS 
and 62.5mM Tris-HCl (pH 6.7) for 30 minutes at 50°C. The membrane was washed two 
times for 10 minutes in TBS. The membrane was incubated for 1 hour with blocking 
solution and incubated for 1 hour with mouse monoclonal anti-human p-actin antibodies 
(R&D clone AC-15; diluted 1/500) in TBS containing 1% BSA. The membranes were 
washed twice with TBS and then incubated for 1 hour with a secondary rabbit anti-mouse 
polyclonal antibody linked to horseradish peroxidase (HRP; R&D; diluted 1/10,000). 
The membrane was washed again and the bands were visualized by using ECL Plus and 
photographic film. Bands of proteins for both ST A T6 and p-actin were measured by 
densitometry, and the expression of STAT6 was norrnalized to expression of p-actin. 
Prestained protein standards were used to deterrnine the size of the prote in bands for the 
sample. 
A luciferase assay was perforrned using an optimized dose of pcDNA-STA T6 and 
TLR4-N reporter plasmid. The plasmid pcDNA3.1 without any cloned insert was used as 
a negative control for the experiment and was also transfected with the TLR4-N reporter 
plasmid. IXI06 U-937 cells were transfected with 6~L of Superfect, 2~g of pcDNA-
STAT6 or pcDNA 3.1, 1.0~g ofTLR4-N reporter vector and O.03~g of Renilla control 
vector. The cells were rested for 24 hours and stimulated with or without lOng/mL of IL-
4. Several time points were taken where cells were harvested and lysates were assayed 
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for firefly and Renilla luciferase activity using the Dual Luciferase Reporter Assay 
System as previously described in section 2.2.4. 
2.2.7 Tyrphostin AG 490 stimulation 
lX106 U-937 cells were incubated with 25j..1.M of AG 490 (2-cyano-3-(3,4-
dihydroxyphenyl)-N-(benzyl)-2-propenamide; Sigma) dissolved in DMSO (stock lOmM) 
for 16 hours as previously described[532]. lOng/mL oflL-4 was then added for 12 hours. 
After stimulations, the cells were centrifuged and the RNA was extracted for reverse 
transcription and TLR4 and ALAS 1 mRNA levels were quantified by real-time QPCR 
(section 2.2.2). AlI samples were compared to baseline expression. Negative controls for 
the experiments included celIs stimulated with the vehicle DMSO and AG 490 without 
IL-4 stimulation. 
2.2.8 Truncations ofTLR4-N Reporter Plasmid 
The luciferase assay was used to determine where IL-4 responsive elements were 
positioned in the upstream region of the TLR4 gene. This was performed by cloning 
progressively shorter inserts of the upstream region of the TLR4 gene into the plasmid 
vector pGL3-Basic. The upstream region of TLR4 was also analyzed by MatInspector 
Release professional 6.0 (www.genomatix.de) to determine potential STAT6 binding 
sites in the upstream region of TLR4. 
The TLR4-N2 (3.4 kilobases) and TLR4-N3 (3.0 kilobases) plasmids were made 
similarly to the TLR4-N plasmid using primers and the TaqPlus Precision PCR System 
(section 2.2.5). The primers contained restriction endonuclease cleavage sites for cloning 
into pGL3-Basic(Table 2.4). 
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Digestion of TLR4-N with HindlII can yields several fragments[496]. One of 
these contains 1.0 kilobases of the upstream region ofTLR4 gene attached to a full pOL3. 
This fragment was extracted from a DNA gel electrophoresis product and was ligated 
using T4 DNA polymerase as described in section 2.2.5. The ligation product was 
transformed into bacteria and the resulting plasmid was named TLR4-H. Similarly, 
digestion of TLR4-N with Pst! and ligation yielded TLR4-P which contains 300 base 
pairs of the upstream region ofTLR4[496]. 
MAX Efficiency DH5a Competent cells were transformed with each of the 
constructs and plasmids were extracted using EndoFree maxipreps. Endotoxin levels 
were assessed to be less than 0.125 EU/mL by the LAL gel clot assay (Biowhittaker) and 
a sample of ail the plasmids were sent for sequencing to confirm the construct sequence. 
U-937 cells were seeded into 12 weil plates and were transfected with 61lL of Superfect, 
l.0llg of each plasmid and 0.031lg of Renilla control vector. The cells were transfected 
for 24 hours and stimulated for 12 hours with lOng/mL of IL-4 before performing the 
luciferase assay (section 2.2.4). Negative controls included cells transfected with the 
plasmids but were not stimulated with IL-4, as weil as untransfected cells, and cells 
transfected with a pOL3 plasmid containing no in sert (pOL3 Basic). 
2.2.9 STAT6 Chromatin Immunoprecipitation assay 
STAT6 chromatin immunoprecipitation (ChIP) was performed using the EZ-
ChIP kit (Upstate). The ChIP allows the precipitation of DNA complexed to ST A T6 
bound to it by ST A T6-specific antibodies. PCR was used to determine what DNA was 
precipitated. 20X 106 cells were grown with or without IL-4 (lOng/mL) for 6 hours. 
Cells were centrifuged and resuspended in lOmL ofRPMI-1640 in a culture dish. 540llL 
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of a freshly prepared 18.5% formaldehyde solution (final concentration 1 %) was added to 
the cells and incubated at room temperature for 10 minutes. 1 mL of 1.25M glycine was 
added to dish, swirled to mix, and incubated for 5 minutes to quench the formaldehyde. 
Cells were centrifuged for 5 minutes at 300g and were resupended in 10mL of co Id PBS 
to wash. The wash was repeated and the cells were resuspended in 1 mL of cold PBS 
containing 5J.lL ofProtease Inhibitor Cocktail II (Upstate). Cells were spun for 5 minutes 
at 4°C at 700g. 1 mL of SDS lysis buffer (1 % SDS, lOmM EDT A, 50mM Tris, pH 8.1) 
was added to the pellet also containing 5J.lL ofProtease Inhibitor Cocktail II. 
The samples in the SDS lysis buffer were put on ice and each tube was sonicated 
for two 15 second pulses with an intensity of 5 using a Fisher model 60 sonic 
dismembrator. Between pulses, the sampi es were cooled on ice for 30 seconds. This 
sonication protocol was optimized to break apart the DNA of the genome into fragments 
ranging from 200 to 1000 base pairs, which facilitates the immunoprecipitation. The 
sonicated lysates were centrifuged at 4°C for 10 minutes at 12,000g. 100J.lL of the 
supematant was aliquoted into microfuge tubes. 
900J.lL of Chromatin Immunoprecipitation Dilution buffer (0.01% SDS; 1.1 % 
Triton X-lOO; 1.2mM EDTA; 16.7mM Tris-HCl, pH 8.1; and 167mM NaCl) containing 
5 J.lL of Protease Inhibitor Cocktail II was added to each 100J.lL aliquot needed for the 
experiment. 60J.lL of Prote in G Agarose beads (Upstate) was added to each sample to 
preclear the samples. The bead mixture is composed of 50% gel slurry containing 
agarose beads, 400J.lg/mL ofsonicated salmon sperm DNA, 1mg/mL ofBSA, 3mg/mL of 
recombinant protein G, 50% TE buffer (lOmM Tris-HCl, pH 8.0; and 1mM EDTA) and 
0.05% sodium azide. The mixture of Protein G agarose beads and the sonicated lysates 
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was incubated for 1 hour at 4°C on an agitator. The beads were pelleted by centrifuging 
the samples for 1 minute at 3000g. Immunoprecipitating antibodies were added to each 
sample and incubated overnight with agitation at 4°C. IJ.lg of mouse monoclonal 
antibodies specifie for human RNA polymerase II (Upstate; clone CTD448) was added to 
samples to serve as a positive control for the experiment. 1 J.lg of nonnal mouse IgG 
(Upstate) was used as a negative control for the RNA polymerase II immunoprecipitation. 
2.5 J.lg of rabbit polyclonal antibodies specifie for human ST A T6 (R&D Systems) was 
added to samples for immunoprecipitation of ST A T6-DNA complexes. 2.5 J.lg of normal 
rabbit serum (R&D Systems) was used as a negative control for the STAT6 
immunoprecipitation. 
60llL of protein G agarose beads were added to the samples and incubated for 1 
hour at 4°C with rotation to make the antibody complexes bind to the Protein G. The 
complexes were precipitated by centrifuging for 1 minute at 3000g. The supernatant was 
removed and the pellet was repeatably washed with 1 mL of cold buffers to remove non-
specifie binding. After each buffer was added, the mixture was incubated for 5 minutes 
on a rotating platform at 4°C followed by a 1 minute centrifugation at 3000g and removal 
of the supernatant. The first buffer was a low salt immune complex buffer (Upstate) 
composed of 0.1% SDS, 1% Triton X-IOO, 2mM EDTA, 20mM Tris-HCl (pH 8.1) and 
150mM NaCI. The second buffer was a high salt immune complex buffer (Upstate) 
composed of 0.1 % SDS, 1 % Triton X-100, 2mM EDT A, 20mM Tris-HCl (pH 8.1) and 
500mM NaCI. The next buffer was a LiCI immune complex buffer (Upstate) composed 
of 0.25M LiCI, 1 % IGEPAL-CA630, 1% deoxycholic acid (sodium salt), ImM EDTA, 
and 10mM Tris (pH 8.1). The pellet was washed with TE buffer two times. 
117 
The samples were resuspended in lOOJ..lL elution buffer (l % SDS and lOOmM 
NaHC03) and incubated for 15 minutes. The agarose was pelleted by centrifugation for 1 
minute at 3000g and the supernatant was collected into a new tube. The pellet was 
resuspended again in 100J..lL of e1ution buffer and incubated for 15 minutes. The 
supernatant was collected and combined to the first one. 
To aIl tubes containing elution buffer, 8J..lL of 5M NaCI was added and incubated 
overnight at 65°C to reverse the DNA-protein crosslinks. 1 J..lL of 10mg/mL of RNase A 
(in sterile water) was added and incubated for 30 minutes at 37°C. Finally, 4J..lL of O.5M 
of EDTA, 8J..lL of lM Tris-HCI (pH 6.5) and 1J..lL of 10mg/mL of proteinase K were 
added to the samples which were incubated at 45°C for 2 hours. 
DNA was purified from the samples by using silica membrane DNA extraction 
columns (Upstate) and eluted in 50J..lL of 10mM Tris-HCl. After purification of the DNA, 
rea1-time QPCR was used to quantify the binding of ST A T6 and RNA polymerase II to 
specifie regions of DNA by using different primers. The L1L1Ct method was used to 
quantify the extracted fragments with the reference condition being cells incubated 
without IL-4 before the ChIP[533]. The reference for the L1L1Ct method was the fragment 
of the promoter of the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), which is known to bind RNA polymerase II. Two sets of primers were 
designed to amplify the regions containing potential STAT6 binding sites determined by 
MatInspector (Table 2.5). Negative controls for the experiment include ChIP using 
antibodies that do not bind to ST A T6, and ce Ils that were not stimulated with IL-4. 
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Table 2.5 Primer sequences for ST AT6 ChIP assay 
PCR Target Primer name Sequence Genome 
Position 
STAT6 site 1 ST A T6-1 Primer 1 5'- ACACATGGTCTGCCT ST A T 6 site 3,550 base pairs 
TCTGG -3' upstream from start codon of 
ST AT6-1 Primer 2 5' - CCAGGGAAGTCCTTT TLR4 
CAACT -3' 
STAT6 site 2 STAT6-2 Primer 1 5' - CTGGCTTGAAA TG AC ST A T6 site 3240 base pairs 
CCACA -3' upstream from start codon of 
ST A T6-1 Primer 2 5' -TGA TTCTTCA TCCTG TLR4 
CTGTTG-3' 
GAPDH GAPDH Primer 1 5'- TACTAGCGGTTTTAC RNA Polymerase II site that 
promoter GGGCG-3' is about 350 base pairs 
GAPDH Primer 2 5'-TCGAACAGGAGGAGC upstream from the start codon 
AGAGAGCGA-3' ofGAPDH 
2.2.10 Statistics 
As the same cell line was used for aIl experiments, a single factor ANOY A was 
performed using Systat. A post-hoc Dunnett's many-to-one test was used to compare the 
stimulation conditions to the baseline. This was to determine whether the control 
(unstimulated) is different from aIl the stimulations. If a difference was seen using the 
Dunnett's test, it was determined where it lies by using a post-hoc Tukey's test. A P 
value less than 0.05 was considered as being significant. 
2.3 Peripheral Blood Experiments 
2.3.1 Patient Characteristics 
Five children (9.8±3.3 years old) were recruited from the Patient Testing Center 
(PTC) of the Montreal Children's Hospital. Children were in the hospital for other tests 
that required blood draw and were recruited on site to participate in this study. Children 
were screened by using a questionnaire filled out by the child and parent. Informed 
consent was obtained from the parents. Patients were of both sexes (three female; two 
male). Individuals were excluded if they had had any viral or bacterial infections during 
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the month or were taking anti-inflammatory medication regularly or had serious blood 
disorders. The study was approved by the Research Ethics Board of the Montreal 
Children's Hospital. 
Intravenous blood was drawn by an experienced blood technician or nurse from 
the PTe. 5mLs of blood were collected into a sterile tube containing sodium heparin to 
prevent the blood from clotting. Blood was kept at room temperature and was brought to 
the Meakins Christie Laboratories for analysis. 
2.3.2 Fieo/! Gradient Centrifugation and Culture 
Blood was taken out of the heparin tubes and room temperature PBS (pH 7.2) was 
added to a volume of 30mL. 15mL of Ficoll-Paque PLUS (Amersham) was aliquoted to 
50mL tubes. The diluted blood was carefully layered over the Ficoll. The samples were 
centrifuged for 30 minutes at room temperature at 1000g. The upper layer containing 
plasma and platelets was drawn off using a sterile pipette but leaving the PBMC layer 
undisturbed at the interface of the Ficoll layer. The PB MC layer was carefully eollected 
without removing exeess Fieol!. The PB MC layer was washed twice with 50mL of PBS, 
centrifuging 10 minutes at 300g each time. The cell pellet was resuspended in 1 mL of 
RPMI-1640 with added factors (section 2.2.1) and a cell count was performed. 
1X106cells/mL were dispensed in a 6 weil culture dish and stimulated with or without 
lOng/mL of IL-4. 
2.3.3 Flow Cytometry on PBMCs 
After 24 hour culture the PBMCs were collected from the culture dish and washed 
with cold PBS. PBMCs were resuspended in PBS at a concentration of 0.5X106cells/mL 
and 1mL aliquots were used for each condition of the flow cytometry. The cells were 
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eentrifuged again and resuspended with 1 mL of PBS eontaining 20~g of human IgGs 
(Bayer Ine.; stock 50mg/mL of human IgG and 10% maltose at a pH 4.2) to block non-
specifie binding antibodies to cells. The cells were incubated with the IgGs for 30 
minutes at 4°C. Cells were centrifuged for 5 minutes at 300g and the supernatant was 
removed. Cell pellets were resuspended in 95~L of cold staining buffer with 5J.1L (0.05 
mg/mL) of the first antibody and were incubated for 30 minutes at 4°C. Antibodies used 
included: mouse monoclonal antibody specifie for human TLR4 (Serotec; clone 
HT A 125) conjugated to the fluorescent dye Alexa Fluor 488, purified mouse IgG2A 
(Serotec; clone MRC OX-34) conjugated with Alexa Fluor 488 was used as an isotype 
control, mouse monoclonal antibody specifie for human CD3ê (R&D Systems; clone 
UCHTI) which was conjugated to FITC and purified mouse IgG 1 (R&D Systems; clone 
MOPC-21) conjugated with FITC used as an isotype control. The ce lis were washed 
twice with co Id staining buffer by centrifugation for 5 minutes at 300g. The cells were 
th en incubated for 30 minutes at 4°C with 5J.1L of the second antibody diluted with 95J.1L 
of staining buffer. The second antibody used was a mouse monoclonal antibody specifie 
for human CD4 (R&D Systems; clone RPA-T4) conjugated to the fluorescent dye 
allophycocyanin (APC) and its isotype control was a mouse IgG 1 (R&D Systems; clone 
MOPC-21). The cells were washed twice with 1 mL of cold staining buffer and the pellet 
was resuspended in 500J.1L of staining buffer before proceeding to analysis using the 
FACSCalibur flow cytometry system and CellQuest Software (BD Biosciences). Both 
the Alexa Fluor 488 and FITC emit green light when excited by an argon laser and their 
fluorescence is captured by the FL 1 sensor of the flow cytometry system. APC emits red 
light when excited by a red diode laser and the fluorescence is captured by the FL4 sensor 
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of the flow cytometry system. Fluorescence in both the FL 1 and FL4 channels was 
detected simultaneously for ceUs stained with both the first and second antibodies. 
Negative controls for the experiment inc1uded ceUs that were not stained with any 
antibodies and ceUs that were incubated with the isotypes of both the first and second 
antibody used. 
The forward scatter (FSC) and side scatter (SSC) parameters were also 
determined during the acquisition of fluorescence and were used to define the monocyte 
and lymphocyte fractions. The monocyte fraction was gated and the MFI was used to 
compare TLR4 expression of monocytes stimulated with and without IL-4. CD4 positive 
ceUs that were also positive for TLR4 were determined by simultaneous analysis of the 
FLI and FL4 data. This data was plotted on a scatter plot and different quadrants were 
assigned for negative cells, cells positive for TLR4, cells positive for CD4 and double 
positive ceUs. The percentage of double positive cells from the total CD4 population was 
determined for each patient in the study. CD3 expression of CD4 positive cells was also 
determined in a similar fashion. 
2.3.4 Statistics 
The average MFI for TLR4 in the monocytic cell fraction that was stimulated 
with IL-4 was compared to unstimulated monocytes using the paired two sample 
Student's T-test. The average percentage of TLR4 positive CD4 positive cells of total 
CD4 positive ceUs stimulated with IL-4 was compared to unstimulated TLR4 positive 
CD4 positive ceUs using the paired two sample Student's T-test. P values less than 0.05 
were considered as being significant. 
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Chapter 3: Results 
3.1 Immune Responses to LPS in Nasal Mucosa 
3.1.1 lnflammatory Cells in Nasal Mucosa after Ex Vivo Challenges 
Immunohistochemistry was perfonned to detennine the presence of inflammatory 
cells in the nasal explants of atopic children (n=8) cultured ex vivo with LPS, allergen and 
LPS and allergen stimulations. In tissues cultured in media (BCM) without challenge 
(baseline), monocyte/macrophages (CD68; me an immunopositive cens per field ± stand 
deviation; 6.4±2.7), eosinophils (MBP; 2.l±1.8), neutrophils (elastase; 3.1±2.5), ma st 
cells (tryptase; 7.9±3.4) and T cells (CD3; 25.8±9.5) were detected (Figure 3.1). 
Exposure of the atopic mucosa to LPS alone caused a significant increases (P<O.05) in 
monocyte/macrophages (15±4.7), neutrophils (7.3±3.4), mast cens (12.6±5.6) and T cells 
(l21.4±24.7) but not eosinophils (1.4± 1.2). Monocyte/macrophages, neutrophils, mast 
cells increased about 2-5 fold from baseline, but the cells present in the greatest number 
after LPS exposure, the T cens, increased about 4-5 five times compared to baseline. 
Exposure of the nasal explants to allergens, depending on the atopy of the patient, 
caused a significant increase in mast cens (17.6±9.7), eosinophils (9.l±2.9) and T cells 
(41.5± 16.3) compared to baseline. A smaller, although significant, increase in 
monocyte/macrophages (9.9±2.2) and neutrophils (6.1±2.7) was detected. When the 
nasal explants were challenged with specific allergens and LPS at the same time, 
differences were seen compared to either challenge alone. LPS inhibited the allergen-
induced increase in monocyte/macrophage (7.3±2.5), eosinophils (3.8±1.5) and mast cens 
(9.1±4.5) making the levels not significantly different from baseline. Neutrophils 
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Figure 3.1. Levels of inflammatory eells in nasal mue osa of explants from atopie 
ehildren after LPS, allergen or allergen and LPS challenge as measured by immuno-
histochemistry. CD68 is a marker for macrophages and monocytes, MBP is a 
marker for eosinophils, elastase is a marker for neutrophils, tryptase is a marker for 
mast cells and CD3 is a marker for T cells. AIl data is expressed in numbers of 
immunopositive cells/field. MBP = major basic protein; CD = Cluster of differen-
tJatlOn. *P<O.05 versus baseline. t P<O.05 versus allergen challenge. § P<O.05 
versus LPS challenge. 
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(l0.3±4.2) were significantly higher than baseline but simultaneous challenge did not 
increase levels more than single challenges. LPS and allergen challenges increased the 
levels of T cells (138.9±48.8). This level was significantly higher than in biopsies 
challenged with allergen alone but not different from biopsies challenged with LPS alone. 
3.1.2 CD25 Expression and IL-2 Expression in the Nasal Mucosa 
IL-2 is a pote nt growth factor for T cells and increases in CD3 positive cells after 
LPS stimulation may be due to induction of this cytokine. A baseline (20.3±8.1) level of 
IL-2 immunopositive cells was found to be present within the nasal mucosa of explants 
(n=8) cultured with BCM (Figure 3.2). Significant increases in IL-2 immunopositive 
cells were seen after incubation of the nasal explants with both LPS (83.l±17.7) and with 
allergen (59.4±14.2). Simultaneous challenge also led to a significant increase in IL-2 
(80± 11.5) compared to baseline and compared to allergen challenges, but was not 
different from LPS challenge alone. 
CD25 is part of the receptor of IL-2, and LPS and allergen may increase number 
of cells responsive to IL-2 by inducing this receptor. A baseline level of CD25 
(15.4±5.3) immunopositive cells was found in the mucosa of the nasal explants (n=8). A 
significant increase in CD25 immunopositive cells was seen upon LPS challenge 
(69.8±8.8) and allergen challenge (52.4±6.l). Simultaneous challenge of LPS and 
allergen also significantly increased CD25 immunopositive cells (73.3±12.5) compared 
to baseline and allergen challenge al one, but this effect was not significantly different 
from LPS challenge alone. With fluorescent immunohistochemistry it was deterrnined 
that about 60% of the T cells were positive for CD25 (data not shown). 
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Figure 3.2. Levels of IL-2 and CD25 in nasal mucosa of explants From atopic 
children after LPS, allergen or allergen and LPS challenge as measured by immuno-
histochemistry. Ali data is expressed in numbers of inflammatory cells/field. 
*P<Û.Û5 versus baseline. t P<û.û5 versus allergen challenge. 
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3.1.3 Cytokine mRNA Expression in the Nasal Mucosa 
The expression of cytokine mRNAs in the explanted nasal mucosa (n=8) of atopic 
children was measured by radioactive in situ hybridization (Figure 3.3). Tissue cultured 
in BCM without challenge expressed baseline levels of IL-4 (mean mRNA positive ce Ils 
per field ± stand deviation; 2.1±2.l), IL-5 (3.3±2.4), IL-13 (4.5±2.6), IFN-y (1.4±1.3), IL-
12 (1.1±1.1) and IL-lO (6.4±3.7) mRNA positive cells. LPS did not cause significant 
increases of mRNA positive cells for the Th2 cytokines IL-4 (2.5±3.0), IL-5 (2.6±2.5) 
and IL-13 (3.3±2.2), but did cause significant increases in mRNA positive cells for the 
Thl cytokines IFN-y (l7.4±1O.1) and IL-12 (6.8±3.9). LPS also caused a significantly 
large increase, almost sevenfold baseline levels, in the immunoregulatory cytokine IL-I0 
(41.8± 15 .5) mRNA positive cells compared to baseline. Allergen challenge caused 
significant increases in IL-4 (6.7±4.1), IL-5 (l6.0±1O.8), IL-13 (l0.0±6.7) and IL-lO 
(l4.4±7.7) mRNA positive cells, but not in IFN-y (1.9±1.4) and IL-I2 (1.3±1.5) mRNA 
positive cells. LPS was added to allergen to determine wh ether it could inhibit induction 
of Th2 cytokine mRNA. LPS abrogated the allergen induced increase in the number of 
cells positive for mRNA of the Th2 cytokines IL-4 (2.4±2.6), IL-5 (5.I±2.2) and IL-I3 
(5.l±3.3) making levels of positive cells not significantly different from biopsies cultured 
in BCM without challenge. Simultaneous challenge of the biopsies with allergen and LPS 
caused significant increases in IL-lO (62.8±24.8), IFN-y (24.3±9.4) and IL-12 (l6.3±6.6) 
mRNA positive cel1s. 
3.1.4 Neutralizing A ntibodies for IL-JO, IL-12 and IFN-r Th2 Cytokines 
Neutralizing antibodies for IL-l 0, IL-I2 and IFN-y were used to determine which 
of these cytokines could mediate the ability of LPS in reducing allergen induced Th2 
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Figure 3.3. Levels of cytokine mRNAs in nasal mucosa of explants from atopic 
children after LPS, allergen or allergen and LPS challenge as measured by in situ 
hybridization. IL-4, IL-5 and IL-13 are known as Th2 cytokines, while IFN-y and 
IL-12 are known as Th 1 cytokines. IL-lOis known as a regulatory cytokine. Ali 
data is expressed in numbers of mRNA cells/field. IL = interleukin; IFN = inter-
feron. *P<O.05 versus baseline. t P<O.05 versus allergen challenge. § P<O.05 versus 
LPS challenge 
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cytokine production (n=4). Allergen induced increases in the rnRNA positive cells for 
the Th2 cytokines IL-4 (6.8±1.5), IL-5 (16.0±4.1), and IL-13 (lO.0±2.5) (Figure 3.4). 
LPS significantly abrogated the allergen induced increase in these cytokine mRNAs 
when the biopsies were simultaneously challenged with LPS and allergen: IL-4 (3.8±O.7), 
IL-5 (4.5±O.5) and IL-13 (5.8±O.5). Neutralization of IL-lO significantly blocked the 
. effect of LPS on IL-4 (7.8±O.9), IL-5 (l4.1±1.3) and IL-13 (12.4±O.5). Neutralization of 
IL-12 also inhibited the effect of LPS on IL-4 (6.6±1.0), IL-5 (13.0±O.8) and IL-13 
(11.5±1.0). Neutralization oflFN-y did not inhibit the effect ofLPS on IL-4(5.1±O.5) but 
did inhibit the effect on IL-13 (8.2±l.O) and IL-5 (1O.1±O.9). The IL-12 and IFN-y 
neutralizing antibodies were combined to determine if inhibiting both major Th 1 
associated cytokines would have a greater effect than either neutralizing antibody alone. 
Neutralization of IFN-y and IL-12 brought the level of IL-4, IL-5 and IL-13 similar to 
levels cells after allergen challenge. When isotype controls for each neutralizing 
antibody were used, leve\s of IL-4(4.2±O.7), IL-5(4.2±O.5) and IL-13(5±O.5) were not 
different to the effects of challenging the tissue with allergen and LPS (data not shown). 
Immunohistochemistry for IL-5 was used to determine if levels of protein 
positive cells were affected by the neutralizing antibodies (Figure 3.5). Levels of IL-5 
immunopositive cells were increased in the mucosa by culturing the tissue with allergen 
(12.4±3.0), and this increase was blocked by the addition of LPS (3.1±O.5). Neutralizing 
IL-lO (l3±4.3), IL-12 (l2.2±2.8), IFN-y (15.1±4.9) and both IL-I2 and IFN-y (l2.9±2.1) 
ail inhibited the effects of LPS on allergen-induced increases in IL-5 immunopositive 
cells. 
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Figure 3.4. Levels ofTh2 cytokine mRNAs in nasal mucosa of explants from atopic 
children after allergen and LPS challenge as measured by in situ hybridization. 
Neutralizing antibodies were used to block the efft~cts of IL-l 0, IL-12, IFN-y, and 
both IL-12 and IFN-y. Ali data is expressed in numbers of mRNA cellslfield. IL = 
interleukin; anti-IL-IO = IL-JO neutralizing antibody; anti-IL-12 = IL-12 neutraliz-
ing antibody; anti-IFN-y = IFN-y neutralizing antibody. *P<0.05 versus allergen. 
tP<0.05 versus allergen and LPS challenge. 
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Figure 3.5. Levels of IL-5 immunopositive cells in nasal mucosa of explants from 
atopic children after allergen and LPS challenge as measured by immunohistochem-
istry. Neutralizing antibodies were used to block the effects of IL-l 0, IL-12, IFN-y, 
and both IL-12 and IFN-y. Ali data is expressed in numbers of protein positive 
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3.1.5 Neutralizing Antibodiesfor IL-IO, IL-12 and IFN-y: Thl Cytokines and IL-IO 
In situ hybridization was also used to measure the impact of the neutralizing 
antibodies on levels of IL-lO, IL-I2 and IFN-y mRNA positive cells (Figure 3.6). This 
was performed to determine if these cytokines could influence the expression of each 
other. Low levels of IFN-y (1.9±O.6), IL-I2 (1.3±O.5) and IL-lO (l4.4±2.9) mRNA 
positive cells were seen when the tissue was incubated with allergen alone. LPS 
challenge in the presence of allergen induced the levels of aIl three cytokines: IFN-y 
(20.3±1.2), IL-12 (17.8±1.9) and IL-lO (55.3±4.2). Neutralization of IL-lO (13.7±O.5) 
and of IL-12 (lO.2±O.5) blocked the induction of IFN-y, but blocking IFN-y (17.2±O.9) 
had no effect. Combination ofneutralizing antibodies against IL-I2 and IFN-y (9.3±O.8) 
significantly blocked the effect of LPS on levels of IFN-y positive cells, but the effect 
was not different from using neutralizing antibodies against IL-I2 alone. Neutralization 
of IL-lO (5.9±O.5) and neutralization of IFN-y (9.4±2.3) reduced the induction of IL-I2 
mRNA positive cells by LPS. Blocking IL-I2 (l6.5±2.3) had no effect on LPS induced 
IL-I2 mRNA positive cells, but combining neutralizing antibodies for both IL-I2 and 
IFN-y (3.5±0.4) produced a greater effect than using either neutralizing antibodies alone. 
Neutralization of IL-lO had no significant effect on IL-lO (50.3±4.8) levels of mRNA 
positive cells induced by LPS, but neutralization of IL-I2 (22.l±O.9) significantly 
lowered levels of IL-lO mRNA positive cells, and was not different from allergen 
challenge alone. Neutralization ofIFN-y (40±2.2) also significantly lowered levels of IL-
10 mRNA positive cells, but not as mu ch as IL-I2 neutralization. Combining IL-I2 and 
IFN-y (18.I± 1.2) neutralizing antibodies significantly decrease IL-lO mRNA positive 
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Figure 3.6. Levels of Th 1 cytokine and IL-I 0 mRNAs in nasal mucosa of explants 
from atopic children after allergen and LPS challenge as measured by in situ hybrid-
ization. Neutralizing antibodies were used to block the effects of IL-I 0, IL-12, 
IFN-y, and both IL-12 and IFN-y. Ail data is expressed in numbers of mRNA 
cells/field. *P<0.05 versus allergen. tP<0.05 versus allergen and LPS challenge. 
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cells induced by LPS, but the effect was not significantly greater than the use of IL-I2 
neutralizing antibodies alone. 
Immunohistochemistry for IFN-y, IL-12 and IL-IO was used to determine if 
neutralizing antibodies affected the levels of cytokine prote in in the positive cells (Figure 
3.7). Levels of IFN-y, IL-12 and IL-IO immunopositive cells were increased by LPS 
challenge with allergen (l7.3±1.1, 11.7±O.9 and 52.9±6.7 respectively) compared to 
allergen stimulation alone (3.7±1.1, 3.6±O.8 and 16.5±2.7 respectively). Neutralization 
ofIL-lO or ofIL-12 with antibodies significantly reduced the LPS induced levels ofIFN-
y (l1.2±O.9) immunopositive cells. IFN-y neutralization had no significant effect on IFN-
y (l4.1±2.2) immunopositive cells, while neutralization ofboth IFN-y and IL-12 reduced 
levels of IFN-y (8.4±O.3) to levels similar tissue incubated with IL-12 neutralizing 
antibodies alone. Blocking IL-IO and IFN-y (6.2±O.2) reduced levels ofIL-12 (8.5±O.6) 
immunopositive cells induced by LPS. Blocking of IL-12 (l3.5±3.3) had no significant 
effect on levels of IL-12 immunopositive cells, while addition of IFN-y neutralizing 
antibodies to IL-12 (4.2± 1.5) neutralizing antibodies caused a significant reduction in IL-
12 immunopositive cells that was significantly greater th an using IFN-y neutralization 
alone. IL-IO neutralization (49. 7±6.6) had no significant effect on IL-IO immunopositive 
cells. Both neutralization of IFN-y (39.9±1.2) or neutralization of IL-12 (30.0±3.9) 
significantly reduced the LPS induction of IL-IO immunopositive cells. IL-12 had a 
greater effect than IFN-y on IL-IO immunopositive cell reduction. Combination of the 
IFN-y and IL-12 (l9.6±4.l) neutralizing antibodies reduced levels of IL-IO 
immunopositive cells, but the combination was not significantly greater than use of IL-12 
alone. 
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Figure 3.7. Levels of Th 1 cytokine and IL-I Û immunopositive cells in nasal mucosa 
of explants from atopic children after allergen and LPS challenge as measured by 
immunohistochemistry. Neutralizing antibodies were used to block the effects of 
IL-IO, IL-12, IFN-y, and both IL-12 and IFN-y. Ali data is expressed in numbers of 
immunopositive cells/field_ *P<û_û5 versus allergen_ tP<û_û5 versus allergen and 
LPS challenge_ 
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3.1.6 TLR4 Immunopositivity in Chi/dren and Cell Proliferation with LPS 
ln an earlier set of experiments, immune responses in the nasal mucosa of non-
atopic children to LPS were measured but not of atopic children[293]. 
Immunohistochemistry for TLR4 was performed on the nasal mucosa of non-atopic 
children (n=7) and also atopic children (n=8) to determine whether a difference occurred 
between the patient groups at baseline and upon stimulation with different doses of LPS 
for 24 hours (Figure 3.8). A dose-dependent increase in TLR4 immunopositive cells was 
detected in the non-atopic group when comparing biopsies incubated in BCM (11. 7± 1.3) 
to stimulations using O.OOlf..lg/mL (15.2±2.2), O.Olf..lg/mL (20.7±2.5), O.lf..lg/mL 
(35.7±3.2) and 1 f..lg/mL (41.5±4.3) of LPS. Similarly, biopsies from atopic children had a 
dose dependent increase in TLR4 (O.OOlf..lg/mL, 13.8±1.8; O.Olf..lg/mL, 22.5±2.2; 
O.lf..lg/mL, 34.0±3.5; and 1f..lg/mL, 43.5±3.0) compared to baseline (10.2±1.0). No 
significant difference was determined between levels of TLR4 between atopic and non-
atopic children at baseline or at any dose of LPS used. 
Proliferation of cells, as measured by BrdU incorporation, was measured in 
explants from atopic children (n=3) to determine if LPS caused proliferation of 
inflammatory cells (Figure 3.9). Incubation of the biopsies for 24 hours with O.lf..lg/mL 
of LPS (47.0±14.6) caused a significant increase in BrdU incorporation compared to 
biopsies cultured in BCM (7 .O± 1.1). Incubation of the tissues with allergen (9± 1.6) did 
not cause a significant increase in BrdU incorporation, but wh en LPS was added to 
allergen (54±8.9), a significant increase in BrdU immunopositive cells was seen. 
Comparison of LPS to LPS and allergen yielded no significant difference, suggesting that 
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Figure 3.8. Levels of TLR4 positive cells in nasal mucosa of explants from 110n-
atopic and atopic children after LPS challenge as measured by immunohistochemis-
try. Increasing doses of LPS were added to media ranging from 0.001 Ilg/mL to 1 
Ilg/mL. AlI data is expressed in numbers of immunopositive cells/field. *P<0.05 
versus 110n-atopic explants cuItured in media alone. tP<0.05 versus atopic explants 
cultured in media alone. 
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Figure 3.9. Levels of BrdU incorporation in nasal mucosa of explants from atopic 
children after LPS, allergen or LPS and allergen challenges as measured by fluores-
cent immunohistochemistry. All data is expressed in numbers ofBrdU immunoposi-
tive cells/field and was semi-quantified using ImageJ software. BrdU = 
5-bromo-2' -deoxy-uridine. *P<O.05 versus explants cultured in media alone. 
tP<O.05 versus explants cultured with allergen. 
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allergen did not cause a significant proliferation of ceUs as measured by BrdU 
incorporation. 
3.1.7 CD3 and IL-10 Expression in Atopic Children and Atopic Adults 
Atopic children (n=8; Figure 3.10) were then compared to atopic adults (n=7) for 
the response of the nasal mucosa to LPS. Atopic children and aduIts both expressed 
similar baseline levels of T ceUs (CD3 immunopositive cells) in the mucosa of the nasal 
tissue (26.5±4.3 and 29.l±3.9 respectively). Allergen stimulation of the tissue led to a 
significant increase ofT cells in both children (42.2±7.0) and aduIts (51.7±8.7), but levels 
of T ceUs were not different between adults and children. LPS caused a great increase in 
T cells in the nasal mucosa of atopic children (123.5±1O.4) but not in atopic aduIts 
(33.5±4.8). Simultaneous challenge of the biopsies with allergen and LPS caused an 
increase of T cells in adults (141.3±20.0) not different from allergen alone. The increase 
was significantly greater in children (54.3± 7.8) and not different from LPS alone. 
The expression of IL-IO mRNA positive cells, as measured by in situ 
hybridization, was determined in atopic adults and was compared to the levels of atopic 
children (Figure 3.11). Baseline levels of IL-1O mRNA positive cells were detected in 
both children (7.0±1.7) and adult (8.2±1.4) atopic nasal mucosa. Significantly, increased 
levels of IL-1O mRNA positive cells were seen in both children (I4.9±3.4) and adults 
(l8.3±2.3) after allergen challenge, but were not different from each other. LPS caused a 
dramatic increase in IL-I0 mRNA positive cells in the nasal mucosa of children 
(42.8±7.0) but not in adults (I8.3±2.3). Simultaneous challenge with allergen and LPS 
led to strong increase in IL-I0 mRNA positive cells in the nasal mucosa from children 
(64.8±9.6) and a smaller but significant increase in the nasal mue osa from adults 
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Figure 3.10. Levels of CD3 positive cells in nasal mucosa of explants From atopic 
children and atopic adults after LPS, allergen or allergen and LPS challenge as mea-
sured by immunohistochemistry. *P<0.05 versus biopsies from atopic children 
incubated in media. t P<0.05 versus biopsies from atopic adults incubated in media. 
Other comparisons P<0.05 are labeled on the graph. 
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Figure 3.11. Levels of IL-I 0 mRNA in nasal mucosa of explants from atopic 
children and atopic adults after LPS, allergen or allergen and LPS challenge as mea-
sured by in situ hybridization. *P<O.05 versus biopsies from atopic children incu-
bated in media. t P<O.05 versus biopsies from atopic adults incubated in media. 
Other comparisons P<O.05 are labeled on the graph. 
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(19.4±2.5). The increase of T cells and IL-IO mRNA positive cells in adults after the 
simultaneous challenge was not different from challenges using allergen alone, 
suggesting that the cells of the nasal mucosa from atopic adults is unresponsive to LPS. 
Sorne commercial LPS preparations can be potentially contaminated with other bacterial 
components such as lipoproteins, which can activate TLR2. A purified version of LPS 
(>99% purity) , that activates only TLR4 LPS receptor, was used to stimulate explants 
from atopic children (n=3) and atopic adults (n=3). The effects of the purified version of 
LPS were not significantly different from the less pure formulations in terms of T cells 
and IL-IO mRNA positive cell levels (data not shown). This clearly supports the 
involvement ofTLR4 in mediating LPS effects in the expIant model. 
3.1.8 TLR4 Expression in Adults and Children 
LPS caused no effects in the nasal mucosa of atopic adults compared to children 
and this may be due to decreased LPS receptor components. Therefore, levels of TLR4 
positive cells where measured by immunohistochemistry in atopic children (n=8), non-
atopic children (n=7), atopic adults (n=8) and non-atopic adults (n=7; Figure 3.12). 
Biopsies were either cultured for 24 hours in BCM or in BCM with 0.1 /lg/mL of LPS. 
Baseline levels of TLR4 were detected in non-atopic children (11.3±1.5), atopic children 
(10.0±1.0) and non-atopic adults (4.3±1.0) and were almost undetectable in atopic adults 
(1.0±0.3). After LPS stimulation, TLR4 positive cells increased significantly in non-
atopic children (34.9±3.0), atopic children (33.0±3.4) and non-atopic adults (13.6±1.7), 
but no observable increase was detected in atopic adults (1.0±0.5). Levels of TLR4 
positive cells in the non-atopic adults were significantly lower compared to children, but 
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levels of TLR4 positive cells in atopic adults were significantly lower to ail other groups 
of patients. 
3.1.9 Coexpression of Markers in Nasal Mucosa ofChildren 
As T cells were the cell type that responded the greatest to LPS stimulation, it is 
possible that LPS had direct effects on these cells. Expression of TLR4 was determined 
on T cells (CD3 positive cells) using flurescent immunohistochemistry (Figure 3.13). 
Many T cells were also positive for TLR4 in the atopic nasal mus osa and stimulation of 
the tissue with LPS led to a strong increase in the number of T cells and TLR4 positive 
cells (Figure 3.14). IL-IO was colocalized to TLR4 positive cells using fluorescent 
immunohistochemistry in tissue challenged with allergen, and levels of double positive 
cells increased greatly when the biopsies were challenged with LPS and allergen (Figure 
3.15). CD4 and CD25 double positive cells were found in allergen stimulated tissue, but 
when the tissue was simultaneously challenged with allergen and LPS, a strong induction 
in the amount of these cells was seen (Figure 3.16). 
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Figure 3.13. Detection of CD3 positive and TLR4 positive cells by colocalization 
using fluorescent immunohistochemistry. Atopic nasal mucosa from children was 
stained with R-phycoerythrin-Iabelled anti-CD3 antibodies and FITC-Iabelled anti-
TLR4 antibodies. Wh en stimulated with a laser, phycoerythrin fluoresces red (CD3 
staining) and FITC fluoresces green (TLR4 staining). When the two signais are 
superimposed, any colocalization of the signais is seen as yellow. Images of isotype 
control antibodies labeled with the same fluoresecent dye as their respective 
antibody are found in the insets. Arrows den ote positive staining or colocalization. 
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Figure 3.14. Detection of CD3 positive and TLR4 positive cells by colocalization 
using fluorescent immunohistochemistry at baseline and with LPS stimulation. 
Atopic nasal mucosa was stained with R-phycoerythrin-labelled anti-CD3 antibod-
ies and FITC-labelled anti-TLR4 antibodies. When stimulated with a laser phyco-
erythrin fluoresces red (CD3 staining) and FITC fluoresces green (TLR4 staining). 
When the two signaIs are superimposed, any colocalization of the signaIs is seen as 
yellow. Arrows denote positive colocalization. 
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Figure 3.15. Detection of IL-l 0 positive and TLR4 positive cells by colocalization 
using fluorescent immunohistochemistry. Atopic nasal mucosa was incubated with 
allergen (middle) and allergen and LPS(bottom panel). Atopic nasal mucosa was 
stained with R-phycoerythrin-Iabelled anti-IL-IO antibodies and FITC-Iabelled 
anti-TLR4 antibodies. When stimulated with a laser phycoerythrin tluoresces red 
(lL-lO staining) and FITC fluoresces green (TLR4 staining). When the two signais 
are superimposed, any co-Iocalization of the signaIs is seen as yellow. The top panel 
shows staining for IL-l 0 alone in allergen stimulated tissue. Phycoerythrin labelled 
isotype control for the anti-IL-l 0 antibody is found in the top panel inset. Arrows 
denote positive staining or colocalization. 
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Figure 3.16. Detection of CD4 positive and C02S positive cells by colocalization 
using fluorescent immunohistochemistry. Mucosa was cultured with allergen 
(bottom left panel) and allergen and LPS (bottom right panel). Atopic nasal mucosa 
was stained with allophycocyanin (APC) anti-CD4 and fluorescein isothiocyanate 
(FITC) anti-CD25 antibodies. When stimulated with a laser, FITC fluoresces green 
(C025 staining) and APC fluoresces red (C04 staining). When the two signais are 
superimposed, any colocalization of the signais is seen as yellow. Images ofisotype 
control antibodies labeled with the same fluorescent dye as their respective antibody 
are found in the insets. Arrows denote positive staining or colocalization. 
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3.2 TLR4 Expression and Regulation in U-937 CeUs 
3.2.1 NF-KR Luciferase Assay 
To determine the effect of IL-4 on the LPS responsiveness of U-937 cells, the 
activation of the NF-KB signal transduction was measured using the NF-KB luciferase 
assay (n = 3; Figure 3.17). Baseline levels of NF-KB activation were detected, and 
incubation of the cells with lOng/ml IL-4 for 24 hours (mean fold upregulation compared 
to baseline level ± standard deviation; 1.1±O.l) did not cause any significant effect. 
Incubation of cells for 6 hours with O.25J!g/ml of LPS (3.0±O.3) caused a significant 
increase in the NF-KB reporter plasmid. When ce lis were incubated for 24 hours with IL-
4 and then stimulated with LPS (IL-4 preincubation), a significant increase in NF-KB 
reporter activity was measured (1.8±O.1), but this increase was significantly decreased 
compared to cells stimulated with LPS without IL-4 preincubation. Conversely, if cells 
were only given IL-4 at the time of LPS challenge (IL-4 coincubation) NF-KB reporter 
activity was significantly induced (2.8±O.5) but was not different to cells stimulated with 
LPS alone. 
3.2.2 TLR4 mRNA and Protein Surface Expression 
As the inhibitory effects of IL-4 required a pre incubation period, this suggests that 
LPS receptor components were downregulated and TLR4 expression in U-937 cells was 
determined after IL-4 stimulation. U-937 cells showed a high basal expression of TLR4 
mRNA as measured by real-time QPCR (n=4; Figure 3.18). Cells were incubated with 
O.lng/ml to 50ng/ml ofIL-4 for 12 hours and the lowest dose required to reach maximum 
suppression ofTLR4 mRNA was found to be lOng/ml. This is the dose used in aH other 
experiments. When the cells were incubated with the optimal dose of IL-4, there was a 
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Figure 3.17. Activation ofNF-KB in U-937 cells by IL-4 and LPS as measured by 
the NF-KB luciferase reporter assay. U-937 cells were transiently transfected with 
luciferase reporter plasmid activated by NF-KB. A Renilla luciferase vector was 
used to correct for transfection efficiency. Transfected cells were either left 
unstimulated, stimulated with lOng/mI of IL-4 for 24 hours, stimulated with 
0.25Ilg/ml ofLPS for 6 hours, incubated with IL-4 for 24 hours (IL-4 preincubation) 
followed by LPS stimulation for 6. hours or stimulated with LPS and IL-4 (IL-4 
coincubation). Relative light units (RLUs) were obtained by performing the dual-
luciferase assay. Results are expressed as the RLU fold expression compared to the 
RLU of unstimulated cells. NF-KB = nuclear factor KB; *P<0.05 versus baseline, 
tP<0.05 versus LPS treatment. 
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Figure 3.18. Expression ofTLR4 mRNA in U-937 cells as measured by real-time 
QPCR. U-937 cells were incubated with lOng/ml of IL-4 for 0 to 24 hours. RNA 
was extracted at different time points and TLR4 and ALAS 1 house-keeping gene 
RNAs were quantified using plasmid standards. Results are expressed as copies of 
TLR4 versus copies of the house-keeping gene ALAS 1 compared to unstimulated 
controls. *P<O.05 versus unstimulated cells (n=4). 
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rapid and significant reduction in the expression of TLR4 rnRNA as early as 6 hours 
(percent of rnRNA expression of unstirnulated cells expression ± standard deviation; 
62.3±4.7%). Downregulation ofTLR4 rnRNA was rnaintained at 12 hours (69.9±17.1) 
but was retumed to baseline by 24 hours (l09.6±20.8). 
Surface expression of TLR4 of U-937 cells was evaluated using flow cytornetry. 
94.8±5% of the U-937 cells were positive for surface staining of TLR4. IL-4 did not 
reduce the nurnber of TLR4 positive cells, but reduced the individual cell surface TLR4 
intensity rneasured by using the MFI, a rneasure of the arnount receptor expression on the 
cells based on the arnount of fluorescence detected (Figure 3.19). TLR4 MFI was 
significantly reduced at 12 hours (percent of unstirnulated cells ± standard deviation; 
91.9±O.9%) and 24 hours (86.9±1.4%) but retumed to basal levels by 48 hours 
(99.4±4.2%). 
3.2.3 TLR4 Promoter Transcriptional Activity 
To determine if IL-4 had an effect on the regulation of transcription, the proximal 
promoter of the human TLR4 gene, ranging from 4.3 kb of the A TG start codon, was 
cloned into a Iuciferase reporter plasmid pGL3-Basic. This construct was named TLR4-N 
as an Nco! restriction endonuclease site was used to clone the fragment. U-937 cells 
were transiently transfected with TLR4-N and the luciferase assay was performed (n= 3). 
As a negative control, U-937 cells were also transfected separately with pGL3-Basic, the 
luciferase reporter plasrnid that does not contain a prornoter upstrearn of the luciferase 
gene. U-937 cells transfected with TLR4-N had a significantIy greater Ievei of luciferase 
activity than the control pGL3-Basic (Figure 3.20; mean foid upregulation compared to 
pGL3-Basic ± standard deviation; 5.9±0.9). This dernonstrates a high baseline level of 
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Figure 3.19. Expression ofTLR4 prote in cell surface expression in U-937 cells as 
measured by flow cytometry. U-937 cells were incubated with lOng/ml ofIL-4 for 
o to 48 hours. Cells were stained with a primary mouse anti-TLR4 antibody and a 
secondary FITC-labelled anti-mouse antibody(top panel). The flow cytometry 
histogram (bottom panel) shows a representative example of 24 hour stimulation 
with IL-4 (0) compared to unstimulated control (0). Background fluorescence was 
determined by incubation of the cells with FITC-conjugated secondary antibody 
alone C.), and was subtracted from the sample MFI values. Results are expressed as 
a percent of unstimulated cells for each time point. *P<O.05 versus unstimulated 
cells. 
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Figure 3.20. Activation of upstream proximal promoter of TLR4 in U-937 cells as 
measured by the luciferase reporter assay. U-937 cells were transiently transfected 
with a luciferase reporter plasmid containing 4.3 kb of the upstream region ofTLR4 
(TLR4-N). pGL3-Basic is the reporter plasmid without any cloned insert and was 
transfected into the U-937 cells to serve as a negative control. Untransfected cells 
were used as another negative control. A Renilla luciferase vector was used to 
correct for transfection efficiency. Relative light units (RLUs) were obtained by 
performing the dual-Iuciferase assay. Results are expressed as the RLU fold expres-
sion compared to the RLU cells transfected with pGL3-8asic. *P<Û.Û5 versus 
pGL3-Basic. 
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transcription in unstimulated cells. TLR4-N transfected U-937 cells were stimulated with 
IL-4 for different lengths of times before performing the luciferase assay (Figure 3.21). 
Decreased reporter activity occurred at 6 hours (percent of activity of TLR4-N in 
unstimulated cells ± standard deviation; 67.0±13.7%), and was maintained at 12 hours 
(71.7±15.4%) but was lost at 24 hours (87.6±12.7%). 
3.2.4 STAT6 transfection and TLR4 promoter transcriptional activity 
IL-4, through the IL-4 receptor activates STAT6 signal transduction [534]. To 
determine if ST A T6 plays a role in inhibiting TLR4 transcription, a plasmid containing a 
fulliength human STAT6 plasmid (pSTAT6) was constructed and transfected into U-937 
cells. Different concentrations of pSTAT6 were transfected into cells ranging from O.5f.lg 
to 2.0f.lg (n=3). STAT6 levels were evaluated by immunoblotting and 2.0f.lg was the 
optimal dose causing a 2.5-fold increase in STAT6 expression compared to baseline 
levels (Figure 3.22). Transfection of pcDNA, which is the expression plasmid used to 
clone and overexpress ST A T6, did not have any effect on endogenous ST A T6 levels 
compared to untransfected cells. 
U-937 cells were transfected with the plasmid TLR4-N and pSTAT6 to determine 
if ST A T6 overexpression could affect transcription of TLR4. pcDNA was also 
transfected with TLR4-N into separate U-937 as a negative control. After transfection, 
the cells were stimulated with IL-4 for different lengths of time. IL-4 caused a decrease 
in TLR4-N activity in cells transfected with pcDNA at 6 hours (percent of activity of 
TLR4-N in unstimulated cells ± standard deviation; 64.9±11.9%), 12 hours (74.9±14.2%) 
but not at 24 hours (94.5±10.9%). The effects ofpcDNA were comparable to the results 
seen when cells received TLR4-N al one (Figure 3.23). When cells transfected with 
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Figure 3.21. Activation ofupstream proximal promoter ofTLR4 in U-937 cells as 
measured by the luciferase reporter assay. U-937 cells were transiently transfected 
with a luciferase reporter plasmid containing 4.3 kb of the upstream region ofTLR4 
(TLR4-N). A Renilla luciferase vector was used to correct for transfection 
efficiency. Transfected cells were stimulated with 10ng/ml of IL-4 for 0 to 24 
hours. Relative light units (RLUs) were obtained by performing the dual-luciferase 
assay. Results are expressed as a percent of the RLU ofunstimulated cells. *P<O.05 
versus baseline. 
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Figure 3.22. Expression of STAT6 by U-937 cells transfected with a constitutive 
STAT6 expression plasmid (pSTAT6), as measured by immunoblotting. U-937 cells 
were transiently transfected wtih different concentrations of pSTAT6 from 
O.5Ilg/mL to 2.0Ilg/mL for 24 hours. An SOS-PAGE was performed on the Iysates, 
and after transfer to a PVOF membrane, STAT6 and ~-actin were probed using 
antibody and chemiluminescence. A representative example of a developed immu-
noblot is shown in the top panel, next to an image of the molecular weight protein 
standards used. Amounts of protein were semi-quantified using densitometry 
(bottom panel). pcONA is the expression plasmid without STAT6 and was used as 
a negative control. Results are expressed as a density units of STAT6 bands 
(expected size 94 kOa) versus the house-keeping gene ~-actin (expected size 42 
kOa) for each condition compared ta untransfected cells. *P<O.05 versus baseline. 
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Figure 3.23. Activation of upstream proximal promoter of TLR4 in U-937 cells as 
measured by the luciferase reporter assay. U-937 cells were transfected with 
TLR4-N luciferase reporter plasmid and pSTAT6. As a negative control, pcDNA, 
the plasmid used to clone STAT6, was transfected in separate cells. A Renilla lucif-
erase vector was used to correct for transfection efficiency. Transfected cells were 
stimulated with IOng/ml of IL-4 for 0 to 24 hours. Relative light units (RLUs) were 
obtained by performing the dual-Iuciferase assay. Results are expressed as a percent 
of the RLU of unstimulated cells. *P<O.05 versus unstimulated cells transfected 
with pcDNA. tP<O.05 versus unstimulated cells transfected with pSTAT6. Other 
comparisons with P<O.05 are labeled on the graph. 
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pSTAT6 were stimulated with IL-4, TLR4-N reporter activity was significantly 
decreased at 6 hours (41.0±8.1 %), 12 hours (55.7±4.5%) and 24 hours (64.3±6.6%). The 
decrease was significantly greater than the decrease seen in cells transfected with pcDNA 
at 6 hours and 12 hours. Unlike cells transfected with pcDNA, pSTAT6 transfected cells 
maintained a significantly lower activity in TLR4-N reporter activity at 24 hours. It is 
possible that stimulation of the cells with IL-4 caused an increased transcription of 
ST AT6 from pST AT6, but this is unlikely as analysis of the plasmid showed no STAT6 
binding sites in its sequence. 
3.2.5 Tyrphostin AG 490 and TLR4 mRNA Expression 
Tyrphostin AG 490 is a potent inhibitor of the Janus Kinase-2 (Jak2) protein 
tyrosine kinase[535-537]. It can also inhibit Jakl and Jak 3, but AG 490 does not 
significantly inhibit other kinases such as Lck, Lyn, Btk, Syk and Src. It is the most 
common agent used to block tyrosine phosphorylation of STAT6 phosphorylation by Jak 
tyrosine kinases; there fore , AG 490 was used to block IL-4 induced tyrosine 
phosphorylation of ST A T6, and TLR4 mRNA levels were measured to determine the 
impact ofthis agent. Spiekermann et al. have shown that AG 490 can be toxic for U-937 
cells[538], but with the dose of 251lM that was used, the cell viability was 95±5% as 
measured by Trypan blue exclusion. Treatment of U-937 cells with DMSO (diluted 
1/400) alone, the vehicle used for AG 490, had no significant effect (Figure 3.24; 
103.9±1O.4%). 251lM of AG 490 alone caused no significant effect on levels of TLR4 
mRNA expression (107.7±9.5%). IL-4 caused a significant decrease in TLR4 mRNA 
expression (79.7±3.4%) compared to unstimulated cells (100%). Pre-incubation ofU-937 
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Figure 3.24. Expression ofTLR4 mRNA in U-937 cells as measured by real-time 
QPCR. U-937 cells were incubated with lOng/mI oflL-4, with DMSO (0.025%), 
and 251lM oftyrphostin AG 490 for 12 hours. Some cells were incubated with AG 
490 for 16 hours before incubation for 12 hours with IL-4 (AG 490 preincubation). 
RNA was extracted at different time points and TLR4 RNA and ALAS 1 house-
keeping gene were quantified using plasmid standards. Results are expressed as 
copies of TLR4 versus copies of the house-keeping gene ALAS 1. *P<0.05 versus 
unstimulated cells (n=4). 
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cells with AG 490 before challenge with IL-4, abrogated the decrease in TLR4 mRNA 
levels caused by IL-4 (111. 9±6. 9%) as it was not significantly different from baseline. 
3.2.6 TLR4 Promoter Transcriptional Activity of Different Plasmid Constructs 
The MatInspector software was used to map out potential ST AT6 binding sites in 
the upstream region of proximal promoter of the TLR4 gene, cloned in the TLR4-N 
plasmid. MatInspector is computer software that uses sophisticated algorithms to 
compare DNA sequences of interest and determine potential transcription factor binding 
sites based on consensus sequences and a probability weight matrix[539]. Results of 
MatInspector are shown as possible transcription factors binding the sequence of interest, 
the core similarity value (maximum value of 1.0), and the matrix similarity value 
(maximum value of 1.0). It is recommended that values for the core be as high as 
possible if not 1.0, and that for a good match the matrix usually has a similarity of 
>0.80[539]. Six potential sites were determined having a core similarity (similarity to 
most highly conserved sequences) of 1.0 and matrix similarity (similarity to ail residues 
in the sequence to known sequences that can bind STAT6) of ranging from 0.92 to 0.96 
(Figure 3.25). 
Different luciferase reporter plasmids containing different lengths of the upstream 
region of TLR4 were constructed to determine the region containing the IL-4 responsive 
region (Figure 3.26). U-937 cells transfected with the plasmid TLR4-N had a significant 
reduction in luciferase reporter activity when incubated with IL-4 for 12 hours (mean fold 
upregulation compared to pGL3-Basic ± standard deviation; 3.3±0.9) versus luciferase 
reporter activity at baseline (4.8± 1.3). IL-4 incubation did not result in a significant 
reduction in luciferase reporter activity of TLR4-N2 (5.1±1.0), TLR4-N3 (6.0±1.5), 
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Number Sequence Core Matrix Position upstream from 
(consensus sequence: similarity similarity start codon (nucJeotides) 
nnnnnTTCCnnnGAAnnnn) 
1 ttcatTTCCcagGAAaagg 1.0 0.960 3346 
2 tccacTTCCtaaGAAtgag 1.0 0.954 3036 
3 tacagTTCCtaaGAAgcgg 1.0 0.937 2616 
4 agcccTTCCtctGAAccac 1.0 0.921 2325 
5 taactTTCCaggGAActaa 1.0 0.938 2079 
6 gtttcTTCCcaaGAAgggg 1.0 0.916 746 
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Figure 3.25. Potential STAT6 binding sites determined using MatInspector Profes-
sional transcription factor analysis software. Six potential sites were determined 
with a high core similarity and matrix similarity. The core nuc\eotides are labelled 
in bold text and in capitalletters. The position and sequence of the potential binding 
sites with respect to the ATG start codon of the TLR4 gene is shown above. 
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Figure 3.26. Activation of upstream proximal promoter of TLR4 in U-937 cells as 
measured by the luciferase reporter assay. U-937 cells were transiently transfected 
with luciferase reporter plasmids containing different lengths of the upstream region 
of TLR4. After transfections cells were incubated with and without lOng/mL of 
IL-4 for 12 hours. pGL3-Basic is the reporter plasmid without any c10ned insert and 
was transfected into the U-937 cells to serve as a negative control. A Reni/la lucifer-
ase vector was used to correct for transfection efficiency. Relative light units 
(RLUs) were obtained by performing the dual-Iuciferase assay. Results are 
expressed as the RLU fold expression compared to the RLU cells transfected with 
pGL3-Basic. *P<O.05 versus baseline. 
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TLR4-H (4.1±2.2) and TLR4-P (7.3±O.5) compared to levels of unstimulated cells 
(6.l±1.9, 6.9±O.2, 4.8±1.9 and 7.0±O.3 respectively). These results suggest that only 
TLR4-N contains an IL-4 responsive region (shown in Figure 3.27). 
3.2.7 STAT6 Chromatin Immunoprecipitation 
ST A T6 ChIP was used in combination with real-time QPCR to determine if the 
potential ST AT6 binding sites can bind to STAT6 protein upon stimulation with IL-4 
(n=3). Only one of the potential STAT6 binding sites determined using MatInspector 
software was found in the IL-4 responsive region determined using the luciferase assay. 
The potential STAT6 binding site in the IL-4 responsive region (site 1) and the potential 
STAT6 binding site closest to the IL-4 responsive region (site 2) were investigated 
(Figure 3.27). Vpon IL-4 stimulation, a significant increase in STA T6 binding to site 1 
(mean fold upregulation compared to baseline level ± standard deviation; 3.7±O.9) was 
determined compared to unstimulated cells. There was no significant increase in binding 
of ST A T6 to site 2 upon IL-4 stimulation (O.5± 1.2). The isotype control was not 
significantly different to the unstimulated cells for both site 1 (O.5± 1.2) and site 2 
(O.3± 1.4). Therefore, it was concluded that ST A T6 can bind to the potential ST A T6 
binding site in the IL-4 responsive region. 
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Figure 3.27. Measurement ofSTAT6 binding to DNA upstream of the TLR4 gene 
measured by STAT6 chromatin immunoprecipitation (ChIP). U-937 cells were 
incubated with lOng/ml oflL-4 for 6 hours and DNA bound to activated STAT6 was 
purified by ChIP. Real-time QPCR was used to determine wh ether STAT6, after 
challenge with IL-4, could bind to the potential STAT6 binding site (site 1) in the 
IL-4 responsive region. An isotype control was used in the ChIP as a negative 
control for background staining. Prim ers were a1so designed for the potential 
STAT6 binding site (site 2) outside of the IL-4 responsive region but closest to site 
1. Quantification was performed using L1L1Ct method using a ChIP for RNA poly-
merase II binding to the GAPDH promoter as a reference. Results are expressed as 
fold expression of IL-4 stimulated cells compared to unstimulated cells. *P<O.05 
versus isotype (n=4). 
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3.3 TLR4 Expression in Peripheral Blood Mononuclear Cells from Children 
3.3. J Flow Cytometry Monocytes and CD4+ CeUs 
IL-4 could inhibit TLR4 expression in the U-937 cell line, and blood from 
children was investigated to confinn that it was not a cell line specific effect. The FSC 
and SSC parameters were used to gate the monocyte and lymphocyte fractions(Figure 
3.28; n=5), similar to a procedure by Mita et al.[489]. Monocyte fractions made up 15-
20% of the PBMCs isolated from children's blood. TLR4 expression of the monocyte 
population cultured in media had a high baseline level of TLR4 positive cells with a 
mean MFI of 155±8.5 (Figure 3.29). When incubated with IL-4 for 24 hours, the 
absolute number of monocytes expressing TLR4 did not differ significantly, but the MF! 
decreased significantly (126±15.5). 
PBMCs were stained with anti-CD4 and anti-TLR4 antibodies (Figure 3.30). A 
population of the PBMCs were positive for both TLR4 and CD4 protein surface 
expressIOn (Figure 3.31; mean percent of total CD4 population±standard deviation; 
16.0± 7.1 %). In contrast to the monocytes, wh en the PBMCs were stimulated with IL-4, 
the population of CD4 positive and TLR4 positive cells was significantly decreased 
(8.1±5.6%). To confinn that the CD4 positive cells were T cells, the PBMCs were 
stained with both anti-CD4 and anti-CD3 antibodies (Figure 3.32). It was detennined 
that greater th an 99.5% of the cells that express high levels of CD4 are T cells (CD3 
positive). Incubation with IL-4 did not significantly alter the levels of expression of CD4 
demonstrating that reduction of the CD4+/TLR4+ is due to decreased surface expression 
ofTLR4. 
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Figure 3.28. Forward and side scatters acquired by flow cytometry from PBMCs 
isolated by Ficoll gradient centrifugation. Two c1ear populations of cells were seen. 
Cells with low forward scatter and low side scatter are the lymphocyte population 
while cells that have a higher forward scatter (Iarger cells) and a higher side scatter 
(more granular cells) are the monocyte population. 
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Figure 3.29. Surtàce expression ofTLR4 on monocyte population from PBMCs as 
measured by tlow cytometry. PBMCs were purified from whole blood by Ficoll 
gradient centrifugation and cultured for 24 hours with and without lOng/mL of IL-4. 
Cells were stained with an Alexa Fluor 488 labelled monoclonal antibody for TLR4 
and fluorescence was acquired on the monocyte population by using the foward 
scatter and side scatter parameters. An isotype control, labelled with Alexa Fluor 
488, was used to detennine background fluorecscence. Results are expressed as the 
raw value of the mean fluorescence intensity minus the background 
fluorecescence. *P<O.05 versus unstimulated cells. 
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Figure 3.30. Dot plots for the surface expression of CD3 and TLR4 from PBMCs 
as measured by flow cytometry (representative example). PBMCs were purified 
from whole blood by Ficoll gradient centrifugation. Cells were cultured with 
lOng/mL of IL-4 (right) or cultured unstimulated (left) for 24 hours. Cells were 
stained with Alexa Fluor 488 labelled monoclonal anti-TLR4 and APC labelled 
monoclonal anti-CD4 antibodies. Isotype controls, labelled with FITC or APC 
respectively, were used to determine background fluorescence. 
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Figure 3.31. Surface expression ofTLR4 and CD4 on PBMCs as measured by flow 
cytometry. PBMCs were purified from whole blood by Ficoll gradient centrifuga-
tion and cultured for 24 hours with and without lOng/mL of IL-4. Cells were 
cultured with or without 1 Ong/mL for 24 hours. Cells were stained with Alexa Fluor 
488 labelled monoclonal anti-TLR4 and APC labelled monoclonal anti-CD4 
antibodies. Isotype controls, labelled with FITC or APC respectively, were used to 
determine background fluorescence. An isotype control, labelled with Alexa Fluor 
488, was used to determine background fluorecscence. Results are expressed as the 
percent of TLR4 and CD4 positive cells from the total population of CD4 positive 
cells. *P<0.05 versus unstimulated cells. 
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Figure 3.32. Dot plot for the surface expression of CD3 and CD4 from PBMCs as 
measured by tlow cytometry (representative example). PBMCs were purified from 
whole blood by Ficoll gradient centrifugation. Cells were stained with a FITC 
labelled monoclonal antibody for CD3 and a APC labelled monoclonal antibody for 
CD4. Isotype controls, labelled with FITC or APC respectively, were used ta deter-
mine background fluorescence. Circled cells are the cells that express high leve\s of 
bath CD4 and CD3. 
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Chapter 4: Discussion 
4.1 Introductory Remarks 
Infectious diseases have been a longstanding and still existing cause of morbidity 
and mortality. It is only recently in history that humans have been able to defend 
themselves with better sanitation, urbanization, vaccination and antibiotics. These 
measures have decreased the load of exposure to pathogens and may be associated with a 
rise in other inflammatory diseases. The hygiene hypothesis suggests that to develop 
proper immunoregulatory mechanisms to pre vent irregular damaging responses, as in the 
case of allergie diseases, the immune system must be exposed to a certain amount of low-
grade pathogens or at least components from pathogens[247]. In other words, bacterial 
components would induce immunoregulatory mechanisms against the development of 
atopy and Th2 inflammation. 
The complex regulatory components of the immune system are slowly being 
elucidated. These components are necessary to pre vent overactive immune responses. 
One immunoregulatory mechanism is the ability of the cytokines of the two arms of the 
immune system, the cell-mediated response and the humoral response, to counter-
regulate each other. Another mechanism is the induction of anti-inflammatory cytokines, 
su ch as IL-10, which has general anti-inflammatory effects. In allergie responses, Th2 
cytokines predominate to produce an IgE-mediated humoral response; therefore, 
promoting Th 1 cytokine production and IL-1 0 production with bacterial components such 
as LPS could reduce Th2 inflammation in allergic disease. 
Th2 cytokines have been shown to inhibit responses to LPS. This may be a 
mechanism for development of persistent allergic inflammation; LPS may be present in 
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the environment, but it can not provide its benefits bec au se of overwhelming Th2 
responses. The Th2 cytokine IL-4 has been shown to downregulate expression of the 
main LPS receptor component TLR4[489], but the mechanism by which this occurs has 
not been elucidated and also ifTh2 cytokines has similar effects on T regulatory eells. 
The above premises form the basis of this thesis. It was determined that LPS can 
benefit allergic inflammation in children, by promoting Th 1 cytokines and IL-lO. The 
results discussed here were acquired by using nasal mucosal tissue reseeted from children 
and adult subjects who were sensitive or insensitive to allergens. Atopic nasal mucosa 
from children reacted to allergen with a typical Th2 cytokine inflammatory profile, but 
allergen could reduce the se effects by inducing IFN-y, IL-12 and IL-lO. The shift in 
cytokine profiles was associated with increased production of immunoregulatory IL-I0 
and proliferation of CD3+ T lymphocytes. T cells also expressed TLR4 and the markers 
CD4 and CD25. The effects of LPS in children were mediated by TLR4, and similar 
responses were not seen in nasal tissue from allergie adults. While TLR4 is generally 
thought to be expressed by dendritic cells, macrophages and monocytes, it has been 
recently reported to be expressed on murine CD4+CD25+ regulatory T cells[433]. Results 
in this thesis provide evidence that TLR4 is highly expressed on CD3+ T lymphocytes in 
humans. 
The difference seen between children and adults and between atopic adults and 
non-atopic adults in TLR4 expression suggests downregulatory mechanisms at play 
during the development of long-standing atopy. In a cell model present in this thesis, IL-
4 rapidly decreased the transcriptional activity of the upstream region of TLR4, TLR4 
mRNA, TLR4 prote in surface expression as well as LPS responsiveness. This suggests a 
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form of transcriptional regulation. ST AT6 is a transcription factor and its activation is 
the result of one of the major pathways of IL-4 signal transduction. IL-4's inhibitory 
effect on TLR4 was enhanced and prolonged if STAT6 was overexpressed and inhibition 
of tyrosine phosphorylation abolished the effect of IL-4 on TLR4 expression. This 
evidence points to the role of STAT6 in downregulating TLR4 expression at the level of 
transcription. ST A T6 mediates its functions by binding to specifie sequences of DNA, 
and computer analysis of the upstream region of the TLR4 gene revealed six potential 
STAT6 binding sites. Truncations of the upstream region ofTLR4 gene revealed an IL-4 
responsive region and ST A T6 was shown to bind to this region. In addition, results from 
this thesis demonstrate for the tirst time that TLR4+CD4+ T cells are found in the 
peripheral blood of children. These cells are also highly responsive to IL-4, which can 
downregulate TLR4 expression after 24 hours of incubation with the cells. Taken 
together, these findings point to a role of LPS in inhibiting allergie responses via TLR4 
and that Th2 cytokines can limit these responses by reducing TLR4 expression. 
4.2 Discussion of ResuUs 
The tirst part of this thesis largely focused on the nasal expIant model, where 
small sections from the inferior turbinate are cultured outside the body with various 
stimuli. The advantage of this technique is that it allows the study of the effects of 
various inflammatory challenges without being confounded with the influence of cellular 
recruitment from the systemic circulation; aIl responses to challenges are solely derived 
from tissue constituents. At the same time, it affords a view into local immune responses 
in a tissue that is regularly exposed to environmental challenges and which participates in 
the symptoms of allergie rhinitis. The explanted nasal mucosa model has been used 
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successfully in the past as part of numerous studies in allergie rhinitis. This model has 
been used to describe local eosinophilic differentiation [43], local upregulation of Th2 
transcription factor GATA3[62] and production of Th2 cytokines and IgE [90, 91]. 
Despite the advantages ofthis model, there are limitations worth mentioning. Firstly, the 
small size of these biopsies limits the ability for the number of stimulations that could be 
used for each patient. Secondly, again due to small amounts of tissue, an aecurate 
quantification of mRNA or prote in production following LPS stimulation is limited even 
with powerful techniques such as laser capture microdissection and real-time QPCR. For 
this reason, histological techniques, such as in situ hybridization and 
immunohistochemistry, were weIl suited for use in the expIant mode\. The techniques 
offer information about cell numbers and cellular expression of both mRNA and prote in 
levels, but not absolute values for these markers. Despite this, these techniques are 
sufficiently robust to measure numbers of cells expressing a specific mRNA and protein 
species giving valuable information about local reactions to LPS or allergen. Thirdly, the 
culture conditions may limit the expIant mode\. The tissue is incubated on filter disks 
that float over the culture media from which the tissue is nourished. This is to mimic the 
environment the biopsy had within the body, where the local blood vessels and 
surrounding tissue would nourish it. In this system, allergen and/or LPS are added to the 
media and absorbed into the tissue from the submucosa; epithelial cells would not be the 
first cells to be in contact with the challenge, as would be the case in vivo. Although the 
tissue is not submerged in media, studies where the tissue was incubated with modified 
nuc1eotides (BrdU), fluorescently tagged oligonuc1eotides or nuc1ear DNA binding dyes 
(Hoeehst 33342) have shown that the elements from the wells of media ean adequately 
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diffuse throughout the tissue[9I, 293]; therefore, allergen, which are small lipophilic 
proteins, or LPS would permeate the tissue as weIl. Regardless of the limitations, the 
expiant model has been sufficiently characterized, has been successfully utilized in past 
reports and offers valuable insight into local immune responses using human tissue. 
The ability of LPS to prevent allergen-induced inflammation has been described 
in animal models, but not in humans. Epidemiological studies point to a potential role of 
LPS inhibiting atopic diseases in children[264, 266, 267], but LPS has been associated as 
a risk factor for occupational asthma[272] [273, 276] and even in the clinical severity of 
asthma in adults[275, 278, 279, 540]. LPS challenge of the tissue from atopic children, in 
this thesis provides evidence supporting the epidemiological studies and points to the 
possibility that responses to LPS in nasal tissue from children are different from adults. 
In the expiant model, LPS induced a strong induction ofThl cytokine mRNA (IL-2, IFN-
Y and IL-12) positive cells and was associated with increased numbers of cells positive 
for CD68(macrophages), elastase (neutrophils), tryptase (mast cells) and large increases 
in CD3 (T cells) positive cells. Allergen challenge produced characteristic increases in 
Th2 cytokine mRNA production such as IL-4, IL-5 and IL-13 and a slight increase in IL-
10. MBP positive (eosinophils) cells and mast cells, prominent cells in allergic 
inflammation, were also increased by allergen, and this increase was probably related to 
increases in Th2 cytokines. It is possible that allergen also increased other growth factors 
for these cell types such as IL-3, stem cell factor (SCF) and GM-CSF involved in mast 
cell growth, but these were not measured. T cells were also increased by allergen and 
this may be due to large increases in IL-2 positive cells. IL-2 is a powerful growth 
inducing cytokine of lymphocytes and is produced upon antigenic or mitogenic activation 
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of T cells[54l]. The receptor for IL-2 is composed of an a-subunit (CD25), a ~-subunit 
(CD122), and a y-subunit (CD132). On resting T cells, the ~ and y chains are expressed 
constitutively and form a low affinity IL-2 receptor, but upon activation, the CD25 
subunit is expressed forming a high affinity receptor[542]. Increased expression ofCD25 
upon LPS and allergen challenge demonstrates an increase of cells with high affinity for 
IL-2. CD25 is also constitutively expressed on T regulatory cells in high levels[543], and 
increased numbers of CD25 positive cells suggests their proliferation. Furthermore, LPS 
could diminish allergen-induced Th2 inflammation and skew it toward Thl inflammation 
in the nasal mucosa of atopic children; in tissues stimulated with both allergen and LPS, 
the Th2 cytokine mRNA positive cells were ail reduced to baseline and IFN-y, IL-12 and 
IL-I0 mRNA levels were elevated. LPS also decreased the allergen induced increases in 
mast cells and eosinophils. Similarly to LPS challenges al one, T cell levels increased 
upon LPS challenge with allergen and was associated with increases in IL-2 and CD25. 
Although IgE forms the basis of sensitization, levels of expression with allergen 
and/or LPS challenge were not measured in this work; this study was restricted to 
cytokine and inflammatory cell numbers. The primary reason for this was the limited 
amounts of tissue that were available for the study. A secondary reason is that levels of 
IgE are much lower in children th an in adults and only reach adult values at the age of 
1 O[ 544]; ail the children from which explants were obtained for this study were younger 
than 4 years old. The production of IgE has been measured in the nasal mucosa of adults 
in the expIant model[90-92]. Not only is IgE production induced by allergen in the tissue, 
but also IgE isotype switching. These events were shown to depend on local production 
of IL-4 and IL-13, as downregulating IL-4 mRNA with antisense oligonuc\eotides or 
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neutralizing antibodies blocks IgE mRNA production and IgE isotype switching[91, 92]. 
LPS can inhibit IgE production In animal sensitization models[285, 286]. The 
mechanism is not clear but may be through induction of Th 1 cytokine and IL-I0 
production. IFN-y, IL-12 and IL-lO have aIl been shown in separate studies to directly or 
indirectly inhibit IgE production[545, 546]. IFN-y can also downregulate IECE RNA and 
CD40L expression, both necessary for IgE isotype switching[547]. Based on these 
studies, LPS could play a role in inhibiting IgE production in the nasal mucosa of 
children by downregulating Th2 cytokines and upregulating Th 1 cytokines and IL-l O. 
Neutralizing antibodies against IFN-y, IL-IO and IL-12 were used to determine 
which of these cytokines induced by LPS had the most prominent role in downregulating 
Th2 inflammation. IFN-y is one of the most important cytokines for the cell-mediated 
inflammatory response, primarily produced by Th 1 cells and has large impacts on 
macrophage functions[548]. IFN-y can inhibit both IgE isotype switching and Th2 cell 
proliferation[549, 550]. Neutralization ofIFN-y, in allergen and LPS challenges, did not 
cause a significant increase in IL-4, IL-5 or IL-13 mRNA positive cells compared to 
allergen stimulation alone. However, neutralization of IFN-y did impact on IL-5 prote in 
positive celIs, demonstrating its inhibitory role in Th2 cytokine production and 
suggesting possible post-transcriptional regulatory mechanisms controlling IL-5 prote in 
synthesis. 
IL-lOis produced by many cell types such as monocytes and macrophages, but it 
is also produced by T celIs, including Thl, Th2 and regulatory T celIs[551-553]. IL-IO 
has numerous anti-inflammatory effects. IL-I0 can inhibit Th 1 and Th2 cytokine 
production[551]. IL-IO can also inhibit MHC class II molecule and B7 expression 
178 
reducing the ability of antigen-presenting cells ta present antigen and aetivate T eells 
[548, 554, 555]. IL-lO can also inhibit IgE synthesis and eosinophil survival[556, 557]. 
When IL-IO was neutralized in the nasal mucosa, the inhibitory effects of LPS on Th2 
cytokine mRNA production were abrogated. Similarly, neutralization of IL-lO 
augmented the number of IL-5 prote in producing cells. These results show IL-IO's 
potent role in downregulating Th2 cytokine production. Surprisingly, neutralization of 
IL-lO caused a reproducible reduction oflL-12 and IFN-y after LPS stimulation. IL-lO 
has been demonstrated to reduce IFN-y[516] and IL-12[558], and its neutralization 
should have caused an increase in their production. This effect needs further investigation 
ta determine if this is an expIant-specifie phenomenon or an unknown regulatory process 
found in children. Immunohistochemistry for Th 1 and Th2 cytokines after IL-IO 
neutralization were similar to the in situ hybridization results, suggesting that IL-lO's 
effects may be at the level of transcription and not translation. 
IL-12 is a heterodimeric cytokine produced by many cell types but mostly 
antigen-presenting cells in response to bacteria or bacterial products[559, 560]. IL-12 
induces cytokine production, proliferation and enhanced cytotoxic ability of NK cells and 
T cells. IL-12 is particularly a potent inducer of IFN-y of both NK cells and T cells, and 
inhibits IL-4 production[56 1 , 562]. IL-12 was greatly induced by LPS challenge of the 
mucosa, similarly to previous results[293]. Neutralization of IL-12 upon simultaneous 
LPS and allergen challenge caused increases in IL-4, IL-5 and IL-l3 mRNA positive 
cells, to levels comparable of allergen challenges. At the same time, neutralization of IL-
12 reduced IFN-y mRNA positive and protein positive cells, further demonstrating the 
functions of IL-12 at inducing Th 1 cytokine production and downregulating Th2 cytokine 
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production. IL-12 is known to induce IL-I 0 production from T cells, possibly to limit its 
pro-inflammatory effects[563, 564]. In explants, IL-12 neutralization significantly 
reduced IL-lO production, supporting the concept that IL-12 plays a role in inducing IL-
10, and may act together to prevent allergen-driven Th2 allergie response. Furthermore, 
it is important to note that the relative number of IL-l O-immunoreactive cells following 
LPS stimulation was almost five times higher than the number of IL-12-immunoreactive 
cells, suggesting that IL-lO may be the dominant cytokine in LPS-induced inhibition of 
allergie inflammation. The effects of IL-12 neutralization were seen at the level of 
mRNA and protein, suggesting that IL-12 inhibits transcription of Th2 cytokines. When 
both IL-12 and IFN -y were neutralized together, no additive effect in inducing Th2 
cytokines was observed, and the effect was comparable to neutralization oflL-12 alone. 
This demonstrates that IL-12 has a greater effect than IFN -y in diminishing allergen 
induced inflammation. Dual neutralization oflL-12 and IFN-y caused a similar effect to 
single neutralization of IL-12 on levels of IL-lO, supporting the greater role IL-12 plays 
in IL-IO induction. Interestingly, neutralization of IL-12 and IFN-y caused an additive 
decrease in IL-12 rnRNA and prote in positive cells, compared to single neutralizations. 
This suggests that IFN-y can have a positive feedback on itself by promoting IL-12 
production in the tissue. This is supported by findings showing that IFN-y can induce 
production of IL-12, and in rnany cases, IFN-y is necessary for IL-12 to be produced 
[565-567]. 
The nasal mucosa from young children, irrespective of their atopic state, is primed 
to respond quickly to bacterial products. Similarly to a previous report[293], the cells 
that seemed to respond the most to LPS stimulation in the mucosa were CD3+ cells. In 
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only 24 hours, LPS caused a dose dependent increase in CD3+ cells in both the nasal 
mucosa of atopic and non-atopic children, and for each dose, no difference was seen 
between the patient groups. Increase in these populations in the nasal mucosa of atopic 
children was shown to be due to local proliferation of these cells by the BrdU uptake 
assay. It is also possible that stimulation may increase marker expression and 
experiments would need to be performed to determine the effects of LPS on total 
cellularity of the tissue. 60% of the CD3+ cells were positive for CD25, and many of 
these cells were also positive for CD4. At the same dose of LPS, CD3+ cells and IL-l 0 
mRNA positive cells both rose about 6-fold in the tissue, suggesting that CD3+ were 
activated to produce IL-I0. In addition, numbers of CD25+ cells were similar to IL-I0 
mRNA positive cells. Taken together, this provides evidence that naturally occurring 
CD4+CD25+ immunoregulatory T cells in the nasal explants from children are likely to be 
the major source of IL-l 0, which is involved in controlling Th2 responses to allergen 
upon LPS stimulation. Many cells were positive for TLR4 that were not CD4+, and these 
may also be involved in production of IL-l O. Further experiments would be needed to 
characterize these cells and their involvment in LPS-mediated downregulation of allergic 
inflammation. 
To activate T cells, usually antigen presentation and accessory costimulatory 
molecules, such as CD80 and CD86, are necessary. In vitro experiments have shown that 
CD4+CD2S+ T regulatory cells seem to mediate fully competent suppression in the 
absence of CD80 or CD86[568]. This suggests that, while costimulation is necessary for 
the development of T-regulatory cells, their suppressor functions may be activated 
independently of antigen presentation[569]. These concepts support the results obtained 
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from LPS challenge of the nasal explants; LPS without antigen caused increases in CD3+ 
cells in both atopic and non-atopic mucosa. A recent report showed that murine 
CD4+CD25+ T regulatory cells selectively express TLR4, TLR5, TLR7 and TLR8[433]. 
ln addition, LPS stimulation of murine CD4+CD25+ T regulatory cells with LPS 
enhanced suppressor function, survival and proliferation, aIl of which was independent of 
antigen-presenting cells. Expression of TLR4 on CD3 positive cells was investigated to 
determine if this population of cells existed in children. Indeed, many CD3+ cells were 
positive for TLR4. In addition, allergen did not increase the TLR4+CD3+, but when the 
tissue was simultaneously challenged with LPS and allergen, a large increase was seen. 
TLR4 expression was also co-Iocalized with IL-IO and an increase in double positive 
cells was seen upon 24 hour incubation with LPS. OveraIl, the results obtained suggest 
that CD4+CD25+ T regulatory cells in the atopic mucosa of children express TLR4, and 
LPS directly causes this population to proliferate and produce IL-l O. 
The LPS-induced increase in CD3 immunoreactivity and associated increase in 
IL-IO mRNA expression in atopic mucosa from children was not observed in atopic 
adults. LPS unresponsiveness of atopic adults was most likely attributable to the 
extremely low basal expression of TLR4 when compared to both atopic and non-atopic 
children. As in other reports, LPS sensitivity seemed dependent upon TLR4 
expression[484]. Non-atopic adults had a significantly higher level of TLR4 positive 
cells and TLR4 positive cells increased with LPS stimulation. Studies have shown that 
several mutations in TLR4 may account for decreased LPS responsiveness[ 498, 570], but 
besides results in this thesis, variability in responsiveness to LPS was never associated 
with differences in TLR4 expression between atopic and non-atopic individuals. 
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The levels of TLR4 positive cells in the nasal mucosa of non-atopic adults were 
significantly lower than both atopic and non-atopic children. Decreased expression of 
TLR4 in non-atopic adults may be related to the ability of the immune system to decline 
with age. Recent studies by Renshaw and colleagues have shown that in mice, TLR 
activation by their ligands and even the abundance ofTLRs decrease with age[571]. In 
other studies, levels of TLR4 on monocytes did not differ with age in both mice and 
humans[572, 573]. Therefore, differences in numbers of TLR4 positive cells between 
children and adults may be cell-type dependent. This is supported by the report that T 
cells in peripheral blood of healthy adults were shown to have low levels of TLR4 
mRNA, but this was never compared to levels in children[432]. Levels of TLR4 
expression may also depend on P AMP exposure during life, and if an individual is 
expressed to a lesser load of PAMPs, levels of TLR4 may decrease. To clarify this issue, 
a larger population of adults would have to be studied and correlations would have to be 
performed with age and LPS exposure levels. 
The protective effect of LPS in atopic children against allergen-induced 
inflammation is most likely driven directly by TLR4 and not other TLR receptors. This 
is supported by results obtained using purified LPS preparations, which selectively 
activates TLR4 only and not TLR2 or other TLRs. Differences in LPS sensitivity 
between adults and children may not only be limited to TLR4 expression. TLR4 is 
physically associated with MD-2 in its extracellular domain, and MD-2 is essential for 
binding of LPS and activation of TLR4[445-447], and its levels have not been 
investigated in this work. In addition, LPS is transferred to TLR4 via the prote in 
CD14[452,453]. Recent studies have shown that neonate monocytes have reduced CD14 
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expression on their surface as weIl as reduced intracellular Myd88 expression[572, 574]. 
It is speculated that reduced neonate responsiveness to LPS are to reduce the risk of 
inflammatory reactions in utero that could lead to premature delivery[572]. Thus, there 
are important differences in the capacity of adults, children and even neonates to respond 
to bacterial LPS, which may play a vital role in maturation of the immune system. 
Atopic nasal mucosa from adults is associated with high expression of Th2 
cytokines and Th2-associated transcription factors[37, 61, 90, 91, 575], which may play a 
role in reducing TLR4 and LPS responsiveness. The immortalized ceIlline, U-937, was 
used as a model to determine the regulation ofTLR4 by the Th2 cytokine IL-4 and by the 
transcription factor STAT6. The U-937 monocytic cell line was obtained from the 
American Type Culture Collection (A TCC), and the original stock was derived by 
Sundstrom and Nilsson in 1974 from malignant cells of monocytic origin, obtained from 
the pleural effusion of a patient with histiocytic lymphoma [576]. This cell line was 
chosen for numerous reasons. U -937 cells are weli characterized, used often in research, 
are easy to culture in vitro, express high levels of baseline TLR4 and are sensitive to LPS 
[577]. They also express functional IL-4 receptor and ST A T6 and respond to IL-4 
similarly to peripheral blood monocytes [538, 578]. The experiments are also simplified 
by use of a homogenous cell line and are therefore more reproducible. Many of the 
experiments required transfection of plasmids into celis and primary ce lis from patients 
are very sensitive and vary significantly in the conditions needed to achieve efficient 
transfection results. Although cell tines give insight into underlying mechanisms, results 
obtained should be confirmed with primary celis from human subjects. 
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Several reports have shown that U-937 cells produce TNF-alpha, IL-l~, and IL-
10 upon LPS stimulation[306, 579-581]. In these reports, IL-4 could reduce LPS-
induced production of TNF -a, IL-I0 and IL-l~, but the mechanism has not been 
determined. Two major pathways of signal transduction are activated by LPS, the early 
MyD88-dependent pathway and the late MyD88-independent pathway[454-456, 467]. 
Activation of the early Myd88-dependent pathway leads to rapid activation of NF-
KB[341, 456, 467]. The MyD88-independent pathway also involved activation ofNF-KB, 
but with slower kinetics than the MyD88-dependent pathway[467]. In this work, NF-KB 
activation by LPS was measured with or without IL-4 stimulation. LPS stimulation 
caused a robust activation of NF-KB which was significantly reduced wh en U-937 cells 
were preincubated with IL-4 for 24 hours. If IL-4 was added at the same time as LPS, 
IL-4 had no significant effect, suggesting that preincubation activates regulatory 
mechanisms which require time to have an effect. In studies on sepsis, for IL-4 to have 
protective effects it needed to be administered before LPS exposure [307, 311, 582]. 
The mechanism by which this is occurs was not determined, but it can be either through 
downregulation of LPS receptor components, inhibition of signal transduction 
components or cross talk between signal transduction pathways. One possibility is that 
IL-4 induces the suppressor of cytokine signaling 1 (SOCS 1 )[583], which can 
downregulate IRAKI activation, necessary for the MyD88-dependent pathway [357, 584]. 
This work also shows that the mechanism by which IL-4 mediates its inhibitory 
effects may be related to regulation of TLR4. IL-4 inhibited TLR4 mRNA and 
transcriptional activity as early as 6 hours in U-937 cells, but it was only after 12 hours 
that surface expression of TLR4 was significantly decreased. This suggests that time is 
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required for IL-4 to inhibit LPS signaling machinery, and this may be due to the time it 
takes for existing TLR4 to be degraded and replaced by nascent TLR4. The time point 
where a significant reduction in surface expression of TLR4 was seen coincides with the 
incubation time that caused decreased LPS responsiveness as measured by the NF-KR 
assay. It is possible that IL-4 can inhibit other components of the LPS receptor, such as 
MD-2 and CD 14, but this was not investigated in this work. IL-4 has been shown to be 
able to reduce CD14 surface expression in monocytes, but this mechanism has not been 
investigated for its effects on LPS responsiveness[585]. 
Downregulation of IL-4 mRNA and transcriptional activity of TLR4 suggests that 
IL-4 activates transcriptional repression of the gene. IL-4 functions by binding the IL-4 
receptor, which consists of an IL-4Ra subunit and the y common (Yc) chain subunit[173, 
174], or by binding to the IL-13 receptor, which consists of the IL-4Ra subunit and the 
IL13Rai subunit[185]. The main signal transduction pathway activated by IL-4 binding 
to its receptor is the Jak-STAT pathway involving Jakl[175] and Jak3 [175, 176] and 
both can phosphorylate STAT6. Phosphorylated STAT6 homodimerizes, migrates to the 
nucleus, binds to ST A T6-response elements and once there it regulates transcription. 
Many genes aetivated by STA T6 are important for allergie inflammation, such as IgE[88, 
89] or the chemokine eotaxin[ 168-170] and ST A T6-deficient animaIs have defective IL-4 
responses[58]. STAT6 has been shown to play an important role in LPS-mediated 
sepsis[314]. ST A T6-deficient mice have uncontrolled production of cytokine and 
chemokine production after challenge with LPS, and the mice also succumb to sub-lethal 
doses of LPS compared to their wild type counterparts. This suggests an essential role 
for ST A T6 in controlling LPS sensitivity. 
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As weIl as an activator of transcription, ST A T6 has been shown to inhibit 
transcription of many genes[586]. The N-terminal do main of STAT proteins mediates 
DNA binding[587, 588]. The C-terminal part ofSTAT6 prote in is a proline-rich domain 
involved in activation of transcription, called the transactivation domain[589-591]. 
Transcription factors function by binding other proteins known as co factors of 
transcription that recruit additional cofactors or the basal transcription machinery to the 
promoter site and/or function as chromatin modifying enzymes. ST A T6 has been shown 
to associate with CREB-binding prote in (CBP) while another region associates with 
nuclear receptor coactivator 1 (NCoA-l)[591, 592]. Both these regions of STAT6 
significantly increase transcription, potentially through induction of histone acetylase 
activity, which opens up chromatin for transcription. STAT6 can inhibit transcription by 
competing for binding sites of other transcription factors such as STATI and NF-KB[593, 
594]. STAT6 can also inhibit transcription by competing with other transcription factors 
for co-activators of transcription[595]. NF-KB has been shown to associate with both 
CBP and NCoA-l[596, 597], but competition between STAT6 and NF-KB for these 
factors has yet to be described. In U-937 cells, Jak kinase activity was essential for 
inhibition of TLR4 mRNA by IL-4; if Jak kinases were inhibited using tyrphostin AG 
490, IL-4 had no effect on levels of TLR4 mRNA. Effects of the inhibitor on TLR4 
surface expression and transcriptional activity were not measured. Transfection ofU-937 
cells with ST A T6, to cause constitutive overexpression of this protein, allowed for 
investigation of transcriptional activity of the upstream region of the TLR4 gene. When 
IL-4 was added to the ST A T6 transfected cells, a great reduction in transcriptional 
activity of the reporter plasmid was observed, which was greater than the reduction and 
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of longer duration than that provided by endogenous ST A T6. As ST A T6 inhibited the 
transcriptional activity of the upstream region of the TLR4 in the reporter plasmid, this 
suggests that ST A T6 plays a direct role in regulating transcription of TLR4. 
ST A T6-binding sites have been identified in many promoter regions of IL-4 
responSlve genes. The STAT6 binding site consensus sequence is 5'-TTC(N)4GAA-3', 
where N4 is any series of four nucleotides[598]. Sequence analysis of the cloned 
upstream region of TLR4, which was determined to be sensitive to IL-4, revealed six 
potential ST A T6 binding sites. Truncation of the upstream region cloned into TLR4 
revealed that the IL-4 responsive region was present about 3400 base pairs upstream of 
the start codon of TLR4. This region contained only one potential STAT6 binding site. 
A ST A T6 chromatin immunoprecipitation confirmed that ST A T6 does indeed bind to 
this region of DNA. Although these results show that IL-4 activates ST A T6 to bind to a 
site in the upstream region of the TLR4 gene, the mechanism by which ST A T6 functions 
remains to be determined. Potentially, at this site, STAT6 can inhibit basal transcription 
of TLR4. In the first analysis of the upstream region of TLR4, Rehli and colleagues 
determined that an inhibitory region of DNA was present upstream of the TLR4 
gene[ 496]. When this region was removed, transcriptional activity increased more than 
double, but the nature of this region has not been determined. The ST AT6 binding site 
that was determined in this work was found to be present in this region of the upstream 
region of TLR4, and it is possible that ST A T6 may promote the effects of this inhibitory 
sequence of DNA. To determine the mechanism by which STAT6 inhibits TLR4 more 
experiments would be required. For example, mutation of the DNA binding site of 
ST A T6 in the overexpression plasmid could help determine if ST A T6 inhibits TLR4 by 
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competing with other transcription factors for the binding of the DNA. Removal of the 
transactivation domain of STAT6 would help determine if this region of the ST AT6 
protein is necessary to mediate its inhibitory effects. 
IL-13, another Th2 cytokine, sharing the IL-4 receptor components, can activate 
ST A T6 and be protective against sepsis. IL-13 has been shown to reduce LPS-induced 
IL-6, IL-8, IL-lp and TNFa[178, 312, 313]. Although this study was largely focused on 
IL-4, preliminary results showed that IL-13 was capable in decreasing U-937 cell 
expression of TLR4 mRNA in a time and dose dependent manner (data not shown). 
These effects are most likely mediated by STAT6 as weil. Other cytokines, such as GM-
CSF and TGFp, may have a role in the regulation of TLR4 with IL-4 and IL-13. When 
used in combination with IL-4, GM-CSF and TGFp decrease TLR4 expression and LPS 
responsiveness in monocytes[599]. 
IL-4 rapidly decreased but did not abolish TLR4 expression. Rapid decrease 
suggests direct inhibition by ST A T6 rather than transcription of indirect inhibitors. 
Moreover, incomplete inhibition as weIl as a transient effect seen suggests that IL-4 and 
ST A T6 fine tune responses rather than completely suppress TLR4. The effect on TLR4 
surface expression was modest but significant and was smaller than what was observed in 
primary monocytes[489]. This effect may be related to cell type differences; U-937 cells 
may be refractory to IL-4 treatment over time. Indeed, it has been reported that there is 
less STA T6 phosphorylation and less Yc chain expression in monocytes after incubation 
with IL-4[306]. This may explain why overexpressing STAT6 in U-937 prolonged IL-
4's inhibition of the upstream region of TLR4. Perhaps in other cell types that possess 
more ST AT6 or are more responsive to IL-4, downregulation of TLR4 would be stronger 
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and of longer duration. Alternate mechanisms to downregulation of signal transduction 
include activation of endogenous inhibitors of ST A T6 such as Src homology-containing 
phosphatase-l (SHP-l)[600], protein phosphatase 2A (PP2A)[601] and SOCS-l[602]. 
Other mechanisms have been proposed for the regulation of ST A T6 activity. Removal of 
a methyl group on Arg27 of STAT6 decreases phosphorylation of ST AT6 and its nuclear 
translocation[603]. Regulation of STAT6 has shown to be more complex than once 
believed, and whether these play a role in the transient nature oflL-4 effects in the U-937 
cell model was not determined. 
For this work, the role oflL-4 in downregulating TLR4 in U-937 was confirmed 
in peripheral blood mononuclear cells from children. Peripheral blood is a quick and 
easy source of leukocytes including lymphocytes, granulocytes, monocytes and 
macrophages. Peripheral blood was taken from children rather than adults as the studies 
in the expIant model revealed a higher expression of TLR4 in children. In addition, Mita 
et al. demonstrated that TLR4 expression in monocytes from peripheral blood of adults 
was downregulated by IL-4[ 489], but this effect was not determined in monocytes and T 
cells from children. Monocytes from children expressed high levels of TLR4, and after 
incubation with IL-4 for 24 hours, the absolute number of monocytes expressing TLR4 
did not differ significantly, but the expression level was significantly reduced. Reduction 
of TLR4 by IL-4 was not as great as that reported by Mita et al., but this may be due to 
differences in the dose of IL-4 used or ev en an age specific effect. In addition, use of 
FSC and SSC parameters to gate for monocytes and lymphocytes provides only a rough 
estimate of the monocyte population. It is also possible that large lymphocytes such as 
natural killer cells were present in the monocyte gate, although these cells are found in 
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lesser numbers in the blood and their expression of TLR4 is still undetermined. Staining 
for specifie cell markers using antibodies is a better strategy to identify the cell 
populations than FSC and SSC parameters. CD3 staining is specific for T cells as it is a 
component of the T cell receptor, and all the cells that expressed high levels of CD4 were 
positive for CD3. Monocytes also express CD4 but have a much lower expression than T 
cells making it easy to discriminate these two populations. Cells expressing TLR4 and 
high levels of CD4 were thus T cells, and these cells responded strongly to IL-4; the 
population of CD4+TLR4+ was significantly reduced after incubation of PBMCs with IL-
4 for 24 hours. Therefore, TLR4+ T cells in the nasal mucosa may be similarly affected 
by IL-4 and would have a reduced responsiveness to LPS, by loss of expression of the 
receptor. This may be the mechanism by which atopic adults have reduced TLR4 protein 
positive cells in their nasal mucosa. 
4.3 Implications of these Results 
These results demonstrate the ability of the bacterial pro du ct LPS to prevent local 
allergen-induced allergic inflammation in the nasal mucosa of children. Moreover, the 
results suggest a possible mechanism for the hygiene hypothesis, where exposure of 
young children to LPS can promote Thl cytokine production and anti-inflammatory 
cytokine production in the nasal mucosa by Thl cells and TLR4+ T-regulatory cells. 
Responses of children were different from atopic adults, suggesting that long-standing 
allergic rhinitis can impair responsiveness to the benefits of LPS. This was dependent on 
TLR4 which could be inhibited by IL-4, a mediator of atopy, in a STAT6 dependent 
mechanism. In addition, IL-4 could inhibit T cell expression of TLR4, suggesting that 
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allergie responses eould downplay the proteetive role of LPS in inducing the aetivity of 
this cell population. 
The protective effects of LPS in reducing atopy seem to depend on the age of the 
patient. This has been observed in epidemiologieal studies and in LPS airway challenges 
in adults. In young children, exposure to LPS reduces the risk of atopy, while exposure 
in adults will aggravate airway inflammation. This may be due to complex interplay 
between alIergens and host cytokine production. Bacterial components may also only 
have a short and temporary therapeutic window to act. While this work shows that T 
celIs and monocytes from children lose expression of TLR4 upon incubation with IL-4, 
peripheral blood B cells from healthy adults can have an increased TLR4 expression with 
IL-4[489]. This denotes both age and cell-specific regulation of TLR4. Activation of 
ma st cells by LPS would promote allergie inflammation instead of downregulating it. 
LPS stimulated ma st cells can produce Th2 cytokines and chemokines to recruit 
eosinophils[604]. In addition, activation ofTLR4 with LPS and FCERI with antigen leads 
to a synergistically increased production of TNF -a, IL-6 and IL-13 by activation of MAP 
kinases[605]. Although not significant, IL-4 seems to increase eosinophil expression of 
TLR4 mRNA[606]. In addition, activation of eosinophils with LPS led to increased 
adhesion molecule expression, survival and superoxide production. The cell and age 
specific effects on TLR4 expression may be due to different levels of expression and 
activity of transcription factors or accessibility of the TLR4 gene for transcription, but 
these mechanisms need to be determined. Therefore, LPS may be protective in the initial 
steps of sensitization to allergen or when IgE levels in the subject are not at their peak. 
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More research is required to determine the individual role of the different cell types, 
especially in children, in LPS responses and sensitization. 
Evidence, in murine models shows that TLRs may have a role in the development 
ofTh2 immune responses[290, 291]. While high doses promote Thl cytokine production, 
low doses of LPS can promote Th2 immune response, primarily through the activation of 
dendritic cells. In addition, TLR4 deficient mice have defective Th2 cytokine production 
and IgE-mediated sensitivity to antigen[292]. Although comparable doses of LPS were 
used in this study, several possibilities may explain the differences obtained. Differences 
seen may be due to tissue, age and species as immune responses seen in mi ce may not 
necessarily translate to immune responses in humans. Deletion of TLR4 gene may also 
have effects on development of the immune system. In Drosophila, Toll protein is not 
only involved in innate immune responses but is also plays an important functional role 
in embryogenesis[333-335]. One cannot discount the fact that systemic recruitment plays 
a role in TLR4 generation of Th2 reactions, and the expIant model separates the tissue 
from the systemic circulation. Despite this, the expIant model provides the advantage 
that human tissue, rather than an animal model is used. Nevertheless, the influence of the 
systemic immune system in allergic rhinitis needs to be determined to further develop the 
conclusion with respect to LPS on allergic inflammation. 
The nasal passages are in constant exposure to the environment and are the site of 
inflammation in allergic rhinitis, but can also be colonized by bacteria. According to the 
results from this study, allergic rhinitis would be a predisposing factor for nasal bacterial 
infections. In allergic rhinitis patients, damage caused by inflammation and frequent 
clearance of protective mucus combined with decreased TLR4 levels would lead to 
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greater colonization of the upper airways by bacteria. The number of studies exploring 
bacterial sinusitis and allergic rhinitis are limited, and a large variability is seen between 
studies; patients with both diseases range from 25% to 70% [607]. Nonetheless, patients 
with allergie rhinitis have a greater incidence of sinusitis than eontrols[608-611]. In one 
study, persistent allergie rhinitis was assoeiated with more than two-fold inereased risk 
for sinusitis than non-allergie eontrols, but it was unclear if it was of baeterial origin[ 612]. 
In other studies, the presence of bacteria was clearer; patients with persistent allergie 
rhinitis are associated with a two fold inerease in Staphylococcus aureus[613], and in 
another study, 90% of subjeets with a positive skin test to allergens had presence of 
potential pathogenie baeteria in their nasal eavity eompared to 36% of patients with a 
negative skin test[614]. Despite the link, the immunopathological reasons for this 
predisposition are unclear and more studies are required. It is possible that decreases in 
innate resistance in allergie rhinitis may play a role in the predisposition. This work has 
focused on TLR4 expression in the nasal mucosa and it would be important to determine 
whether other PRRs are also reduced in allergic rhinitis, leading to an even greater 
predisposition to infection. 
Few reports have looked In detail at the transcriptional regulation of TLR4. 
Studies include investigation of basal transcription factors in monocytes[ 496] and 
transcription under conditions of hypoxia[497]. This work has added to the CUITent 
knowledge by demonstrating a role of ST AT6 in downregulating TLR4 in monocytes and 
potentially T -regulatory cells. Other transcription factors involved in allergic 
inflammation may also regulate TLR4. The transcription factor GAT A3 has a large role 
to play in the development of Th2 reactions. Naïve, freshly activated T cells and Th2 
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cells express high levels of GATA3 but not Thl cells [59, 615]. The role of GATA3 in 
the development of Th2 reactions cannot be shown by simple deletion as GAT A3 
knockout mi ce die 11-12 days after conception displaying massive internaI bleeding, 
marked growth retardation, severe deformities of the brain and spinal cord, and gross 
aberrations in fetal liver hematopoiesis[616]. Inhibition of GATA3 with antisense 
oligonucleotides showed a crucial function for this transcription factor in activation of 
Th2 cytokines[59]. GATA3 is critical for the production of IL-5 and IL-13 but not for 
IL-4[617-619]. Like STAT6, GATA3 has been associated with chromatin remodeling of 
the IL-4, IL-5 and IL-13 genes[620, 621]. The chromatin ofthese genes is maintained in 
an open state, by modification of DNA and proteins such as histones, to promote 
transcription of these genes. In addition, GAT A3 has been shown to be important in 
maintenance of chromatin in its remodeled state[60]. GATA3 has been shown to be 
increased in allergic asthma in humans and in allergen sensitization models in mice[62, 
63, 622]. The CUITent consensus is that GATA3 is a master regulator of Th2 cell 
generation. The DNA binding sequence of GA TA3 is known and preliminary analysis of 
the upstream region of TLR4 by computer analysis demonstrates nine potential GAT A3 
binding sites (data not shown). This suggests a potential role of GA TA3 in regulating 
TLR4 expression in T cells. It is known that TLR2 expression can be controlled by 
chromatin remodeling[623, 624], and it is possible that TLR4 is as weil. IL-4 activation 
of GAT A3 may potentially inhibit TLR4 expression by modifying chromatin to shut 
down gene expression, and this would provide longstanding inhibition of gene expression. 
This may explain the low expression ofTLR4 in adults with allergie rhinitis. 
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It is still not clear by what mechanism allergens are seen as a threat to the host, as 
they cause little damage. Similar responses to allergens denote possible structural 
similarities or even a common receptor. Inhaled allergens are stable proteins, are often 
proteases of low molecular weight, and have a high proportion of hydrophobie 
residues[625]. It is possible that a eonserved moleeular pattern on allergens causes them 
to reaet with a PRR. It is even possible that TLR4 may funetion as a reeeptor for 
allergens, as the extracellular domain of this reeeptor has a broad hydrophobie surface for 
binding of ligands. Low dose stimulations of LPS induee the production of Th2 
cytokines from dendritic cells and TLR4 is essential for the development of Th2 immune 
responses[290-292]. It is possible that TLR4 has low affinity for allergens and 
suboptimal signal transduction would induce the production of Th2 inducing cytokines 
from antigen-presenting cells rather than Th 1 inducing cytokines. In this case, part of the 
mechanism of the hygiene hypothesis would be a competition between allergens and 
bacterial PAMPs for PRRs and induction of adaptive immune responses. It is of crucial 
importance to determine the mechanisms that allergens induce allergic inflammation to 
prevent the development of allergic diseases in children. 
4.4 Therapeutic Implications 
The results of this work suggest important considerations in the development of 
therapies for atopic disease. Inflammatory cells of the nasal mueosa, their expression of 
TLR4 and their responsiveness to LPS are different between children and adults. In 
addition, neutralizing antibodies to IL-JO, IL-12 and IFN-y shows the importance ofthese 
cytokines in reducing allergic inflammation induced by LPS. Allergic rhinitis is 
associated with lowered IL-JO production compared to normal individuals[548]. Therapy 
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may focus on promoting Th 1 cytokine production and IL-lO or promoting the generation 
of T -regulatory cells that express TLR4 if not in adults, more importantly in developing 
children to curb the increase in allergie disease prevalence. Aside from potentially 
reducing allergic symptoms, promoting TLR4 expression may be also helpful in 
providing protection from predisposition of developing bacterial sinusitis. 
The current pharmacologieal therapies for allergic diseases including adrenergic 
agonists, anti-histamines and steroids have numerous problems associated with them. 
These include side effects, tolerance development, short-lasting effects and immune 
system suppression. Inhaled corticosteroids may even increase the severity of allergic 
diseases by suppressing Th 1 development and enhancing Th2 cytokine synthesis such as 
IL-4 and IL-5[626, 627]. An alternative to pharmacotherapy is allergen immunotherapy. 
This is the practiee of administering gradually increasing doses of allergen to a patient to 
ameliorate the symptoms associated with subsequent exposure with the specific causative 
allergen[628]. Allergen immunotherapy is effective at reducing IgE-mediated disease but 
requires numerous injections over the course of 3 to 5 years[629]. Allergen 
immunotherapy is highly effective at reducing IgE-mediated disease. It is one of the few 
immunomodulatory therapies used routinely for treatment of an inflammatory disease. 
Rhinitics and allergic asthmatics on immunotherapy can tolerate seasonal exposure to 
allergens with decreased symptoms, an effect that can last three years after treatment 
completion[630]. Unfortunately, as allergens are used, there is a chance of IgE-mediated 
systemic reactions and anaphylaxis. The mechanisms of allergen immunotherapy are not 
clear. Current understanding focuses on the deviation from a Th2 phenotype to a Th 1 
phenotype, a decreased responsiveness of the Th2 biased cells[520] or immune regulation 
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by cytokines, such as IFN-y or IL-1O[631]. There is also the possibility of the other 
mechanisms such as the induction of IL-IO production by CD4+CD2S+ T regulatory 
cells[632], although, in sorne cases, Thl cytokines may play a greater role in 
immunotherapy than immunoregulatory T cells[633]. These mechanisms are similar to 
the mechanisms by which LPS functions to diminish allergen-induced inflammation in 
the nasal mucosa of atopic children. Immunotherapy possibly reestablishes the 
mechanisms present in children but lost in atopic adults. Perhaps attempts to increase the 
regulatory T cell population or activity may improve immunotherapy. One method 
would be to stimulate tumor necrosis factor receptor superfamily 9 (TNFRSF9), as 
stimulation of the mouse homolog 4-1BB can induce the proliferation of CD4+CD2S+ T 
regulatory cells in vitro and in vivo[634]. Another possibility is increasing the 
recruitment of Th 1 cells from the circulation or to increase their local differentiation with 
cytokines such as IL-12 or IFN-y. 
It is possible that combination of PAMPs to immunotherapy may increase the 
efficiency, shorten the duration and avoid potential side-effects of the treatments. This 
treatment has as its aim a deviation of Th2 cytokine responses to Th 1 cytokine responses. 
The PAMPs are used as adjuvants, which are substances that enhance the immune 
responses to an antigen. One adjuvant used for immunotherapy is derived from LPS and 
consists of 3-deacylated monophosphoryl lipid A (MPL). MPL can promote Thl 
responses primarily through induction of IL-I2 production[635]. Wh en MPL was 
conjugated to grass pollen allergen, after only four preseasonal injections, reduced 
symptoms and IgE production were seen in patients with hay fever[636]. Similarly, the 
TLR9 ligand CpG DNA, when conjugated to purified ragweed and injected in patients 
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with allergie rhinitis, could reduce symptom scores to allergen during ragweed season, 
reduce nasal eosinophilia, Th2 cytokine production and could increase IFN-y positive 
cells[637]. Unfortunately, for these therapies to be successful, adequate PRR expression 
is necessary and if Th2 cytokines reduce PRR expression, th en allergie inflammation may 
reduce the potential benefit of these therapies. It is possible that to promote P AMP 
conjugated allergen immunotherapy, Th2 cytokines should be reduced prior to the 
treatments. Allergen immunotherapy is also performed by sub-cutaneous injections, and 
perhaps localized nasal immunotherapy may provide greater and faster therapeutic 
benefits and be more effective than by altering systemic immune responses to the 
allergen. In addition intranasal administration of P AMPs may be potential treatment 
option to protect atopic children from developing lifelong allergic inflammation. 
Investigation of these avenues may lead to development of alleviation of symptoms if not 
a complete protection from allergic inflammation. 
4.5 Future Studies 
The findings of this work set the stage for further research. Here presented are 
future studies that can be conducted to further the work ofthis thesis: 
1. A full characterization of the TLR4+ CD4+CD2S+ T cells found in the nasal mucosa of 
children or the TLR4+CD4+ T cells found in the peripheral blood of children would be 
interesting. It is necessary to determine whether these cells possess the other proteins of 
the LPS receptor, MD2 and CDI4, as weIl as the necessary signal transduction 
components for LPS responsiveness. In addition, a determination of what genes are 
activated upon activation of the cells with TLR4 ligands would be necessary. The 
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mechanisms by which TLR4 is regulated in these cells, or what can cause these cells to 
proliferate would also yield potential information to promote TLR4 expression in allergie 
adults. 
2. It would be also important to determine whether Th2 cytokines have an impact on 
other components of the LPS receptor or LPS signal transduction events. Aiso it would 
be of interest to determine if other TLRs have reduced expression in the nasal mucosa of 
allergie adults. It would also help in showing different potential P AMPs that would 
benefit the early immune system against the production of allergie disease. This would 
help to determine which ligands would function most efficiently in adjuvant modified 
immunotherapy. 
3. The regulation of TLR4 and other TLRs needs to be further elucidated. Further 
characterization of the mechanism by which STAT6 functions to inhibit TLR4 is needed. 
In addition, Tyrphostin AG 490 may cause unrecognized nonspecific effects on the cells 
and another method, such as ST A T6 antisense oligonucleotides or small interfering RNA 
(siRNA), to inhibit STAT6 is required to confirm these results. Numerous potential 
transcription factor binding sites were observed during computer analysis of the upstream 
region of TLR4. This included potential GAT A3 binding sites. GAT A3 may play an 
important role in the regulation of TLR4 in chronic allergic rhinitis. In addition, other 
potential regulators of TLR4, such as the novel Th2-associated cytokine IL-33, and their 
mechanisms of action need to be better characterized. 
4. Perhaps of greatest interest is the elucidation of the mechanisms by which allergens 
function to cause sensitization and activation of primary Th2 immune responses. This is 
especially important, since increases in allergie disease incidence is a world-wide 
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phenomenon. It is possible that a PRR plays a role in binding to allergen and can induce 
the necessary IL-4 to prime Th2 immune responses. Potentially TLR4 or other TLRs 
may play a role in the recognition of allergen and this possibility needs to be investigated. 
4.6 Summary and Conclusion 
In summary, this thesis demonstrates the ability of bacterial LPS to prevent local 
allergen-induced allergic inflammation in the nasal mucosa of atopic children. This was 
shown to occur by down-regulation of local Th2 cytokine production and induction of 
Th 1 cytokine and IL-IO production. LPS also caused the proliferation and activation of 
TLR4+IL-1O producing cells and CD4+CD2S+ cells. These events are dependent upon 
local tissue constituents and independent of systemic recruitment of inflammatory cells, 
and require TLR4 for this process to occur. In addition, CD3+ cells were shown to be one 
of the major cell types expressing TLR4 in the nasal mucosa of children. Moreover, it 
was shown that responses to LPS and expression of TLR4 are significantly different 
between children and adults, especially adults with allergie rhinitis. Allergie 
inflammation may downregulate TLR4 expression as IL-4 and ST A T6 can downregulate 
TLR4 in an in vitro model and IL-4 can downregulate peripheral blood T cell expression 
of TLR4. Activation of ST A T6 led to binding of ST A T6 to an upstream region of the 
TLR4 gene, where it may mediate the inhibitory actions of IL-4. TLR4 is an important 
bridge between the innate and adaptive immune systems and its activation may provide 
protection against the development of atopic diseases by promoting the maturation of the 
immune system. This provides one of the potential molecular mechanisms of the hygiene 
hypothesis, where bacterial components promote immunoregulatory responses to allergen. 
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On the other hand, in adults, Th2 cytokines may promote allergie inflammation by 
downregulating components of the innate immune system; aside from stimulating pro-
inflammatory mediators, IL-4 can downregulate the innate immune receptor TLR4, 
potentially affecting the immunoregulatory effeet of LPS in allergie disease. 
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